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         Honour the springtide life ever adorning. 
That all things has made! 
Things smallest have some resurrectional morning. 
The forms alone fade. 
Life begets life, 
Potencies higher surprise; 
Kind begets kind, 
Heedless of time as it flies; 
Worlds pass away and arise. 
 
Join in the joy of all life, every being,  
Brief bloom of its spring; 
Honor th`eternal, our human lot freeing 
From fetters that cling; 
Adding your mite, 
With the eternal unite; 
Though you decay, 
Breathe as a moment you may, 
Air of eternity`s day! 
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For my grandparents and Carmen 
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Abbreviations 
 
> FRT (abbreviation in genotype annotations, e.g. ey>dmP0)  
aa  amino acid 
AED [time] after egg deposition 
b-HLH-LZ basic helix-loop-helix leucine zipper 
DCMW asparic acid(D)-cysteine(C)-methionine(M)-tryptophan(W) 
DNA deoxyribonuclein acid 
dsRNA double stranded RNA 
FRT flipase recombination target 
GFP green fluorescent protein 
GM y w/Y; (GMR-GAL4 UAS-dMyc132; UAS-dMyc13 UAS-dMyc42)/(SM5^TM6B) 
IgG immunglobulin G 
HAT  histone acetyltransferase 
kb kilo base pair 
L1, L2, L3 first, second and third larval stage 
MB1 (2,3) Myc Box 
OreR OreR (wildtype strain) 
ORF open reading frame 
PEST proline(P)-glutamic acid(E)-serine(S)-threonine(T) 
PCR polymerase chain reaction 
Pol polymerase 
qRT-PCR qualitative real-time PCR 
RNA ribonucleic acid 
RNAi RNA interference 
SAGA Spt-Ada-Gcn5-acetyltransferase 
UAS upstream activating sequence 
UTR untranslated region 
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Zusammenfassung  
 
Das Proto-Onkogen myc ist in menschlichen Krebsarten häufig fehlreguliert. Die Familie der 
myc Gene kontrolliert viele verschiedene zelluläre Prozesse wie zum Beispiel Zellwachstum 
und –proliferation, Metabolismus oder Apoptose. Die Faktoren, welche die Wirkung des 
Myc-Proteins von innen heraus bestimmen, beispielsweise welche Aufgabe die konservierten 
Bereiche innerhalb dieses Proteins in einem Organismus ausführen, sowie die Faktoren, die 
von ausserhalb auf Myc einwirken und dadurch Myc`s biologische Funktionen bestimmen 
sind noch immer unzureichend erforscht. 
In dieser Arbeit haben wir die Rolle von dMyc, dem einzigen Homolog der Familie der Myc-
Proteine in Drosophila, in Zellkultur und in einem voll entwickelten Organismus, der Fliege 
untersucht. dMyc kann teilweise tierisches c-Myc ersetzen. In einem ersten Projekt haben wir 
die konservierten Bereiche von dMyc (den N-Terminus, MB2, MB3) im Hinblick auf 
Zellwachstum, -proliferation und Apoptose genauer untersucht. Wildtypische und mutante 
dMyc-Proteine wurden in Drosophila S2 Zellen und in Fliegen exprimiert. Alle getesteten 
biologischen Funktionen von dMyc zeigten eine starke Abhängigkeit vom N-terminalen 
Bereich des Proteins. Erstaunlicherweise war MB2, welche in Vertebraten eine wichtige Rolle 
für die Rekrutierung von HAT-Komplexen zu Myc (TRRAP, RUBVL1) spielt, nur teilweise 
nötig für die Funktionen von dMyc. Eine dMyc-Mutante, welcher MB2 fehlt, konnte sogar 
ein dMyc Null-Allel bis zur Ausbildung einer voll entwickelten Fliege retten. Zudem konnten 
wir zeigen, dass MB3 die Stabilität von dMyc negativ beeinflusst. Darüber hinaus führte eine 
dMyc-Mutante, welche MB3 deletiert, zu einem erhöhten Wachstum sowie einer starken 
Zunahme von Zelltod. Die Fähigkeit, die Transkription der E-box abhängigen Zielgene oder 
der von RNA Polymerase III transkribierten Gene in vivo zu aktivieren, wurde jedoch nicht 
erhöht. 
In einem zweiten Projekt haben wir einen loss-of-function Screen durchgeführt, um neue 
Kofaktoren von dMyc zu finden.  Der Screen führte zu zwei Proteinen: Delta, einem Notch-
Liganden, und Chinmo, welches die zeitliche Identität der Neuronen während der 
postembryonalen Entwicklung des Gehirns von Drosophila reguliert. Beide Proteine 
interagieren genetisch mit dmyc während der Augenentwicklung. Wir zeigen Beweise dafür, 
dass dMyc die Funktionen von Chinmo limitiert, da die schädlichen Effekte, die durch eine 
Überexpression von Chinmo entstehen, durch eine Reduktion der Proteinmenge von dMyc 
verringert werden können. Umgekehrt braucht dMyc Chinmo, um seine biologischen 
Funktionen in Flügelimaginalscheiben auszuführen. Darüber hinaus zeigen unsere Daten, dass 
Chinmo und dMyc physisch über die BTB/POZ Domäne von Chinmo interagieren und dass 
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Chinmo endogene Zielgene von Myc, welche im Zusammenhang mit der Proteinbiosynthese 
stehen, aktivieren kann. Chinmo transaktiviert zudem effizient Zielgene von dMyc und diese 
Aktivierung der Transkription is abhängig von dMyc. 
Zusammenfassend deuten unsere Daten darauf hin, dass Chinmo ein wichtiger Koaktivator 
von dMyc ist und für die Ausführung einiger biologischer Funktionen von dMyc Bedeutung 
hat. 
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Summary 
 
The Myc protein is a potent oncogene that is frequently misexpressed in human cancers. myc 
family genes control a wide variety of cellular processes such as cellular growth and 
proliferation, metabolism or apoptosis. However, the cis-acting determinants, for example the 
conserved protein domains, and the trans-acting determinants, e.g. the identity of the Myc-
interacting proteins affecting Myc`s biological activity, are still incompletely understood. 
In this study we investigated the role of dMyc, which is the only homologue of the Myc 
family members in Drosophila and can partially substitute for vertebrate c-Myc, in cell 
culture assays and in vivo. In a first project conserved motifs within the Myc protein (N-
terminus, MB2, MB3) were analysed with regard to their role for cellular growth, 
proliferation and apoptosis. Wildtype and mutant forms of dMyc were expressed either in 
Drosophila S2 cells or in transgenic animals in vivo. We showed that the N-terminus of dMyc 
is necessary for all dMyc dependent functions. Amazingly, a deletion in the highly conserved 
MB2, which in vertebrate Myc proteins was shown to recruit proteins of HAT complexes to 
Myc (TRRAP, RUBVL1), only weakened dMyc activity, and a dMyc mutant lacking this 
domain was even able to rescue a dMyc null allele to adulthood. We further demonstrate that 
MB3 affects dMyc stability in a negative way. Moreover, a deletion of MB3 enhanced Myc`s 
ability to promote cell growth and apoptosis, but not its efficiency to activate transcription of 
E-box dependent target genes or RNA Pol III dependent endogenous targets in vivo. 
In a second project we performed a loss-of-function screen in order to find new dMyc co-
factors. The screen identified two proteins, Delta, a Notch ligand, and Chinmo, a protein that 
governs neuronal temporal identity during postembryonic development of the Drosophila 
brain. Both genetically interact with dmyc during eye development. We present evidence that 
dMyc is limiting for Chinmo since the deleterious effects of Chinmo overexpression are 
reduced by a reduction of dMyc levels. Conversely, dMyc depends on Chinmo to fulfil its 
biological activities in wing imaginal discs. Furthermore, our data show that Chinmo binds 
dMyc physically via its BTB/POZ domain and activates endogenous dMyc target genes 
associated with ribosome biosynthesis. Chinmo efficiently transactivates dMyc target genes, 
and this activation of transcription is fully dependent on dMyc. Taken together, our data 
suggest that Chinmo is a co-activator of dMyc that is necessary for some biological functions 
of dMyc. 
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General Introduction 
 
The transcription factor Myc is a potent oncogene known to be involved in a wide variety of 
cancers. Originally, the c-myc gene was discovered as the cellular homologue of the avian 
myelocytomatosis retroviral v-myc oncogene in 1982 (Bishop, 1982). Myc family genes, c-
myc, N-myc, and L-myc activate and repress a large number of target genes. Moreover, they 
were shown to have neoplastic potential (Marcu et al., 1992). Recent publications suggest, 
that c-Myc influences a wide variety of target genes involved in cellular processes like 
differentiation, angiogenesis, metabolism, cell growth, cell cycle progression and apoptosis 
during normal development (reviewed in Dang et al., 2006). Deregulation of Myc contributes 
to uncontrolled cell proliferation, genomic instability, escape from immune surveillance, 
immortalisation and independence of growth factors, which in turn leads to the formation of 
tumours. Therefore, Myc needs to be tightly regulated by external signals like growth factors. 
 
Myc`s functional domains 
 
The c-myc gene is located on human chromosome 8 and consists of three exons (Battey et al., 
1983).  The ORF starts at the second exon and codes for a protein of 439 amino acids (c-Myc 
2). Translation initiation at a CUG in the first exon leads to a 454 amino acids long protein (c-
Myc 1), and a third form arises from translational initiation at a conserved downstream AUG 
(c-Myc S), lacking most of the N-terminal part of the protein (Hann et al., 1988; Spotts et al., 
1997). 
 
b-HLH-LZ 
 
Several years after the identification of c-myc, the Myc C-terminus was found to contain a 
helix-loop-helix motif (HLH) and a leucine zipper (LZ), motifs that had earlier been shown in 
other proteins to bind DNA (Landschulz et al., 1988). Myc family proteins appear to not 
homodimerise under physiological conditions but instead form heterodimers with the Max 
protein (Blackwood and Eisenman, 1991). So far, Myc was shown to depend on its binding 
partner Max, a small b-HLH-LZ protein. The heterodimer binds to so-called E-boxes 
(CACGTG) in order to bind DNA and activate target genes. Additionally, E-box related sites 
are bound by the heterodimer (Grandori et al., 1996). 
However, we found out recently that dMyc, the homologue of c-Myc in Drosophila, is able to 
fulfil some functions independently of dMax. Thus, dMyc does not require dMax for 
induction of growth or endoreplication in polyploid larval tissues (Steiger et al., submitted). 
 
 
 11 
In the rat PC12 pheochromocytoma cell line, a functional Max protein is not expressed 
(Hopewell and Ziff, 1995). Since overexpression of Myc in these cells leads to apoptosis, this 
suggests that Myc acts independently of Max in PC12 cells (Wert et al., 2001). 
 
The N-terminus 
 
The Myc N-terminus was found to function as a transactivation domain, spanning two 
conserved motifs, Myc Box 1 (MB1), located between amino acid 45-63 and Myc Box 2 
(MB2), located between amino acid 128-144 (the numbering corresponds to human c-Myc). 
Consistent with its role as transcriptional activation domain the Myc N-terminus was shown 
to recruit several co-factors like TRRAP (McMahon et al., 1998) or P-TEFb (Eberhardy and 
Farnham, 2002). Moreover, the evolutionary highly conserved MB2 is specifically implicated 
in the recruitment of the co-factors Tip48, Tip49 (Wood et al., 2000) to Myc. 
In agreement with this observation, c-Myc S and an N-Myc truncation analogous to c-Myc S 
that lack the N-terminal region of Myc including MB1, but retain MB2, are unable to activate 
transcription (Cowling and Cole, 2008; Spotts et al., 1997). Surprisingly, c-Myc S retains the 
ability to regulate proliferation and apoptosis (Xiao et al., 1998), even in the absence of 
endogenous Myc. 
These observations for MB1 contrast with other studies that suggest that MB1 is not 
necessary for transactivation (Oster et al., 2003). Moreover, a deletion of MB2 blocks all 
biological functions of Myc that were analysed in cell culture assays. Thus, Myc`s ability to 
induce proliferation in cell culture is inhibited when MB2 is deleted (Conzen et al., 2000; 
Hirst and Grandori, 2000). Myc is also unable to promote apoptosis and transformation when 
MB2 is missing (Conzen et al., 2000; Oster et al., 2003). Moreover, stable transfection of a 
MB2 mutant in 3T3-L1 preadiposite cells showed that such a mutation cannot block 
differentiation into adiposites anymore (Freytag et al., 1990). 
However, Myc is not able to repress certain target genes, like gas1 and C/EBPα, when MB2 
is deleted indicating that this domain is normally involved in the repression of those genes 
(Lee et al., 1997; Li et al., 1994). Altogether, the ability to activate and repress target genes is 
dramatically reduced when MB2 is missing (Cowling and Cole, 2006; Li et al., 1994). Myc is 
also capable of autoregulation by repressing the c-myc locus itself. A c-Myc mutant lacking 
MB2 was not able to repress c-myc anymore but it was still able to repress gadd45 (Oster et 
al., 2003). Thus, two different repression mechanisms by Myc must exist. Additionally, c-
Myc S and a truncated form of N-Myc were shown to still repress c-Myc repressed targets, 
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but did not activate the c-Myc induced genes anymore (Cowling and Cole, 2008; Spotts et al., 
1997). 
Stabilization and degradation of Myc by the Ras pathway was also linked to the N-terminus, 
since Ras-induced phosphorylation of Ser62 leads to a stabilization of the Myc protein (Sears 
et al., 2000; Yeh et al., 2004). However, the role for MB1 and MB2 regarding their biological 
activities needs to be confirmed in vivo. 
 
MB3 & MB4 
 
The c-Myc protein contains two additional conserved domains (besides MB1, MB2 and the b-
HLH-LZ), Myc Box 3 (MB3188-199), located between amino acid 188-199 and Myc Box 4 
(MB4), located between amino acid 317-334 (the numbering corresponds to human c-Myc 
(MB3) and human N-Myc (MB4)), which are situated in the central part of the protein. 
Deletion of MB3188-199 potentiates Myc dependent induction of apoptosis and inhibits cell 
transformation (Herbst et al., 2005). A different nomenclature was used for a different region 
also called MB3, located between amino acid 259-270 (the numbering corresponds to human 
c-Myc), which we are going to use in the future, containing a highly conserved PEST-domain 
(Cowling and Cole, 2006). PEST regions (sequences rich in proline, glutamic acid, serine and 
threonine residues) are often associated with unstable proteins (Rogers et al., 1986). A 
deletion of 11 amino acids in the acidic region (MB3) of v-Myc reduced the efficiency to 
transform bone marrow cells (Heaney et al., 1986). Mutants containing deletions in the central 
acidic portion in the v-Myc protein moreover show differences in transformation of Japanese 
quail and chicken macrophages (Biegalke et al., 1987). 
The MB4 motif was shown to be involved in apoptosis, transformation and G2 arrest 
(Cowling et al., 2006). 
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Biological functions of Myc 
 
Regulation of the cell cycle by Myc 
 
The cell cycle is defined by a series of events that lead to the duplication of a cell. It involves 
two major periods, the interphase in which cell growth takes place and the M-phase in which 
the cell divides. Defects in cell cycle regulation can result in cancerous growth and 
developmental abnormalities. To prevent such defects, the cell cycle needs to be tightly 
controlled. Early studies implicated c-Myc in the G0/G1 transition (Freytag, 1988). Some E-
box containing genes that are involved in cell cycle regulation have been identified as direct 
Myc target genes. Among these genes are: cyclinD1 & D2, cdk2, cyclinA, cdk4, cyclinB1, 
cdk1, cdc25A and E2F (Bouchard et al., 2001; Hermeking et al., 2000; Menssen and 
Hermeking, 2002). A scheme of the cell cycle is shown in Figure I. Cyclin-dependent kinases 
(CDKs) are key regulatory proteins, which in connection with their positive regulators, 
cyclins, trigger the transition from one cell cycle phase to another. 
Extracellular growth signals induce the expression of D-cyclins, the first cyclins to be 
synthesized in the cell cycle. CyclinD2 was for example shown to be a direct target of Myc in 
vivo (Bouchard et al., 2001). Upon binding of Myc to the cyclinD2 promoter, expression of 
cyclinD2 is enhanced. The D-cyclins themselves activate cdk4 (also a Myc target gene) and 
cdk6. After phosphorylation and inactivation of the Rb protein by cyclinD/cdk4 and 
cyclinD/cdk6, the transcription factor E2F is released, which itself activates cyclinE, cyclinA 
and other S-phase specific genes. It was demonstrated that constitutive expression of Myc 
leads to an increase in cyclinE & A (Jansen et al., 1993). Moreover, Myc and Ras accumulate 
active cyclinE/cdk2 and E2F (Leone et al., 1997). Finally, as a result of the above processes, 
the cyclinE/cdk2 complex drives the cell into S-phase.  
Overexpression of Myc was shown to drive quiescent cells into the cell cycle, to promote S-
phase entry and a shortening of G1-phase in cycling cells (Karn et al., 1989; Steiner et al., 
1996). On the other hand, reduction of Myc levels prevents quiescent cells from entering the 
cell cycle in response to mitogenic signals (Roussel et al., 1991). Similar observations were 
made with a derivative of the rat1 fibroblast cell line, in which the endogenous c-myc gene 
had been knocked out. Those c-myc-/- cells had a prolonged G1 and G2 phase and three fold 
reduced proliferation rate. Thus, not only G1 is affected by Myc but also G2 (Mateyak et al., 
1997). 
Induction of growth promoting genes, but also suppression of growth inhibitory genes, leads 
to cell proliferation. The CDK inhibitors p21 and p15INK4B were for example, shown to be 
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repressed by Myc (Staller et al., 2001; Wu et al., 2003). Myc was also shown to repress genes 
involved in growth arrest like gas1 and gadd45 (Lee et al., 1997; Marhin et al., 1997). The 
Cdc25 proteins are a family of phosphatases that remove inhibitory phosphates from Cdks. c-
Myc was shown to induce cell proliferation by activation of genes like cdc25A (Galaktionov 
et al., 1996). 
In summary, Myc directly controls genes involved in cell cycle regulation. This makes clear 
that misregulation of Myc directly affects the cell cycle. 
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Figure I:  The human cell cycle. Different CDKs and cyclins regulate different phases of 
the cell cycle. The dashed line indicates the two cell cycle checkpoints G1/S 
and G2/M. Damaged cells arrest in their progression through the cycle and, if 
the damage is irreparable, will be directed to undergo cell death. Myc directly 
regulates components of the cell cycle. 
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Regulation of cell growth by Myc 
 
Regulation of cell growth is a major feature of Myc function. This has become even clearer as 
Myc was found to be involved not only in the activation of RNA Polymerase II-transcribed 
genes (reviewed in Dang 2006), but Myc was also found to activate the expression of RNA 
Polymerase I- & III-transcribed genes (Gomez-Roman et al., 2006; Gomez-Roman et al., 
2003; Grewal et al., 2005). The protein synthetic machinery is regulated at two stages− 
ribosomal synthesis and translation initiation. Ribosomal biogenesis starts with rRNA 
transcription (Jacob, 1995), followed by RNA processing (Eichler and Craig, 1994) and is 
completed by transcription and translation of ribosomal proteins and assembly of the 
ribosomes. Translational initiation requires mRNAs and translation initiation factors 
(Hershey, 1991). Myc`s target genes include genes that encode rRNAs and proteins involved 
in ribosome biogenesis and protein synthesis and a number of those genes are direct targets of 
c-Myc, such as 5S RNA and tRNA genes, which are transcribed by Polymerase III (Gomez-
Roman et al. 2003). Thus, c-Myc promotes growth through enhancement of ribosomal 
biogenesis by regulation of all three RNA Polymerases. 
This activity of Myc is demonstrated by Schuhmacher et al., 1999. These authors observed 
that Myc positively regulated protein synthesis in the B-cell line P493-6 that carries a 
conditional myc allele, and that Myc could induce a size increase in these cells. Additionally, 
liver cells and B-lymphocytes of mice overexpressing Myc were significantly larger (Iritani 
and Eisenman, 1999; Kim et al., 2000). 
These data contrast with the observation that, after reduction of Myc levels, mice were 
smaller because of a reduction of cell number rather than cell size (Trumpp et al., 2001). 
However, the previous observation regarding Myc`s role in protein biosynthesis favours a role 
for Myc in the regulation of growth. 
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Regulation of cell death by Myc 
 
There are two different pathways of apoptosis, the intrinsic pathway, which can be triggered 
by various intracellular cues such as DNA damage, hypoxia or oncogene activation. On the 
other hand there is the extrinsic pathway, which includes hormones, growth factors or 
cytokines. Myc was shown to affect both pathways. The first evidence that Myc is involved in 
the regulation of apoptosis was found in the early 1990s as a lot research on cell death was 
done (Askew et al., 1991; Evan et al., 1992). One of the earlier studies implicated that c-Myc-
induced apoptosis can be inhibited by the proto-oncogene Bcl-2 in serum starved ovary cells 
or Rat1/MycER fibroblasts (Bissonnette et al., 1992; Fanidi et al., 1992). Later on, Myc was 
shown to enhance apoptosis by activating the ARF-Mdm2-p53 axis (reviewed in Meyer et al., 
2006). In contrast, Myc proliferation-promoting activity is reduced when co-overexpressed 
with ARF, a tumour suppressor that stabilizes and thereby activates p53. The tumour 
suppressor p53 induces the cell cycle inhibitor p21, thus blocking cell cycle progression. Myc 
was demonstrated to inhibit p21 through interaction with Miz-1, thus the cell undergoes 
apoptosis rather than cell cycle arrest (reviewed in Meyer et al., 2006). In addition, p53 can 
directly repress c-myc by binding to the c-myc promoter (Ho et al., 2005). Thus, the levels of 
p53 and Myc determine the cell fate -cell cycle arrest or apoptosis. However, Myc-induced 
apoptosis seems to be influenced by various cues. The pro-apoptotic protein PUMA (P53-Up-
regulated Modulator of Apoptosis) was shown to act downstream of Myc and p53. Loss of 
PUMA leads to a decrease of Myc-induced apoptosis (Jeffers et al., 2003). In 2007, the E3-
ligase Cullin 7 (Cul7) was shown to directly bind to p53, leading to elevated p53 protein 
levels. Thus, Myc induced apoptosis is inhibited and Cul7 and Myc co-operate to transform 
Rat1 cells (Kim et al., 2007). 
In summary, one can group a variety of pro-apoptotic proteins as “ambassadors of Myc-
induced apoptosis” that act as tumour suppressors when Myc is deregulated and whose 
absence will favour Myc induced apoptosis and transformation, e.g. p53, ARF, BIM, 4EBP1 
(reviewed in Meyer et al., 2006). Another group are the “abrogaters of Myc-induced 
apoptosis”, oncogenes that cooperate with deregulated Myc, block apoptosis and will trigger 
Myc to proliferation, e.g. Mdm2, Cul7, BCL-2, GSK3/FBW7, eIF4E (reviewed in Meyer et 
al., 2006). 
Recently, a new aspect of Myc induced apoptosis was discovered in Drosophila. Wing 
imaginal discs containing clones that express lower levels of dMyc compared to their 
neighbouring cells were shown to be influenced by “cell competition”. Cells that express 
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higher levels of Myc (dmP0/+) induced cell death in neighbouring cells that were homozygous 
mutant for the weak hypomorphic myc allele dmP0 (dmP0/dmP0) (Johnston et al. 1999). 
Conversely, cell clones that overexpress dMyc reduced the growth rate of their neighbouring 
wildtype cells and finally eliminated them (De La Cova et al., 2004; Moreno and Basler, 
2004). 
 
Myc, Max, Mxd: The network 
  
The small Max protein was shown to be incapable of activating reporter genes (Kato et al., 
1992), but to have very weak repressor activity when expressed at high levels (Kretzner et al., 
1992). As described earlier, Myc forms heterodimers with its partner Max in order to activate 
target genes. Both proteins contain a b-HLH-Zip domain, which is necessary for dimerisation 
of the proteins and binding to DNA. In contrast to Myc, Max is able to form homodimers that 
can bind to E-box sequences in vitro (Berberich and Cole, 1992; Kato et al., 1992). The two 
complexes, Myc-Max and Max-Max, compete with each other for shared target genes 
(Sommer et al., 1998). Apart from Myc, Max interacts with other b-HLH-Zip proteins. Those 
proteins include Mnt (Hurlin et al., 1997), Mxd1-4 (Ayer et al., 1993; Hurlin et al., 1995; 
Zervos et al., 1993) and Mga (Hurlin et al., 1999). All of those proteins behave like Myc in 
the sense that they are unable to form homodimers, appear to be incapable to bind DNA alone 
and bind to E-box sequences together with Max. In contrast to Myc, they act as transcriptional 
repressors and (at least some of them) were shown to block Myc-dependent cell 
transformation in cell culture (Koskinen et al., 1995; Vastrik et al., 1995). As only one protein 
of the Mnt/Mxd/Mga transcription factors is present in Drosophila, dMnt, this introduction 
will predominantly focus on Mnt. To some extent the Mxd proteins are thought to have 
similar properties (with certain restrictions). 
Since Max either binds to Myc or the Mnt/Mxd/Mga transcription factors, the question arose 
whether Max becomes rate limiting in some situations. Indeed, Max can become rate limiting 
in mouse embryo fibroblasts when c-Myc levels are elevated (Walker et al., 2005). A 
homozygous deletion of the Mnt protein led to different types of tumours in mice (Hurlin et 
al., 2003). The role of Mnt as a direct antagonist of Myc became even clearer by the fact that 
both regulate a similar set of target genes (Toyo-oka et al., 2006). Interestingly, elimination of 
Mnt partially rescues the slow growing phenotype of cells that contain reduced Myc levels 
and a loss of Mnt, like overexpression of Myc, sensitizes cells for apoptosis (Nilsson et al., 
2004). Thus, the Max-Mnt complex is a direct antagonist of the Max-Myc complex. 
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Transcriptional activation by Myc 
 
The Myc-Max complex is thought to recruit proteins of Histone Acetyl Transferase (HAT) 
complexes (TIP60, SAGA) and chromatin remodelling complexes (SWI/SNF), thereby 
creating a “histone code” which in turn loosens the chromatin structure and allows other 
factors to bind (Cowling and Cole, 2006; Wierstra and Alves, 2008). The above mentioned 
complexes are thought to facilitate transcription initiation and elongation. Consistent with this 
notion, Myc binds to DNA and activates transcription by recruiting TRRAP and increasing 
especially histone H4 acetylation on Myc target genes (Frank et al., 2001). Myc was also 
shown to bind to the DNA-helicase/ATPases Tip48 and Tip 49, which are components of the 
TIP60 HAT complex, like TRRAP (Wood et al., 2000). 
On the other hand, the Max-Mnt heterodimer was shown to recruit the co-repressors Sin3A 
and Sin3B, which themselves interact with histone deacetylases (HDAC) (Hurlin et al., 1997; 
Popov et al., 2005), suggesting that these complexes promote a nucleosomal confirmation that 
is unfavourable for transcription by deacetylation of the chromatin (or by other actions). 
 
TRRAP/ GCN5  
 
One major co-factor of Myc is the huge TRansactivation/ tRansformation Associated Protein 
(TRRAP) (McMahon et al., 1998). The N-terminus of Myc is required for the interaction 
since deletions of parts that inhibit transformation also inhibit interaction with TRRAP 
(McMahon et al., 1998). TRRAP is not only part of the TIP60 complex (Ikura et al., 2000), 
but also part of the SAGA complex (Grant et al., 1998). An internal domain (aa 1899-2026) 
of TRRAP was shown to be bound by Myc (Park et al., 2001). So far it is not clear whether 
the binding of Myc to TRRAP has a special effect on TRRAP activity or if it only recruits 
TRRAP (and the associated complexes). 
The SAGA complex contains only one known catalytic subunit, GCN5 (Grant et al., 1997). 
GCN5 functions as a histone acetyltransferase and is recruited to Myc via TRRAP (McMahon 
et al., 2000). Myc was also demonstrated to be a substrate of GCN5 in mammals where it was 
shown that GCN5 acetylates Myc in vivo and thus increases Myc`s stability. As a 
consequence, the transcription of Myc target genes is increased (Patel et al., 2004). 
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Recently, TRRAP and GCN5 were implicated in the recruitment of RNA Polymerase III by 
Myc. The complex (c-Myc, TRRAP, GCN5) binds to the promoter of the RNA Poll III targets 
5S RNA and tRNA and histone H3 gets hyperacetylated, and in parallel TFIIIB binds to DNA. 
These two processes recruit RNA Pol III and lead to initiation of transcription (Kenneth et al., 
2007). 
 
RUVBL1&2 
 
RUVBL1 (Tip49) and RUVBL2 (Tip48) are subunits of the TIP60 and SRCAP (Snf-2-
related CREB-binding protein activator protein) complex in animals (reviewed in Gallant, 
2007). However they can also bind independently of TRRAP to Myc (Wood et al., 2000). 
Tip48 and Tip49 were not only implicated in binding to Myc but also to other transcription-
associated proteins like β-catenin or E2F1 (only Tip49) (Bauer et al., 2000; Dugan et al., 
2002). RUVBL1 & 2 are thought to be involved in chromatin remodelling in yeast, since 
RUVBL1 deletion disrupted the INO80 chromatin remodelling complex (Jonsson et al., 2004; 
Shen et al., 2000). A dominant-negative version of RUVBL1 enhanced Myc-induced 
apoptosis and inhibited transformation by Myc; proliferation was not affected by this mutant 
(Dugan et al., 2002). 
 
HECTH9/SKP2 
 
The activity of transcription factors is closely regulated by ubiquitination (Conaway et al., 
2002). Also, ubiquitination of Myc was shown to enhance Myc`s potential to activate target 
genes and this went along with a reduced half-life (Salghetti et al., 1999). Ubiquitin ligases 
were found to interact with Myc, e.g. Skp2 (Kim et al., 2003; von der Lehr et al., 2003), 
HectH9 (Adhikary et al., 2005) and Fbw7 (see below). 
Skp2 is an F-box protein and mediates ubiquitination by binding two regions in Myc (amino 
acids 129-147 [MB2] and 379-418). A Luciferase reporter assay revealed that Skp2 
stimulated the activity of the α-prothymosin (a Myc target gene) promoter as efficiently as 
Myc alone and overexpression of both proteins increased the activity even further (von der 
Lehr et al., 2003). Skp2 was also able to activate endogenous Myc targets and this activation 
was Myc dependent. This suggests that activation of Myc target genes correlates with 
ubiquitination of Myc. 
The E3 ubiquitin ligase HectH9 site-specifically ubiquitinates Myc in vitro and a mutation of 
six lysine residues in the centre of Myc reduced ubiquitination in transient assays. Moreover, 
 
 
 21 
inhibition of HectH9 was shown to impair gene activation by Myc (Adhikary et al., 2005). 
Miz-1 was shown to antagonize the ubiquitination of Myc by HectH9. 
 
Transcriptional repression by Myc 
 
Myc is also capable of target gene repression by different mechanisms, one of which involves 
the transcriptional activator Miz-1. Myc causes trans-repression of Miz-1 target genes by 
direct interaction with Miz-1 (reviewed by Wanzel et al., 2003). The CDK inhibitor p15 INK4B 
is upregulated upon binding of a Miz-1-p300 complex. The Myc-Max complex directly binds 
to Miz-1 and prevents activation of p15INK4B by competing with p300 for the binding site in 
Miz-1 (Staller et al., 2001).  
If DNA damage occurs p53 will be activated (by stabilization of the protein) and the affected 
cells will be stalled at the G1/S phase transition. P53 induces PUMA and other pro-apoptotic 
factors and p21Cip1, resulting in apoptosis or cell cycle arrest. Myc repression of p21Cip1 was 
shown to influence DNA damage response by flipping the choice from cytostasis towards 
apoptosis by direct interaction with Miz-1 at the p21Cip1 promoter and thus preventing the 
inhibition of cell death by p21Cip1 (Seoane et al., 2002). P21Cip1 and p15INK4B do not contain 
a sequence specific E-box, consistent with the observation that repression by Myc influences 
a different set of target genes than activation (Seoane et al., 2002; Staller et al., 2001). Hence, 
Myc can activate and repress target gene expression by direct interaction with other co-
factors. 
 
Stabilization of Myc 
 
GSK3/FBW7 
 
Different serine/threonine-directed-kinases were shown to directly phosphorylate distinct sites 
in the c-Myc protein. Glykogen synthase kinase 3 (GSK3) phosphorylates T58 in the Myc N-
terminus (reviewed in Hann, 2006). This phosphorylation requires a previous phosphorylation 
at S62 by RAS-activated pathways or by Cdk1 (Lutterbach and Hann, 1994; Sears et al., 
2000). The ubiquitin ligase Fbw7 was shown to depend on phosphorylation of T58 to 
ubiquitinate c-Myc (Welcker et al., 2004). Fbw7 is mutated in many human epithelial cancers 
and this loss of Fbw7 is thought to increase tumourigenesis by stabilizing Myc. Thus, 
phosphorylation of Myc modulates Myc`s biological activity. 
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Myc in flies: The dMyc protein 
 
In contrast to humans, flies carry only one Myc, Max and Mxd//Mnt homologue each, dMyc, 
dMax and dMnt (Gallant et al., 1996; Loo et al., 2005; Steiger et al., 2008). The first Myc 
mutant of any organism was found in the 1930s in Drosophila (Bridges, 1935). This mutation 
was called diminutive for its small body and bristle size and could be mapped in 1996 to the 
dmyc gene (Gallant et al., 1996; Lindsley and Zimm, 1992). The dMyc-dMax heterodimer 
binds canonical E-box sequences to activate the transcription of target genes and the dMax-
dMnt complex antagonizes this function (Gallant et al., 1996; Loo et al., 2005). 
In contrast to mammals, the N-terminus of dMyc in not very well conserved but it contains a 
well-conserved DCMW motif in MB2. Moreover, a centrally located PEST region and a b-
HLH-LZ in the C-terminal part of the protein are conserved (reviewed in Gallant, 2006). 
Importantly, the c-Myc and dMyc proteins are partially interchangeable. On the one hand, 
dMyc can rescue proliferation defects in mouse embryo fibroblasts that lack c-myc (Trumpp 
et al., 2001), transform rat fibroblasts when expressed along with human RasV12 (Schreiber-
Agus et al., 1997) and substitute for c-Myc in transactivation assays in human cell culture 
(Gallant et al., 1996). On the other hand, c-Myc S and c-Myc 2 rescued a lethal dmyc allele to 
adulthood (Benassayag et al., 2005). 
This shows that the Myc, Max and Mxd/Mnt proteins are functionally conserved from 
humans to flies, although the network is less complex, since only one homologue of each 
component exists in flies. 
Two pathways controlling the expression of Myc in Drosophila have been identified so far: 
Wingless/Wnt and Decapentaplegic/BMP/TGF-β (reviewed by de la Cova and Johnston, 
2006). Wingless was for example shown to repress dMyc in the zone of non-proliferating 
cells in the Drosophila wing imaginal disc (reviewed by de la Cova and Johnston, 2006). 
 
Biological functions of dMyc  
 
Weak hypomorphic dmyc alleles (dmP0, dm1) have a small body size, thin bristles and a 
prolonged development. In contrast to c-Myc mutants in vertebrates, those mutants only 
contain smaller, but not fewer, cells (Johnston et al., 1999; Trumpp et al., 2001). Among the 
dMyc target genes one can find ribosomal protein genes. Ribosomal gene mutations (so-
called Minute mutations) lead to a smaller body size as a consequence of smaller cells, which 
is comparable to the phenotype of dmyc mutant alleles. Moreover, Minute mutants exhibit a 
thin bristle phenotype comparable to dmyc mutants. Conversely, nucleolar size is enhanced 
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upon overexpression of dMyc, indicating that ribosomal biogenesis is enhanced (Grewal et 
al., 2005). These observations suggest a link between dMyc activity, cell growth and 
ribosomal proteins. 
Overexpression of dMyc in clones of wing imaginal discs resulted in an increase in cell size 
(by accelerating cellular growth) and in a shortened G1 phase of the cell cycle. Conversely, 
imaginal disc cells mutant for dmyc are reduced in size and have a prolonged G1 phase (Hulf 
et al., 2005; Johnston et al., 1999). Endoreplication, a process where DNA replication takes 
place in the absence of mitosis, resulting in enlarged nuclei, is occurring in the Drosophila fat 
body and salivary glands. This process is responsible for the massive growth of larvae during 
their development, since endoreplicating tissue makes up the major part of those larvae. 
Overexpression of dMyc in this tissue increases the size of endoreplicating cells (Pierce et al., 
2004). This indicates that larval growth and endoreplication are controlled by dMyc. 
Like dmyc mutants, dmax mutants are small, however the phenotypes are less severe (Steiger 
et al., 2008). This observation led to the question whether there are dMax-independent 
functions for dMyc. Indeed, not all biological functions of dMyc fully require dMax, like cell 
competition, endoreplication and the regulation of Pol III transcribed genes (Steiger et al., 
2008). 
The only member of the Mxd//Mnt family of Myc antagonists was called dMnt since it is 
most similar to Mnt regarding its size and structure. In contrast to an mnt knock-out in mice, a 
dmnt mutation in flies is viable; the mutant flies have larger cells and are bigger (Loo et al., 
2005). DMnt was also shown to antagonize larval growth and endoreplication in the 
developing larvae (Pierce et al., 2004). Thus, dMyc, dMax and dMnt are required for proper 
regulation of cell and organismal size in vivo. 
 
Transcriptional targets of dMyc  
 
With the DamID technique, a protein of interest is tethered to Escherichia coli DNA adenine-
methyltransferase (Dam). The Dam fusion will bind binding sites of the protein of interest in 
vivo, which in turn leads to local methylation. These sites can be mapped afterwards (van 
Steensel and Henikoff, 2000). This DamID technique was used to identify genomic binding 
sites of dMyc, dMnt and dMax in Drosophila KC cells. The methylated DNA fragments were 
analyzed by microarrays, which revealed that about 15% of the Drosophila coding regions 
was bound collectively by the 3 proteins. Those binding regions correlated with the presence 
of E-boxes, CG-repeats and DNA Replication Elements (DRE). Binding of dMyc to genomic 
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sites was significantly increased when dMax was expressed at high or low levels indicating 
that dMyc is very sensitive to dMax levels (Orian et al., 2003). 
Microarray analysis revealed that upon downregulation of dmyc in Drosophila Schneider 2 
cells by RNAi about 30 genes were significantly downregulated at 3 different time points 
after addition of dsRNA (Hulf et al., 2005). Those genes were predominantly involved in 
ribosome biogenesis, rRNA processing or RNA binding like fibrillarin or CG1542. A large 
number of those genes were also shown to be upregulated after dMyc overexpression. 
Moreover, those target genes contained specific Myc binding sites (E-boxes) that are located 
within the first 100 nucleotides after the transcription start site (Hulf et al., 2005). Those 
microarrays did not include RNA Polymerase I & III transcribed genes, which were later also 
shown to be target genes of Myc in mammals (Pol I & III) and Drosophila (Pol I) (reviewed 
by Gomez-Roman et al., 2006). During larval development dMyc controls ribosomal 
biogenesis and Pol I transcribed rRNA genes (Grewal et al., 2005). 
Moreover, qRT-PCR experiments were performed on larvae overexpressing dMyc in the 
absence of dmax. The RNA polylmerase III transcribed gene 5S RNA and tRNALeu were 
strongly upregulated in those larvae (Steiger, 2007, PhD thesis). Thus, dMyc controls the 
expression of a wide variety of target genes, which account for Myc`s potential to induce 
growth. 
 
Stability of dMyc 
 
Moberg et al. (2004) found that Archipelago (Ago), an F-box component of SCF-ubiquitin 
ligase and the Drosophila ortholog of a human tumour suppressor (Fbw7), negatively 
regulates the levels and activity of dMyc protein in vivo. The interaction between c-Myc and 
Fbw7 is mediated by the WD repeat of Fbw7 and a conserved motif whose central feature is 
L-L-T-P-P in c-Myc. These authors also found 7 degenerated copies of this motif in dMyc 
and the copy with the best fit to the consensus was located within MB3. Therefore, there may 
be a connection between ubiquitination and degradation of dMyc and MB3. 
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Myc in tumours: Approaches for therapy 
 
Myc controls cellular processes like cell growth and proliferation, apoptosis, cell cycle 
progression or differentiation. Thus, it is not surprising that Myc needs to be tightly regulated 
by external signals. Misregulation of Myc contributes to tumourigenesis, e.g. upon mutations 
in the pathways that control Myc (such as the Wg pathway). Such mutations lead to 
uncontrolled cell proliferation, apoptosis or independence of growth factors. 
Myc`s involvement in human neoplasia was first shown by the observation that c-myc mRNA 
and protein is constitutively overexpressed in Burkitt`s lymphoma. This is caused by a 
chromosomal translocation that brings the immunoglobulin enhancer close to c-myc 
(reviewed in Vita and Henriksson, 2006). Since then Myc was found to be frequently 
deregulated in many types of human cancers. The chromosomal aberrations that lead to such 
tumours are not only translocations, but also gene amplification or point mutations (reviewed 
by Vita and Henriksson, 2006). 
Since elevated Myc levels contribute to tumourigenesis, the question arose whether one could 
specifically inactivate Myc in the affected cancer cells. Myc inactivation in tumours results in 
proliferative arrest, differentiation and apoptosis, as shown by conditional transgenic mouse 
models (Arvanitis and Felsher, 2006). However, upon reactivation tumourigenesis is rapidly 
restored in some cases. Moreover, by additional genetic events tumours can become 
independent of Myc overexpression (Arvanitis and Felsher, 2006). 
Although drugs that specifically target Myc could act on a wide variety of human cancers like 
haematological malignancies (e.g. Burkitt`s lymphoma, B-cell acute lymphocytic leukaemia) 
and solid tumours (e.g. breast cancer, melanoma, prostate caner), up to date there are no such 
drugs available. In part, this may be because Myc is a nuclear transcription factor lacking 
specific enzyme activity. Nevertheless, there are different strategies for targeting Myc in 
tissue culture cells. Antisense oligonucleotides and RNAi silence myc gene expression (Harel-
Bellan et al., 1988; Wang et al., 2005) and small molecule inhibitors disrupt Myc/Max 
heterodimers, block interaction with co-factors, modulate the function of key target genes or 
affect Myc protein stability (Berg et al., 2002; Sundberg et al., 2006). We try to understand 
Myc functions in vivo, by using mutations to get a better understanding on how Myc controls 
cell proliferation, cell growth, apoptosis and differentiation. On the basis of this research an 
optimal drug might be established to control Myc induced cancers in humans. 
 
 
 26 
Specific Aims of the project 
 
Mutational analysis of dMyc protein in vivo (Chapter 1) 
  
The aim of this project was to analyse the specific roles for the N-terminus as well as MB2 in 
vivo with regard to some biological aspects of Myc in tissue and in a living organism. 
Defining the function of the less understood MB3 was also of interest to this project. 
For this purpose we used the model organism Drosophila to analyse effects of different dMyc 
mutants in a developing animal under controlled conditions. Conserved domains of Myc were 
either mutated (dMycMB2A) or deleted (dMycΔN, dMycΔMB2, dMycΔMB3) and the 
resulting proteins analysed with regard to their effects on cell size, cell number and apoptosis. 
A deletion of the N-terminal domain in Myc completely abolished Myc`s biological activity. 
Surprisingly, mutation of MB2 only weakened, but did not fully inactivate dMyc function, 
such that an MB2-mutant form of dMyc could rescue the survival of a sizeable fraction of 
dmyc-null mutant flies. Transactivation, and the abilities to induce cell growth and apoptosis 
were only slightly affected by this deletion. Thus, the N-terminal part seems to be essential 
for all of dMycs biological functions and MB2 is important, but not essential, for all dMyc 
functions in vivo. 
A special point was to analyse the functions of the highly conserved acidic domain (MB3), 
which is only poorly understood. We thought that such a highly conserved domain must have 
a specific function. We could show that a deletion of this acidic region stabilized the protein. 
Moreover, upon overexpression of dMycΔMB3 apoptosis was strongly enhanced. 
Interestingly, MB3 seems to be important for the activation of endogenous targets of dMyc 
like RNA Polymerase III transcribed genes. In summary, MB3 destabilizes dMyc and reduces 
some of Myc`s activities (apoptosis, growth) but not all (transactivation). 
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In vivo mutagenesis screen for dMyc co-factors (Chapter 2) 
 
The aim of this project was to identify yet unknown dMyc co-factors in vivo. 
Flies carrying the hypomorphic myc allele dmP0 are normally patterned and display only 
moderate growth defects: Very rarely they also show an aberrant eye morphology (<1 fly in 
1000). Experiments with Pontin, a dMyc co-factor also known as RUVBL1 (Tip49) showed 
that the eye is particularly sensitive to a reduction in dMyc activity and that a transcriptional 
co-factor complex containing Pontin is critically required for dMyc function in the eye 
(Bellosta et al., 2005). 
Encouraged by the results with Pontin, we carried out a large-scale loss-of-function 
mutagenesis screen to identify Pontin-like co-factors for dMyc. In parallel, the publicly 
available Exelixis and Drosdel collections of large genetically isogenic deletions were tested 
for interaction with dMyc. Since the breakpoints of those deletions are molecularly 
characterized, this facilitates the identification of genes of interest. So far we focused on one 
gene: chinmo (CG31666, rm, chnöpfli), which was found in both screens. Chinmo not only 
interacted genetically with dmyc but the Chinmo protein also interacts physically with dMyc. 
Moreover, Myc was dependent on Chinmo to induce cell growth in clones of wing imaginal 
discs. Since transactivation of target genes was enhanced upon Chinmo and dMyc 
overexpression, we think that Chinmo acts as a co-activator of Myc. 
 
 
 28 
 
  
  
  
 Chapter I 
 
 
 
 
 
 
 
 
Mutational analysis 
of dMyc protein in vivo 
 
 
 
 29 
The conserved Myc Box 2 and Myc Box 3 regions are important, 
but not essential, for Myc function in vivo 
 
D.Schwinkendorf & P.Gallant 
 
 
 
Manuscript 
 
 
 30 
The conserved Myc Box 2 and Myc Box 3 regions are important, 
but not essential, for Myc function in vivo 
 
 
 
 
D.Schwinkendorf 2 & P.Gallant1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zoologisches Institut,  
Universität Zürich,  
Winterthurerstrasse 190,  
CH-8057 Zürich,  
Switzerland 
 
 
 
 
1 author for correspondence:  
gallant@zool.uzh.ch, +41446354812 
 
2Molecular Life Sciences 
University of Zurich 
Winterthurerstrasse 190 
CH-8057 Zurich 
Switzerland 
 
 
 31 
Abstract 
 
Myc proto-oncoproteins are important regulators of growth and proliferation in development. 
Their functions have been evolutionarily conserved from insects to vertebrates, although the 
sequence conservation is limited to a few short domains. Here, we analyse the role of the 
most highly conserved domains, called Myc Boxes 2 and 3 (MB2 and MB3), and of the 
weakly conserved N-terminus for the biological activity of the single Myc protein in 
Drosophila, dMyc, in an animal in vivo. We find that a dMyc mutant lacking the N-terminus 
retains very little activity, even though this region does not affect dMyc protein levels. In 
contrast, deletion of MB3 stabilizes dMyc protein and increases its ability to promote growth 
and apoptosis, but at the same time also impairs Myc`s ability to activate RNA Polymerase 
III. Finally, mutation of the MB2 reduces transcriptional output and the biological activities of 
dMyc. Surprisingly though, dMyc without MB2 retains enough activity to partially rescue the 
lethality of a dmyc null mutation. Thus, although MB2 and MB3 are highly conserved in 
evolution, loss of either domain has comparatively mild consequences on Myc activity. 
 
Keywords: growth, apoptosis, transcription, proteolysis 
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Introduction 
 
Myc has been identified as a proto-oncogene that is frequently mutated and overexpressed in 
human and animal cancers (reviewed by Oster et al., 2002). During normal development and 
tissue homeostasis, Myc controls several cellular processes, most prominently growth, 
proliferation and apoptosis (de la Cova and Johnston, 2006; Pirity et al., 2006). These 
different activities of Myc have been attributed to its ability to stimulate or repress the 
transcription of many target genes (reviewed by Amati et al., 2001; Dang et al., 2006; 
Grandori et al., 2000). Myc is a rather atypical transcription factor, though, in that it controls a 
very large number of targets (up to 15% of all genes have been proposed to be modulated by 
Myc proteins; Fernandez et al., 2003; Orian et al., 2003), including genes transcribed by RNA 
Polymerases I & III. However, most of its targets are only moderately affected by Myc 
(reviewed by Dang et al., 2006). Experiments using chromatin immunoprecipitations 
followed by microarray analysis (ChIP-chip) even extrapolated that 25’000 genomic regions, 
many of which intergenic, are bound by c-Myc in human cells (Cawley et al., 2004; although 
these results were later disputed by Guccione et al., 2006). Some of these genomic targets 
may also reflect a transcription-independent role for Myc in the control of DNA replication 
that was recently described (Dominguez-Sola et al., 2007). 
To molecularly understand how Myc controls its target genes and what might distinguish Myc 
from other transcription factors, several structure/function analyses of Myc have been carried 
out. Myc`s best understood domain, and the only one for which structural information is 
available (Nair and Burley, 2003), is the C-terminal basic-helix-loop-helix-leucine zipper 
region (bHLH-LZ) which serves as a dimerisation interface with a protein called Max 
(Blackwood and Eisenman, 1991) and also mediates the contact of Myc:Max heterodimers 
with DNA. In addition, several other proteins have been shown to contact this C-terminus, 
such as Miz-1 (see Cowling and Cole, 2006 for a recent review of Myc-interacting proteins; 
Peukert et al., 1997). This region is generally assumed to be essential for all of Myc`s 
activities, although recent reports suggest the existence of some C-terminus independent 
functions of Myc (Cowling and Cole, 2007; Steiger et al., 2008).  
Myc`s N-terminal 143 amino acids contain a transcriptional regulatory domain (Kato et al., 
1990) that interacts with different co-factors, such as TRRAP, a component of several histone 
acetyltransferase (HAT) complexes (McMahon et al., 1998), the STAGA HAT (Liu et al., 
2003; Liu et al., 2008; McMahon et al., 2000), the DNA helicases Tip48 and Tip49 which 
also belong to different HAT and chromatin remodelling complexes (Wood et al., 2000), and 
the elongation factor P-TEFb (Eberhardy and Farnham, 2002). Accordingly, a version of c-
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Myc that lacks the first 100 amino acids is inefficient in trans-activating its target genes (Hirst 
and Grandori, 2000; Spotts et al., 1997; Xiao et al., 1998), and it is unable to transform 
primary cells in culture (Xiao et al., 1998) or promote cell cycle re-entry of serum-starved 
fibroblasts (Hirst and Grandori, 2000). Surprisingly, though, such a truncated c-Myc protein 
retains substantial biological activity: it induces apoptosis in response to limitation of survival 
factors (Xiao et al., 1998), stimulates the rate of proliferation of exponentially growing 
fibroblasts (Hirst and Grandori, 2000), even in the complete absence of endogenous c-Myc 
(Xiao et al., 1998), and it can rescue a lethal mutation of the only Drosophila myc gene, dmyc, 
to viability (Benassayag et al., 2005). 
These properties contrast with those of a short motif called Myc Box 2 (MB2) that is located 
between amino acids 128 and 143 in human c-Myc. The MB2 sequence is unique to Myc and 
evolutionarily highly conserved in all Myc proteins, down to invertebrates (reviewed in 
Gallant, 2006). Elimination of MB2 blocks or severely impairs all of Myc`s biological 
activities that have been tested in cultured cells: the ability to promote cellular proliferation 
(Conzen et al., 2000; Hirst and Grandori, 2000; Kenney et al., 2003; Lee et al., 1997), 
apoptosis (Conzen et al., 2000; Cowling et al., 2006; Dugan et al., 2002; Evan et al., 1992; 
Oster et al., 2003), transformation (Brough et al., 1995; Conzen et al., 2000; Cowling et al., 
2006; Li et al., 1994; McMahon et al., 1998; McMahon et al., 2000; Nikiforov et al., 2002; 
Oster et al., 2003; Sarid et al., 1987; Stone et al., 1987), and block differentiation (Freytag et 
al., 1990a). Furthermore, an MB2-mutant Myc very inefficiently rescues the proliferation 
defect of rat fibroblasts lacking endogenous c-Myc (Bush et al., 1998; Nikiforov et al., 2002; 
Oster et al., 2003; Xiao et al., 1998). The MB2 motif is required for the efficient interaction 
with several co-factors such as TRRAP and associated HATs (Bouchard et al., 2001; Frank et 
al., 2001; McMahon et al., 1998; Nikiforov et al., 2002), the HAT complex component 
BAF53 (Park et al., 2002), TIP48 & TIP49 (Wood et al., 2000), Skp2 (Kim et al., 2003; von 
der Lehr et al., 2003), and for the stimulation of pre-mRNA capping (Cowling and Cole, 
2007). Nevertheless, it has been shown that a Myc mutant lacking MB2 still efficiently 
activates the expression of some target genes and artificial reporters (Bello-Fernandez et al., 
1993; Brough et al., 1995; Kato et al., 1990; Lee et al., 1997; Li et al., 1994; Nikiforov et al., 
2002; Xiao et al., 1998), although many targets are only poorly activated by such a protein 
(Bouchard et al., 2001; Conzen et al., 2000; Cowling et al., 2006; Cowling and Cole, 2007; 
Hirst and Grandori, 2000; Kenney et al., 2003; Nikiforov et al., 2002). Such a MycΔMB2 
mutant also fails to repress the genes that are normally down-regulated by wildtype Myc (Lee 
et al., 1997; Li et al., 1994), including the c-myc locus itself (Bush et al., 1998; Oster et al., 
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2003; Penn et al., 1990). Importantly, the biological function of the MB2 cannot be replaced 
by the strong transactivation domain of the viral transcription factor VP16 (Brough et al., 
1995), confirming that transcriptional activation is not the only job for this domain that is so 
important for the normal function of Myc. 
Much less is known about the central 240 amino acids of Myc. This region is less conserved, 
with the exception of a motif called Myc Box 3 (MB3) that is found in all Myc proteins from 
insects to vertebrates (Cowling and Cole, 2006; note that the term "Myc Box 3" has been 
applied to a different region by Herbst et al., 2005). Although MB3 resembles a PEST 
domain, and hence might be expected to contribute to the degradation of Myc protein, its 
deletion does not affect Myc`s half-life (Herbst et al., 2004); this region also does not seem to 
contribute to transcriptional regulation by Myc (Kato et al., 1990). To date, MB3 has only 
been shown to be required for Myc`s ability to transform certain cell types (the rat fibroblast 
line Rat1a and primary chicken hematopoietic cells; Biegalke et al., 1987; Heaney et al., 
1986; Stone et al., 1987). However, given its high evolutionary conservation, we consider it 
likely that MB3 fulfils some additional essential functions that may not be evident in cultured 
cells in vitro - and the same might possibly hold true for other conserved domains as well.  
Therefore, we set out to address the importance of the conserved domains for Myc function in 
vivo in the context of intact tissues. We used Drosophila melanogaster, which contains a 
single Myc gene (dmyc) that is functionally interchangeable with its vertebrate counterparts 
(Benassayag et al., 2005; Gallant et al., 1996; Schreiber-Agus et al., 1997; Trumpp et al., 
2001). Mutations in dmyc impair growth, such that flies carrying hypomorphic dmyc alleles 
(e.g. dmP0) are delayed in their development and eclose as small adults (Johnston et al., 1999), 
whereas dm4 mutant flies (null for dmyc) fail to grow as larvae and die within a few days of 
hatching (Pierce et al., 2008b; Pierce et al., 2004; Steiger et al., 2008). Conversely, 
overexpression of dMyc promotes cellular growth (Johnston et al., 1999), endoreplication 
(Maines et al., 2004; Pierce et al., 2004), and apoptosis (De La Cova et al., 2004; Montero et 
al., 2008b). In the present study, we expressed wildtype and mutant forms of dMyc (carrying 
mutations in MB2, MB3, or the N-terminus) in Drosophila S2 cells or in vivo. These 
experiments revealed a strong requirement for the N-terminus for all dMyc-dependent 
activities. Surprisingly, mutation of MB2 only weakened, but did not fully inactivate dMyc 
function, such that an MB2-mutant form of dMyc could rescue the survival of a sizable 
fraction of dmyc-null mutant flies. Finally, deletion of MB3 stabilized dMyc protein, and 
increased several of dMyc`s activities, but not its efficiency of transactivation.  
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Results 
 
MB3 contributes to transactivation and to dMyc degradation 
 
To investigate the in vivo roles of the most highly conserved domains of dMyc, we mutated or 
deleted MB2, MB3 and the entire N-terminus (Fig. 1A). The different mutants, as well as 
wildtype dMyc were tagged with a triple HA-epitope at their N-termini and cloned under the 
control of GAL4-activatable UAS-elements. For transient expression in Drosophila S2 cells, 
these constructs were then co-transfected with a GAL4-expression plasmid, yielding 
comparable levels of proteins of the expected sizes (Fig. 1B). Upon transient co-transfection 
with a GAL4-expression plasmid in Drosophila S2 cells, all constructs produced comparable 
levels of proteins of the expected sizes (Fig. 1B). 
The same UAS-plasmids were also used to generate transgenic flies. The transgenes that were 
used in this and all following experiments were generated with the help of the ΦC31 system 
for targeted transgenesis (Bischof et al., 2007; Groth et al., 2004; Venken et al., 2006). With 
this method, all constructs are integrated at the same, molecularly defined, genomic region, 
thus equalizing mRNA expression levels for all mutants and eliminating potentially 
confounding integration site effects. Indeed, all dMyc proteins accumulate to similar levels 
(Fig. 1C), with the exception of the more stable dMycΔMB3 protein. 
Although dMycΔΜΒ3 accumulated to somewhat higher levels (Fig. 1B); this difference was 
more pronounced upon stable expression of the different dMyc proteins in transgenic flies 
(Fig. 1C). These increased levels of dMycΔMB3 are due to a higher stability of the mutant 
protein, as shown in Fig. 1D. When protein synthesis was blocked in S2 cells that ectopically 
expressed different dMyc versions, the wildtype protein disappeared with a half-life of 23±1 
min (Fig. 1D), which is similar to the stability of vertebrate c-Myc (Oster et al., 2002). The 
ΔMB3 mutant had a significantly longer half-life of 49±8 min (average of 3 independent 
experiments; p=0.02), suggesting that MB3 normally contributes to the destabilization and 
proteolytic degradation of dMyc. Although no such role has been described for the vertebrate 
MB3, it should be noted that c-Myc MB3 has only been analysed in one cell line (U2OS 
cells), and that c-Myc domains have been shown to contribute differentially to its degradation 
in different cell types (Herbst et al., 2004). From the data shown in Figs. 1B and C, we deduce 
that MB3 plays a role in dMyc degradation in S2 cells and in vivo. 
To confirm that the conserved domains also have a role in trans-activation in Drosophila (as 
has been extensively shown for Myc`s N-terminus and MB2 in vertebrates – see 
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Introduction), we transfected the different dMyc mutants in S2 cells, together with a plasmid 
coding for Renilla luciferase under the control of the promoter of the dMyc target CG5033 
(Hulf et al., 2005), and with a second plasmid in which firefly luciferase is controlled by a 
mutant derivative of the same promoter that lacks the sole dMyc binding site. Thus, the ratio 
of Renilla to firefly luciferase faithfully reflects dMyc activity, such that RNAi-mediated 
down-regulation of dmyc decreases this ratio by up to 4-fold (Furrer et al., in preparation), 
whereas overexpression of dMycWT increases the ratio by more than 2-fold (Fig. 2A). 
Consistent with published observations for c-Myc MB2, mutation of MB2 reduces the ability 
of dMyc to transactivate this reporter, but does not completely abolish it, whereas the deletion 
of the N-terminus eliminates dMyc`s transactivation potential. Surprisingly, dMycΔMB3 
transactivates the reporter with a similarly reduced efficiency as dMycΔMB2, suggesting that 
MB3 is also required for full transcriptional activation of a dMyc reporter.  
This observation prompted us to investigate the ability of dMycΔMB3 to activate different 
endogenous targets of dMyc. Specifically, we wanted to determine how efficiently the mutant 
protein controls its target genes in vivo, in the absence of endogenous dMyc. The transgenes, 
that were used in this and all following experiments, were generated with the help of the 
ΦC31 system for targeted transgenesis (Bischof et al., 2007; Groth et al., 2004; Venken et al., 
2006). With this method, all constructs are integrated at the same, molecularly defined, 
genomic region, thus equalizing mRNA expression levels for all mutants and eliminating 
potentially confounding integration site effects. Indeed, all dMyc proteins accumulate to 
similar levels (Fig. 1C), with the exception of dMycΔMB3, which is more stable than 
dMycWT (Fig. 1D). To assay their effects on target gene expression, the dMycWT and 
dMycΔMB3 transgenes were first combined with a chromosome carrying the dmyc null allele 
dm4, a “tub-FRT-dMyc-FRT-GAL4” transgene (which drives ubiquitous expression of a 
dMycWT cDNA and thereby fully rescues the lethality of the dmyc mutant; Bellosta et al., 
2005) and a hs-FLP construct. Following a massive heat-shock of 2 hours at 37°, virtually all 
cells have eliminated the rescuing dMyc cDNA and express GAL4 instead (Hulf et al., 2005), 
which in turn drives the expression of the UAS-controlled dMycWT or dMycΔMB3 
transgenes. Eight hours later (before any overt signs of apoptosis – see below), total RNA was 
isolated and analysed for the abundance of dmyc and some of its targets. As shown in Fig. 2B, 
by this time the level of endogenous dmyc mRNA has dropped by 4-fold (and the same is 
presumably also true for dMyc protein, given its short half-life). As a consequence, the dMyc 
targets CG5033, nnp1 (both controlled by single dMyc-dependent E-boxes and transcribed by 
RNA Pol II; Hulf et al., 2005) and tRNALeu (activated via a dMax-independent pathway and 
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transcribed by RNA Pol III; Steiger et al., 2008) are all clearly reduced in abundance 
(compare “control” samples, that have not been subjected to a heat-shock, with “-“ samples, 
that do not express any dMyc transgene). Both dMycWT and dMycΔMB3 flies overexpress 
the transgenic dmyc mRNA to the same level, but the latter flies contain significantly lower 
amounts of the dMyc target nnp1 (p<0.01) and comparable amounts of CG5033 – even 
though the mutant dMyc protein is likely to be present at higher concentrations. dMycΔMB3 
is even more impaired in activating the Pol III targets tRNALeu and snoRNA U3. These results 
are consistent with a role for MB3 in controlling transactivation, and they suggest that this 
domain is particularly important for the activation of Pol III. The molecular basis for this 
effect is currently unclear; the only Myc-interacting protein that is currently known to be 
specifically involved in Pol III-dependent transcription, Brf (Gomez-Roman et al., 2003; 
Steiger et al., 2008), binds with similar efficiency to both dMycΔMB3 and dMycWT (data not 
shown).  
 
Overexpression of dMyc mutants in vivo 
 
Myc proteins are important both for normal development and tissue homeostasis, when they 
are expressed at physiological levels, and in the etiology of tumours, where they are 
frequently overexpressed. While Myc`s physiological activities can account for much of its 
potency as an oncoprotein, it is conceivable that Myc takes on additional, qualitatively 
different, functions when expressed at supra-physiological levels. For these reasons, we 
wanted to investigate the activities of our dMyc mutants first in mere overexpression 
situations, and second in the presence of hypomorphic or amorphic dmyc alleles, where the 
ability of the mutant proteins to substitute for endogenous dMyc could be probed. 
As a first step, we analysed the ability of the different dMyc mutants to promote growth upon 
overexpression. It has previously been shown that overexpression of dMycWT under the 
control of GMR-GAL4 strongly increases the size of adult ommatidia (Montero et al., 2008b; 
Secombe et al., 2007; Steiger et al., 2008); since this driver expresses GAL4 in the eye 
imaginal discs from the late 3rd larval instar on, it mainly influences the final growth and 
differentiation phase of the eye cells, but not the proliferation of their precursors and the final 
number of ommatidia. Consistent with their effect on the dMyc reporter in S2 cells, the MB2 
mutants are still able to promote growth, albeit to a lesser extent than dMycWT, and dMycΔN 
is inactive in this assay (Figs. 3A, B). Surprisingly, dMycΔMB3 increases ommatidial size 
more than dMycWT and additionally induces considerable roughness of the eye. Such a 
morphology (caused by a combination of excessive growth and apoptosis) is also observed 
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when dMycWT is expressed at higher levels (Steiger et al., 2008), indicating that dMycΔMB3 
is more active than dMycWT in this assay (which contrasts with the situation in S2 cells). 
Most likely, this increased activity is due to the higher levels to which dMycΔMB3 
accumulates. When dMyc degradation is reduced, by heterozygosity for the F-box protein 
Archipelago/Fbw7, which has been shown to control dMyc proteolysis (Moberg et al., 2004), 
dMycWT increases ommatidial size much more efficiently, virtually to the same extent as 
dMycΔMB3 (in an ago/+ background, the difference between these two proteins is not 
statistically significant; Fig. 3C). Since the effect of dMycΔMB3 is only marginally enhanced 
by the ago mutation, this further suggests that this mutant is not further stabilized, and hence 
that the Ago-dependent dMyc-ubiquitination and -degradation requires MB3. 
The different dMyc mutants show similar growth-promoting abilities when over-expressed 
under the control of ap-GAL4 in the dorsal compartment of wing imaginal discs. The 
resulting size difference between the dorsal and the ventral compartments results in a 
moderate (ΔMB2, MB2A; Fig. 3D3, 4) or strong (WT, Fig. 3D5) bending down of the adult 
wings. dMycΔN again shows no activity (Fig. 3D2), even though this bending provides a very 
sensitive read-out for growth inducers (see Montagne et al., 1999). dMycΔMB3 reveals other 
phenotypes (Fig. 3D6) that can also be observed upon overexpression of a different, stronger 
dMycWT transgene (e.g. dissociation of the dorsal and ventral wing surface, necrotic patches; 
data not shown), and that suggest that the dMyc-induced excessive apoptosis overwhelms its 
growth-promoting ability. Indeed, TUNEL staining of 3rd instar larval wing discs (Fig. 4) 
reveals that all dMyc proteins (except for dMycΔN) induce apoptosis (as previously reported 
for dMycWT; Montero et al., 2008b), but that dMycΔMB3 clearly has the highest activity. 
Thus, like in the eye, dMycΔMB3 is more active than dMycWT. 
The experiments described so far document the effects of the different dMyc mutants on final 
adult tissue size. To demonstrate directly to which extent dMyc proteins promote the rate of 
cellular growth, we expressed the different proteins in clones of cells in wing imaginal discs 
carrying an “act-FRT-stop-FRT-GAL4” cassette, an hs-FLP transgene and a UAS-GFP 
marker. Overexpression clones were induced by a 10’ heat-shock at 37°, which drives the 
expression of FLP recombinase leading to the activation of GAL4 in a few (random) cells of 
the disc, and analysed 73 hours later (after 6 to 7 cell doublings). The co-expressed GFP 
allowed for the identification of the clones; since larval wing discs consist essentially of a 
monolayer of undifferentiated cells, the areas of such clones provide a good measure for their 
volume increase, i.e. their rate of growth. Consistent with published observations (Johnston et 
al., 1999), dMycWT overexpression strongly promotes clonal growth (Figs. 5A, B), and so 
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does dMycMB2A. As expected, dMycΔN does not affect the growth rate of these clones. 
However, dMycΔMB3 significantly reduces clonal area, suggesting that its powerful pro-
apoptotic ability (see Fig. 4) overcomes the proliferative capacity of these clones. 
Taken together, the overexpression studies demonstrate that the N-terminus is essential for 
dMyc`s ability to promote growth, whereas a mutation of MB2 only moderately impairs 
dMyc activity; loss of MB3 increases dMyc protein levels and concomitantly also the 
biological activity of dMyc.  
 
Rescue of dmyc mutant eyes by dMyc protein mutants 
 
Normal eye development requires dMyc, and strong hypomorphic or null alleles of dmyc 
result in smaller eyes, composed of fewer and smaller ommatidia (Bellosta et al., 2005; 
Steiger et al., 2008; see also Fig. 6, below). Therefore the eye constitutes a good organ for 
analysing the normal biological activities of dMyc proteins. To reveal the phenotype of such 
dmyc mutant eyes without lowering dMyc activity in the rest of the body (which would 
interfere with organismal viability), we combined the rescuing transgene “tub-FRT-dMyc-
FRT-GAL4” (described above) with a transgene expressing FLP recombinase under the 
control of the eyeless regulatory region (ey-FLP), such that the dMyc cDNA is “flipped-out” 
in eye precursor cells specifically, starting early in development, and GAL4 is expressed 
instead. The FLP-mediated replacement of dMyc with GAL4 is highly efficient, as shown in 
Fig. 6A, where the flies described above also carried a mini-white gene (conferring red eye 
colour), flanked by two FRT-sites (Brogiolo et al., 2001): only a small patch of ommatidia 
retains the mini-white gene and hence has not expressed sufficient amounts of FLP 
recombinase. This picture also reveals the eye size reduction caused by the loss of dmyc. We 
used this system to express the different dMyc variants in eyes that were wildtype for dMyc, 
or carried the hypomorphic allele dmP0, or the null allele dm4. Importantly, transgene 
expression in this assay is maintained from earliest eye specification to the terminal 
differentiation phase, and therefore affects both the final number and size of the resulting 
ommatidia. 
All dMyc mutants significantly increase ommatidial size as compared to control, with the 
effects being largest in the dm4 background that lack endogenous dmyc altogether, as might be 
expected (Figs 6B, C). Even dMycΔN, which was inactive in all other assays, increases 
ommatidial size by 10% in a dm+ background; the difference to the GMR-driven 
overexpression experiment shown above is presumably due to the different expression 
dynamics of the two GAL4 drivers [GMR is not expressed in all cell types of the 
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differentiating eye (Ellis et al., 1993), but tub should be ubiquitously expressed, and 
furthermore level and duration of GAL4 expression are likely to differ between the two 
systems]. The ΔN mutant also stimulates proliferation and significantly increases the number 
of ommatidia in dm4 mutant eyes (Fig. 6D, compare “-“ and “ΔN”), thus demonstrating its 
activity both during the earlier proliferative and the later differentiation phase. Note that we 
would not expect any dMyc mutant to increase the number of ommatidia in dm+ and dmP0 
eyes, since these genotypes have a wildtype number of ommatidia to start with (Fig. 6D; 
Bellosta et al., 2005) and dMyc overexpression does not increase cell division rates in 
wildtype cells (Johnston et al., 1999). Instead, expression of the other dMyc forms slightly or 
significantly reduces the number of ommatidia in this assay, reflecting the pro-apoptotic 
activity of these proteins (Bellosta et al., 2005). As before, this effect is strongest for 
dMycΔMB3, as can also been seen by the obvious roughness of the eyes expressing this 
mutant (Fig. 6B). Taken together, this experiment confirms the growth- and apoptosis-
promoting capabilities of the different dMyc mutants, and it shows that the dMycΔN form 
also retains some activity.  
 
Organismal rescue of dmyc mutants  
 
As a final, most stringent functional assay we wanted to determine to which extent the 
different dMyc mutants could drive the entire development in the absence of endogenous 
dMyc. For this purpose, we first expressed the transgenes under the control of different 
ubiquitous GAL4 drivers (Table 1). The weak line arm-GAL4 produced no detectable effect 
(lethality or rescue) in any cross, whereas the other GAL4 drivers resulted in excessive 
expression of the dMyc transgenes that killed wildtype (dm+) animals, and they did not rescue 
different lethal dmyc alleles (dmPL35, dmPG45 and dm2 are hypomorphic, and dm4 is a null). 
Partial rescue of lethality was only observed in three combinations: when expressed under the 
control of da-GAL4, dMycΔN rescued dmPL35, and the enhancer trap allele dmPG45 (which is 
both mutant for dmyc and expresses GAL4 in a dmyc-like pattern; Benassayag et al., 2005) 
was rescued by both dMycΔN and dMycMB2A. This is the second observation to 
demonstrate that the ΔN mutant retains some biological function in vivo. Note that expression 
of dMycWT under the control of dmPG45 has been reported to cause dominant lethality (i.e. in 
a dmPG45/dm+ background; Benassayag et al., 2005), presumably because the GAL4/UAS 
system amplifies the transcriptional output of the dmyc locus to lead to excessive expression 
of the UAS-transgene. An analogous amplification explains the lethality of a dMycWT 
transgene when expressed under the control of a tub-GAL4 driver, whereas a transgene 
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expressing dMycWT directly under tubulin control causes no harm in flies and even rescues a 
dmyc null mutant (see above). Such considerations prompted us to generate a second series of 
transgenes, in which the expression of the different dMyc mutants is controlled directly by the 
tubulin regulatory sequences; these transgenes were integrated in the same chromosmal 
location as before using the ΦC31 system. All transgenes could be established, although tub-
dMycΔMB3 showed some dominant lethality in a dm+ background and could not be 
maintained as a homozygous line. Both dMycWT and dMycΔMB3 rescued the lethality of 
dm4 mutant flies (Fig. 7A, B), although the resulting adults were smaller than control (Fig. 
7B, C). Expression of dMycΔN did not lead to any escapers, but much to our surprise, a 
substantial fraction of dMycΔMB2 expressing dm4 flies (15% of the expected number) 
survived development when 2 copies of the transgene were present and enclosed as normally 
patterned adults (Fig. 7). This fraction even increases to around 39% when the dMyc 
antagonist dMnt is simultaneously mutated, i.e. in a dm4 dmnt1 background, where dMyc 
targets have been shown to be partially derepressed (Pierce et al., 2008b). Thus, in the 
absence of any endogenous dMyc MB2 is not absolutely required to promote the full 
development from egg to adult. 
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Discussion 
 
Myc proteins show a comparatively low overall sequence conservation between the most 
distant known family members from insects and vertebrates, but they all contain a short, 
highly conserved sequence motif, the Myc Box 2 (MB2). The very fact that this domain is 
conserved suggests an indispensable function, and MB2 has indeed been shown to play an 
essential role in different tissue culture based assays. However, the variety of cell types that 
have been tested in tissue culture (most frequently fibroblasts), as well as the types of 
biological read-outs that have been used (typically proliferation, apoptosis or transformation), 
are both limited. As Myc interacts with many different transcriptional co-factors, we 
speculated that the proteins contacting MB2 might be important for the expression of only a 
subset of Myc`s targets, or essential only in certain cell types, or required for only certain 
biological processes. By expressing MB2-mutant forms of Myc in vivo, we exposed the 
proteins to a variety of different contexts. We expected that the mutants would be inactive in 
most situations, but possibly retain some activity in a particular assay. Unexpectedly however, 
MB2 mutants showed an intermediate activity in all our assays (often close to that of 
dMycWT). Most strikingly, dMycΔMB2 was able to rescue mutant animals lacking all 
endogenous dMyc, which would otherwise all have died during development. This finding 
suggests that MB2 does not contribute a qualitatively unique and essential function to Myc, 
but instead may act to enhance Myc`s transcriptional output or modulate it in response to 
external signals. It further implies that no essential co-factor relies on MB2 for its interaction 
with Myc, either because no MB2-interacting protein is essential for Myc function, or because 
all MB2-interacting essential co-factors also contact Myc via additional redundant domains. 
At present we cannot address these possibilities experimentally, since no protein has been 
found to contact MB2 in Drosophila; two candidates we investigated (dGCN5 and 
Tip49/Pontin) bound dMyc independently of the presence of MB2 (data not shown). Thus, we 
can only speculate about reasons for the partial dispensability of MB2; for example, the 
activation of a Myc target that normally relies on an MB2-dependent HAT might be partially 
taken over by an MB2-independent HAT, or such a Myc target gene might instead be 
activated by a histone acetylation-independent process (such as nucleosomal remodelling), or 
other targets might supplant the function of such genes. In either case, our observations 
provide an example of unexpected biological plasticity, in light of the exceptional 
evolutionary conservation of this MB2. 
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By comparison, the elimination of the entire N-terminus has substantially more severe effects. 
Nevertheless, the dMycΔN protein (which corresponds to the naturally occurring c-Myc S 
variant in vertebrates) clearly retains some activity. Similar to human c-Myc S (Benassayag et 
al., 2005), dMycΔN can rescue the lethality of the dmPG45 allele; as dmPG45 is a hypomorphic 
(albeit strong) dmyc allele, some dMyc activity must still be present in these flies and might 
cooperate with dMycΔN in this rescue. However, dMycΔN also significantly enhances the 
size and number of ommatidia that lack dmyc altogether (Fig. 6), demonstrating that this 
mutant has the ability to stimulate cellular growth and proliferation on its own (although, like 
c-Myc S, it cannot induce apoptosis – Fig. 4). This growth effect is comparatively weak and 
not seen in other overexpression experiments, though, essentially confirming studies of 
vertebrate Myc that have assigned an important biological role to this part of the protein. 
A primary goal of our work was to investigate the second highly conserved domain in dMyc, 
MB3. MB3 resembles PEST motifs that control protein degradation, and indeed deletion of 
MB3 stabilizes dMyc; consistent with the increased abundance, expression of dMycΔMB3 
leads to more growth and apoptosis than expression of dMycWT. However, PEST motifs are 
normally similar in their amino acid composition rather than in their exact amino acid 
sequence, suggesting that additional evolutionary constraints are imposed on MB3. One such 
constraint may be found in myc`s genomic structure: in all myc genes MB3 straddles the 
boundary between exons 2 and 3 (Gallant, 2006), and the codons adjacent to the splice site 
may be under selective pressure that has nothing to do with the amino acids they are coding 
for. We favour the converse explanation, though, that the position of the splice sites may have 
been conserved as a consequence of the conservation of the adjacent exonic sequences. In the 
context of our overexpression cDNA`s (that obviously lack the large myc intron 2, and where 
splicing does not occur) the dMycΔMB3 mutant also shows an impairment in transcriptional 
activation towards an E-box dependent reporter in tissue culture cells, and towards RNA Pol 
III dependent endogenous targets in vivo. In many transcription factors, including c-Myc 
(Kim et al., 2003; von der Lehr et al., 2003), protein domains controlling degradation and 
transcriptional activation overlap, and these two processes are functionally coupled, possibly 
to ensure a short half-life of the transcriptionally active protein (Muratani and Tansey, 
2003b). Thus, MB3 might link Myc degradation and its activity, in particular towards certain 
targets. However, at present we cannot exclude the possibility that the control of transcription 
and degradation are two uncoupled activities of MB3, and future experiments will be required 
to address this issue. 
 
 
 44 
Figure legends 
 
Figure 1. Description of dMyc mutants. 
A, schematic representation of the dMyc mutants used in this work. All constructs contain an 
N-terminal triple HA-tag, with the coordinates referring to the untagged dMyc. The MB2 and 
MB3 sequences shown on the top are derived from human c-Myc (upper line) and dMyc 
(lower line); the dots in c-Myc represent a 6 residue acidic stretch lacking in dMyc, and the 
vertical line shows the junction between exons 2 and 3 that is conserved in myc genes. B, 
average ommatidial area (± standard deviation) for the indicated genotypes (corresponding to 
the eyes in panel A), calculated from 20 centrally located ommatidia from at least 5 
independent eyes per genotype. All areas are significantly larger than the corresponding “-“ 
control with p<0.01 (Students t-test), except for “dm+; ΔN” where p=0.03. B, Western blot of 
Drosophila S2 cells transiently transfected with UAS-plasmids coding for the indicated 
HAdMyc variants together with a tub-GAL4 plasmid. The cells were lysed at 48 hours after 
transfection. The same blot was probed with anti-HA antibodies (top panel) to reveal 
HAdMyc and with anti-α-Tubulin antibodies (bottom panel) as a loading control. C, 
expression level of the HAdMyc variants in transgenic flies. Third instar larvae of the 
genotype “y w/Y; tub-HAdMyc” were collected at 5 days of age and processed for Western 
blot. In each lane, the equivalent of 2.2 larvae was loaded. The same blot was probed with 
anti-HA antibodies (top panel) to reveal HAdMyc and with anti-α-Tubulin antibodies (bottom 
panel) as a loading control. The anti-α-Tubulin blot serves as a loading control. D, 
HAdMycWT and HAdMycΔMB3 were expressed in S2 cells as described above. At 48 hours 
after transfection, cycloheximide was added to the cells to a final concentration of 100 µg/ml 
and at the indicated times thereafter cell lysates were prepared and analysed by SDS-PAGE 
and Western blotting using an anti-HA antibody. 
 
Figure 2: Effect of dMyc mutants on target gene expression. 
A, endogenous dMyc was down-regulated with RNAi in S2 cells and the indicated dMyc 
mutants were expressed instead. The graph shows the relative activity of the co-transfected 
luciferase reporter (wildtype reporter divided by mutant reporter), with the relative activity of 
dMycWT set to 100%; shown are the averages (± standard deviations) of 2 independent 
transfections from a representative experiment. B, expression of endogenous dMyc targets in 
dmyc-mutant larvae in response to the indicated transgenes. The dmyc-null mutation was 
exposed, and the transgene expression triggered, by a heat-shock; “control” samples did not 
receive any heat-shock and “-“ did not express any transgene. Shown are the averages (± 
standard deviations) of two biologically independent samples. 
 
Figure 3: Effect of dMyc overexpression on ommatidial size and wing shape. 
A, scanning electron micrographs of representative eyes expressing single UAS-transgenes 
with the indicated dMyc mutants under the control of GMR-GAL4; “-“ eyes express a UAS-
transgene lacking any cDNA. B, average ommatidial area (± standard deviation) for the 
indicated genotypes (corresponding to the eyes in panel A), calculated from 20 centrally 
located ommatidia from 5 independent eyes per genotype. “**” indicates genotypes whose 
ommatidia are significantly larger than “-“ ommatidia with p<0.01. C, analogous experiment 
in flies that are heterozygous for the archipelago alleles ago1 or ago3; the first three values for 
wildtype eyes (labelled +/+) are identical to the corresponding genotypes in panel B. D, 
representative frontal views of adult wings of flies carrying one copy of ap-GAL4 (driving 
GAL4 expression in the dorsal wing compartment) and one UAS-transgene coding for the 
indicated dMyc version, or no cDNA at all (“-“). 
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Figure 4: Induction of apoptosis by overexpressed dMyc.  
TUNEL-staining of third instar larval wing imaginal discs carrying one copy of ap-GAL4 and 
one UAS-transgene coding for the indicated dMyc version, or containing no cDNA at all (“-
“). The TUNEL-positive region in the panel showing a ΔMB3 wing disc provides a good 
reflection of the GAL4 expressing domain. 
 
Figure 5: Stimulation of clonal growth by overexpressed dMyc. 
A, third instar larval wing imaginal discs with typical 73 hour old clones (marked in green) 
expressing GFP and the indicated dMyc variant. Blue colour shows the nuclei stained with 
Hoechst 33342 dye. B, average clonal area from discs corresponding to the genotypes shown 
in panel A. Number of analysed clones (in parentheses the corresponding genotype): 50 (-), 
45 (WT), 42 (ΔN), 53 (MB2A), 40 (ΔMB3). 
 
Figure 6: Effects of continuous dMyc expression on ommatidial size and number.  
A, efficiency of the ey-FLP system. Red ommatidia in either panel retain the “FRT-w+ stop-
FRT” cassette and express the rescuing dMyc cDNA, whereas the white ommatidia lack this 
cassette and the dMyc cDNA, and hence expose the dm4 mutant. Genotypes: 1, “w dm4 tub-
FRT-dMyc stop-FRT-GAL4 ey-FLP/Y; GMR-FRT-w+ stop-FRT-GAL4/+”; 2, “w dm4 tub-
FRT-dMyc y+ stop-FRT-GAL4 hs-FLP/Y; GMR-FRT-w+ stop-FRT-GAL4/+”. B, scanning 
electron micrographs of representative eyes of the indicated genotype. Sex chromosomes are 
“y w tub-FRT-dMyc stop-FRT-GAL4 ey-FLP/Y” (labelled “dm+”), “w dmP0 tub-FRT-dMyc 
stop-FRT-GAL4 ey-FLP/Y” (labelled “dmP0”), “w dm4 tub-FRT-dMyc stop-FRT-GAL4 ey-
FLP/Y” (labelled “dm4”); in addition, these flies carry one UAS-transgene coding for the 
dMyc variant indicated in the picture; “-“ corresponds to a UAS-transgene lacking any cDNA. 
C, average ommatidial area (± standard deviation) for the indicated genotypes (corresponding 
to the eyes in panel B), calculated from 20 centrally located ommatidia from 5 independent 
eyes per genotype. All areas are significantly larger than the corresponding “-“ control with 
p<0.01 (Students t-test), except for “dm+; ΔN” where p=0.03. D, average ommatidial number 
(± standard deviation) for the indicated genotypes (corresponding to the eyes in panel B). 
Asterisks indicate significance of difference to the corresponding “-“ genotype, with p<0.05 
(*) and p<0.01 (**). 
 
Figure 7: Rescue of a dmyc-null mutation by the expression of dMyc protein mutants 
under the direct control of the tubulin-promoter.  
A, dissecting microscope pictures of rescued dmyc-null mutant adult males expressing two 
copies of the indicated transgenes. B, relative survival rate for the indicated genotypes (the 
expected number of “w dm4/Y” or “w dm4 dmnt1/Y” males carrying one or two copies of the 
indicated “tub-HAMycmut” transgenes was calculated from the number of recovered dm4/dm+ 
heterozygous females from the same cross, and set to 100%). For each genotype 300-800 flies 
in total were scored (except for w dm4/Y; tub-HAMycΔMB3/+: 91 flies, w dm4 dmnt1/Y; tub-
HAMycΔN: 64 flies, w dm4 dmnt1/Y; tub-HAMycWT: 229 flies), of which rescued Myc-mutant 
made up one quarter (one eight for the tub-HAMycΔMB3 transgenes). C, average weight of at 
least 13 male flies per genotype (except dm4/Y; tub-HAMycΔMB3/+: 8 flies); the error bars 
indicate standard deviation. The control genotype is “y w”. 
 
Table 1: Ability of dMyc mutants to rescue the lethality of dmyc alleles.  
“yes” indicates that some adult males carrying the dmyc allele indicated in the first column 
plus a single copy of the GAL4 driver shown in the second column and of the UAS-transgene 
listed above the table survived to adulthood; “-“ indicates that no such flies were ever 
observed, and an empty field indicates that the corresponding cross was not done. 
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Materials and Methods 
 
Cloning and expression of dMyc proteins 
 
A cDNA for wildtype dMyc with a triple HA-epitope at its N-terminus (Bellosta et al., 2005) 
was cloned into a pBS-vector carrying a single ΦC31 attB site, 5 UAS repeats, a hsp70 basal 
promoter, the SV40 polyA signal, and mini-white as a marker (Bischof et al., 2007). By site-
directed mutagenesis the following mutant derivatives were created (numbering relative to 
untagged dMyc): dMycΔN: lacking amino acids 1 – 65; dMycMB2A: containing “AAAA” 
instead of “DCMW”; dMycΔMB2: “GP” substituted for residues 68-84; dMycΔMB3: “F” 
substituted for residues 405-422. The same cDNAs were also cloned directly under the 
control of the β-tubulin promoter (see Bellosta et al., 2005) into an analogous pBS-vector 
lacking UAS- and hsp70-sequences. Full sequences are available upon request. 
 
Tissue culture: transfections & biochemistry 
 
Drosophila S2 cells were cultured at 24°C in 1x Schneider`s Drosophila medium 
(Gibco/BRL), supplemented with 10% fetal bovine serum, 1% Penicillin/Streptomycin. To 
assess dMyc stability, 5x106 cells were seeded per well of a 6-well culture plate and 
transfected in 1ml of serum-free medium containing 10µl cellfectin (Invitrogen) and 10µg 
plasmid DNA made up of 5µg tub-GAL4 and 5µg UAS-plasmids; 15-16h later, complete 
medium was added for 48h, before cells were either directly processed for SDS-PAGE or 
cycloheximide (Sigma) was added to 100µg/ml. Cells were harvested at the indicated time 
points and washed with 1xPBS, lysed in Laemmli sample buffer and analysed by SDS-PAGE 
and immunoblotting. Western blots were then either exposed on X-ray films (using multiple 
exposures for each experiment) or scanned with a CCD camera (Fuji LAS-3000). Band 
intensities were determined using ImageJ software, and half-lives calculated by linear 
regression of log-transformed data. To document transgene expression in vivo, uncrowded 
wandering larvae were homogenized directly in sample buffer and analyzed as described. 
Primary antibodies for Western blotting were: mouse anti-HA epitope (BAbCO), rabbit anti-
HA epitope (Dunn Labortechnik GmbH), mouse anti-α-Tubulin (Sigma). Secondary 
antibodies were HRP-coupled anti-rabbit or anti-mouse (GE Healthcare) and for detection the 
enhanced chemiluminescence kit (Amersham) was used. 
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Luciferase reporter experiments 
 
Reporter assays were carried out as previously described (Hulf et al., 2005). Briefly, 1.3x106 
cells/well of a 24-well cell culture plate were transfected with 0.65ml serum-free medium 
containing 4.2µl cellfectin (Invitrogen) and 2.6µg plasmid DNA (consisting of a 1:1 mix of 
“CG5033wt-Renilla luciferase” and “CG5033ΔEbox-firefly luciferase” reporters, tub-GAL4 and 
UAS-plasmids). After 15-16h, 0.65ml complete media was added; 24h later, cells were 
washed in 1xPBS, lysed in 1x Passive Lysis Buffer (Dual-Luciferase kit, Promega), and 
relative reporter expression determined on a Wallac luminometer. 
 
Drosophila lines 
 
Transgenic flies were established by integrating the different attB plasmids into the attP 
landing site ZH-86Fb (Bischof et al., 2007; http://www.frontiers-in-genetics.org/), and 
confirmed by PCR. Source of additional flies: GAL4 drivers (Drosophila stock centre at 
Bloomington), act-FRT-CD2-FRT-GAL4 (Neufeld et al., 1998), GMR-FRT-w+-FRT-GAL4 
(Brogiolo et al., 2001), tub-FRT-dMyc-FRT-GAL4 (De La Cova et al., 2004), ago1 & ago3 
(Moberg et al., 2001), dmP0 (Johnston et al., 1999), dm2 (Maines et al., 2004), dm4 (Pierce et 
al., 2004), dmnt1 dm4 (Pierce et al., in press), dmPL35 & dmPG45 (Benassayag et al., 2005). 
 
Immunocytochemistry 
 
For TUNEL staining of wing imaginal discs, wandering third instar larvae were fixed in 4% 
paraformaldehyde for 20’, washed with 1x PBT (0.1% Tween-20 in PBS [130mM NaCl, 
7mM Na2HPO4, 3mM NaH2PO4]) for 20’, post-fixed in ethanol/PBS (2:1) for 5' at –20° C, 
washed with 3 changes of 0.1% Tween-20/PBS over 15’, pre-treated with 10mM sodium 
citrate (pH 6) for 30’ at 70°C, equilibrated in Equilibration Buffer (ApopTag Red In Situ 
Apoptosis Detection Kit, Chemicon) for 10’, then incubated with TdT enzyme (Chemicon kit) 
for 1h at 37°C, Stop/Wash Solution (Chemicon kit) for 10’, Rhodamine-coupled anti-DIG 
antibodies (Chemicon kit) for 30’, and 3 changes of 0.1% Tween-20/PBS (containing 0.5 
µg/ml Hoechst 33342 for the first step).  
For anti-cleaved caspase 3 stainings, wandering third instar larvae were fixed in 4% 
paraformaldehyde/PBS for 20’ at room temperature and washed with 1x PBT. Rabbit anti-
cleaved caspase 3 (Cell Signalling Technology) was added over night at 4°C. Samples were 
washed with PBT, incubated with Texas Red-coupled anti-rabbit antibodies (Jackson Immuno 
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Research Lab) and 0.5µg/ml Hoechst 33342 for 2h at room temperature, and washed again 
with PBT. 
For clonal area measurements, larvae carrying the “act-FRT-CD2-FRT-GAL4” construct, 
UAS-GFP and the appropriate UAS-dMyc transgene, were heat-shocked for 10’ at 37° C in a 
water bath, dissected 73h later, fixed in 4% paraformaldehyde for 20’, and washed with 3 
changes of PBT (containing 0.5µg/ml Hoechst 33342 for the first step) over 60’.  
Wing discs were dissected and mounted in Vectashield Mounting Medium (Vectashield), and 
analysed on a Leica DMRA compound microscope at a 10x ocular magnification. Clonal area 
was determined from at least 40 clones per construct using Adobe Photoshop. 
 
QRT-PCR 
 
Larvae were grown under uncrowded conditions, heat-shocked at wandering stage for 2h at 
37°C in a water bath, collected 8h later into liquid nitrogen, and stored at -80°C. To extract 
RNA, 10 whole larvae were homogenized in 1ml TRIZOL (Invitrogen) with a Polytron tissue 
homogenizer, following the manufacturers instructions. Upon precipitation, RNA was 
redissolved in 20µl RNAse-free water and analysed for its integrity on a Bioanalyzer 
(Agilent). Genomic DNA was eliminated using the Turbo DNAse free kit (Ambion) and 
cDNAs were synthesized from 1µg of template RNA using the Omniscript kit (Qiagen). 
Parallel control reactions containing only RNA provided templates for “-RT” samples. 
Quantitative real-time PCR (qRT-PCR) reactions were performed in triplicates on an 
ABI7900 Real Time PCR Instrument (Applied Biosystems), using the SYBR Green PCR 
Master Mix (Applied Biosystems). Data were analysed with SDS 2.0 software (Applied 
Biosystems) and Microsoft Excel, using the ΔΔCt method and the average of the expression 
levels of actin5C, Rab6 and Sec24 as internal reference for each biological sample.  
Primer sequences: Rab6: 5’-TGCACGTGGCCAAGTCCTA & 5’-
CAGCGAACGCGACTGCTA; Sec24 5’-CCACTCCCCTGCCATCCT & 5’-
ACCCCAAACCCAGCAACA; CG5033: 5’-TAACCGCTCGGCTTTAATTCA & 5’ 
CCCTTGCTCTTGGAGAATGG. The remaining primers and the PCR conditions have been 
described (Steiger et al., 2008). 
 
Analysis of adult flies 
 
Flies were kept on standard Drosophila medium and test crosses performed in climate-
controlled chamber at 25°. 
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Scanning electron microscope pictures were taken with a JEOL JSM-6360 LV microscope 
and a magnification of 180x. Flies were frozen at –20°C for at least one day, slowly defrosted 
at 0°C and directly used for electron microscopy. For determination of ommatidial size, the 
area of 20 centrally located ommatidia was determined from 5 fly eyes of the same genotype 
using Adobe Photoshop. The same photomicrographs were also used to determine the total 
number of ommatidia per eye. Obvious fusions of two ommatidia were counted as two 
individual ommatidia.  
To determine adult weights, 1-2 day adult flies were frozen at –20°C for at least one day, 
defrosted at room temperature and weighed on a Mettler Toledo MX5 micro balance. 
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Additional experiments not shown in the manuscript 
 
1.  Integration site determination 
 
The site-directed phage φC31 integration system was used for transgenesis to integrate all 
constructs in the same locus and eliminate differences in expression levels or pattern caused 
by differences in genomic environment. All UAS-dMyc (mutant) constructs were generated 
by integration into the line ZH-86Fb (Bischof et al., 2007). In order to confirm that the 
different UAS-constructs of our dMyc mutations were integrated into the correct position in 
the fly genome, PCR assays were performed on genomic DNA of the different UAS-dMyc 
transgenic flies. 
The first primer iPCRSV40F1 was selected to bind directly after the open reading frame in 
the SV40 polyA site of the pUASTB plasmid, the second primer ZHattP14R was selected to 
bind in the attP landing site of the fly genome. A product length of 950 base pairs was 
expected in the case of correct integration. All transgenics show a band with the expected 
length (shown in Figure 1). As a control, genomic DNA of y w animals was taken. As 
expected no band could be observed for the control. Therefore, all constructs are integrated at 
the expected location. 
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Figure 1: Electrophoretic separation of the PCR products for confirmation of the correct 
integration site of the different dMyc mutant constructs in the fly genome. The 
expected band of 950bp was observed in two independent experiments for all 
strains except y w genomic DNA. 
 
 
Label:  Genotype: 
yw y w 
-  y w; M{3xP3-RFP.attP'}ZH-86Fb 
WT y w; M{3xP3-RFP.attP/B UAS-dMycWT}ZH-86Fb 
ΔN y w; M{3xP3-RFP.attP/B UAS-dMycΔN}ZH-86Fb 
MB2A y w; M{3xP3-RFP.attP/B UAS-dMycΜΒ2Α}ZH-86Fb 
ΔMB2 y w; M{3xP3-RFP.attP/B UAS-dMycΔMB2}ZH-86Fb 
ΔMB3 y w; M{3xP3-RFP.attP/B UAS-dMycΔMB3}ZH-86Fb 
    yw    -      WT      ∆N  MB2A  ∆MB2 ∆MB3 marker 
950bp 
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2. Luciferase assay (nnp1) 
 
Previously, we analysed how the different dMyc mutants activate a dMyc-dependent 
luciferase reporter construct derived from the dMyc target gene CG5033. To demonstrate that 
the effects on transactivation that we saw for the different dMyc domain mutants show the 
same activities towards a second reporter system, we repeated the Luciferase assay and used 
the promoter of another dMyc target gene nnp1, instead. 
For this reason, S2 cells were transfected with the different dMyc mutants, together with a 
Renilla luciferase reporter construct under the control of the promoter of the dMyc target gene 
nnp1 (Hulf et al., 2005) and a second construct, where the E-Box, which is the binding site for 
Myc, was mutated into an EcoRI site. This mutation abolishes dMyc-binding and thus renders 
the reporter construct dMyc-unresponsive. This mutant promoter was used to drive firefly 
luciferase. Hence, the ratio of Renilla to firefly luciferase directly reflects dMyc activity. 
A deletion of the N-terminus strongly reduces dMyc`s transactivation ability not only when 
CG5033 was used as a promoter but also in case of nnp1 (as shown in Figure 2). A deletion 
(dMycΔMB2) or mutation (dMycMB2A) of the highly conserved Myc Box 2, as well as a 
deletion of the highly conserved Myc Box 3 (dMycΔMB3) reduces the potential of dMyc 
transactivation, however some function still remains. In the manuscript we showed that all 
proteins are expressed at comparable levels and that (if anything) dMycΔMB3 is more 
abundant than dMycWT. This confirms that MB2 and MB3 are both necessary for full 
transactivation of dMyc target genes. Moreover, this demonstrates that the effects of the 
different dMyc mutants with respect to their transactivation ability are not restricted to one 
dMyc target gene, since another target gene, nnp1 shows the same response to the dMyc 
mutants. 
 
 
 71 
 
 
 
Figure 2: Transactivation ability of the different dMyc mutants relative to dMycWT for 
Myc target genes nnp1 and CG5033. Plotted is the mean of 2 repeats, error 
bars indicate the standard error of the mean. 
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3. Expression levels of dMyc target genes not shown in the manuscript 
 
In the manuscript we pointed out that dMycΔMB3 differentially activates different 
endogenous target genes of dMyc in vivo. For example, the ability of dMycΔMB3 to activate 
the Pol III genes tRNALeu and snoRNA U3 was clearly reduced as compared to dMycWT. 
However, both proteins activated other dMyc target genes equally efficiently. 
For this experiment we used flies that are null for dmyc and carried a ubiquitously expressed 
dMycWT cDNA “tub-FRT-dMyc-FRT-GAL4” and an hs-FLP construct, to rescue the null 
mutant phenotype. A massive heat shock (2 hours at 37°C) was given 5 days after egg 
deposition (AED) in order to uncover the null mutant phenotype. At the same time, GAL4 
was expressed in these flies and drove the expression of the UAS-controlled dMycWT or 
dMycΔMB3 transgenes, allowing us to analyse the effect of the different constructs in the 
absence of endogenous dMyc. By TUNEL staining we observed increased numbers of 
apoptotic cells in wing imaginal discs of flies with the genotype “w dm4 tub-FRT-dMyc-FRT-
GAL4 hs-FLP; UAS-dMycΔMB3” compared to control flies carrying the empty transgene 
pUASTB 12 hours after the heat shock; however, 8 hours after the heat shock no cell death 
was observed. Therefore, we decided to analyse the dMyc target levels 8 hours after the heat 
shock, because this furthermore increases the chance for observing direct dMyc effects. 
To examine leakiness of the GAL4-system described above, a probe for the HA-tag was 
included that only detects the UAS-HAdMyc transgenes. Since control flies do not get a heat-
shock they should not express the HA-tag. To analyse, if this holds true, responsiveness of the 
different cDNAs on HA-tag primers was examined. We could show that HA-tag levels are 
upregulated by about 20x upon heat-shock (compare control and WT). However, the UAS-
HAdMyc transgene seems to be a bit leaky since HA-tag levels are 10x higher compared to a 
second control, lacking an HA-tag (w dm4 tub>dMyc>GAL4 hs-FLP/Y; pUASTB/+). In the 
manuscript we showed, that dmyc mRNA levels were 10x higher after induction (compare 
control and WT). Thus, the total amount of dMyc before the heat-shock (tub>dMyc and 
leakiness of UAS-HAdMyc) equates to 10% of UAS-HAdMyc after the heat-shock. In this 
experiment we could show, that the amount of UAS-HAdMyc before the heat-shock equates 
to 5% of UAS-HAdMyc after the heat-shock. Thus, the tub>dMyc transgene contributes 
another 5% (as compared to the sample “WT + heat-shock”) of the expression before heat-
shock. 
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The microarray analysis of dMyc targets (Hulf et al., 2005) included all RNA Polymerase II 
protein-coding genes known at that time, but RNA Polymerase I & III transcribed genes were 
not analysed. Several dMyc targets, that were consistently responsive to changes in dMyc 
levels (i.e. in several different microarray experiments) and that contained (or not) a 
downstream E-box (i.e. potentially belong to different classes of dMyc targets) were selected 
as examples for RNA Pol II transcribed genes, to identify genes that are differentially 
regulated by dMycΔMB3 and dMycWT. One of these genes is CG18610, which is assumed 
to be involved in transcription elongation (based on sequence annotation). As illustrated in 
Figure 3, CG18610 is induced to about 150% by expression of dMycWT, but no difference 
could be observed between the expression levels of CG18610 in dMycWT or dMycΔMB3 
larvae. 
We also included genes transcribed by RNA Pol III for our analysis since it had been shown 
previously that Myc also controls the transcription of those genes (Gomez-Roman et al., 
2003; Grewal et al., 2005; Steiger et al., 2008). In the manuscript we show that dMyc ΔMB3 
is impaired in activating the Pol III targets tRNALeu and snoRNA U3. The mRNA level of a 
third Pol III target, 5S RNA, was not affected by overexpression of dMyc (shown in Figure 3).  
As a last group of candidates we analysed genes of the apoptotic pathway since we have 
shown that apoptosis is strongly enhanced after overexpression of dMycΔMB3 in the wing 
imaginal disc. Since a deletion of MB3 enhanced not only stability of the dMyc protein but 
also its ability to induce apoptosis, we thought that direct dMyc target genes might also be 
affected by this deletion in a positive manner. Montero et al. 2008, showed that the pro-
apoptotic genes reaper and sickle are potential targets of dMyc. Thus, we analysed sickle and 
reaper by qRT-PCR. Overexpression of dMycΔMB3 did not affect the expression of sickle 
and reaper (as demonstrated in Figure 3). 
Taken together, these data show that there is a role for MB3 in controlling transactivation at 
least of RNA Pol III genes since the RNA Pol III genes tRNALeu and snoRNA U3 showed a 
clear upregulation upon overexpression of dMyc but not upon overexpression of dMycΔMB3 
in this assay. However, no upregulation of other E-box dependent genes or genes of the 
apoptotic pathway were observed, which suggests that MB3 plays a specific role in the 
activation of Pol III genes. 
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Figure 3: Transcript levels of different dMyc target genes as determined by qRT-PCR of 
larvae overexpressing dMycWT, dMycΔMB3 or no dMyc protein (-) compared 
to control larvae (dMycWT without hs). Samples were taken 8h after the hs 
(for details see Materials and Methods). Error bars indicate standard deviation 
of the mean of two independent biological replicates. 
 
 
Label:  Genotype: 
control (no hs)    w dm4 tub>dMyc>GAL4 hs-FLP/Y; UAS-dMycWT/UAS-dMycWT 
 - w dm4 tub>dMyc>GAL4 hs-FLP/Y; pUASTB/pUASTB  
WT w dm4 tub>dMyc>GAL4 hs-FLP/Y; UAS-dMycWT/UAS-dMycWT 
ΔMB3               w dm4 tub>dMyc>GAL4 hs-FLP/Y; UAS-dMycΔMB3/UAS-
dMyc∆MB3 
ΔMB3 
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4. Inhibition of apoptosis by co-overexpression of p35 
 
To find out if the apoptosis we saw after overexpression of the different dMyc mutants in the 
dorsal compartment of the wing disc (see Figure 4, manuscript) carries all the hallmarks of 
classical apoptosis, i.e. can also be inhibited by the pan-caspase inhibitor p35, we co-
overexpressed p35 together with the dMyc mutants. An additional motivation for this 
experiment was to see what happens when the death-promoting activity of dMycΔMB3 is 
blocked - do we then see a massive overgrowth, because dMycΔMB3 is much more active 
than dMycWT? 
Apoptotic cells were marked with anti-cleaved caspase 3 antibody and visualized by a red 
fluorescent antibody. P35 fully inhibits apoptosis in all cases, also for a deletion of the acidic 
domain, which otherwise showed the strongest apoptotic effects (Figure 4, panel G). Thus, the 
observed apoptosis is a result of caspase activation. However, we could not observe an 
overgrowth of the dorsal compartment of the wing discs using this assay. 
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Figure 4: Overexpression of dMycΔMB3 causes apoptosis (G); co-overexpression of 
UAS-p35 completely inhibits apoptosis for all genotypes (A-F). Transgenes 
are expressed in the dorsal compartment of the wing disc. The white line 
marks area of expression. Top=dorsal, bottom=ventral. The phenotype was 
observed in the majority of the wing discs of one biological replicate. White 
dots seen in panel G are apoptotic cells that are marked with an anti-cleaved 
caspase 3 antibody. 
 
 
Label:  Genotype: 
A  y w; ap-GAL4/+; UAS-p35/pUASTB 
B  y w; ap-GAL4/+; UAS-p35/UAS-dMycWT 
C  y w; ap-GAL4/+; UAS-p35/UAS-dMycΔN  
D  y w; ap-GAL4/+; UAS-p35/UAS-dMycMB2A 
E  y w; ap-GAL4/+; UAS-p35/UAS-dMycΔMB2 
F  y w; ap-GAL4/+; UAS-p35/UAS-dMycΔMB3 
G  y w; ap-GAL4/+; +/UAS-dMycΔMB3 
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5. Inhibition of apoptosis leads to overgrowth in the eye 
 
Co-overexpression of p35 in the wing imaginal discs (see results section, 4.) inhibited 
apoptosis caused by overexpression of dMyc. Moreover, ommatidial size is reduced after 
additional overexpression of dMyc mutants in eyes that already highly overexpress dMycWT 
(Steiger et al., 2008; Montero et al., 2008) presumably because, at high levels of expression, 
dMyc-induced apoptosis overcomes dMyc-induced growth, resulting in a net decrease of 
ommatidial and tissue size. As we have previously shown that ommatidial size of eyes highly 
overexpressing dMycWT can be increased by blockage of apoptosis (Montero et al., 2008; 
Steiger et al., 2008), we were interested if the size of ommatidia expressing mutant dMyc 
proteins can be enhanced after inhibition of apoptosis. 
For this purpose we overexpressed the dMyc mutants with GMR-GAL4, either alone or in 
combination with the pancaspase-inhibitor p35. Overexpression of the different dMyc 
mutants does not affect roughness of the eye (except for dMycΔMB3), suggesting that only 
growth and not apoptosis are affected by such mutants (see manuscript, Figure 3). This goes 
along with the observation that strong overexpression of dMyc is necessary to induce 
apoptosis (Steiger et al, submitted). Moreover, overexpression of one copy of dMyc in third 
instar eye imaginal discs does not induce apoptosis (P.Gallant, unpublished observation). 
Thus, only overexpression of dMycΔMB3 induces apoptosis. After co-overexpression of p35 
and dMycWT or dMycΔMB3 the ommatidial pattern gets distorted, all other eyes look 
normal (Figure 5). The size of 20 centrally located ommatidia of 5 individual eyes per 
genotype was analysed and plotted in Figure 6. We observed an increase in ommatidial size 
for all dMyc expressing lines. However, the strongest increase was monitored with 
dMycΔMB3. Ommatidial size is enhanced by 35% when p35 is co-expressed (Figure 6).  
This supports that the rough eye phenotype we observed (Figure 5, panel F) is caused by a 
combination of excessive growth and apoptosis, since ommatidia blocked from undergoing 
apoptosis, which overexpressed dMyc showed a strong increase in ommatidial size.  
The p-values for “GMR-GAL4; UAS-p35/+” vs. “GMR-GAL4; UAS-p35/UAS-dMycΔN” 
were not significant (p≥0.5) indicating that this mutant is biologically inactive as described 
earlier. However, the observation that all other dMyc mutants were capable of inducing 
apoptosis (since all of them showed a significant increase in ommatidial size after co-
overexpression with UAS-p35) suggests that not only dMycΔMB3 induces apoptosis after 
overexpression in the eye. There are three possible explanations for this observation. First, 
p35 also blocks normal occurring apoptosis, since even the control genoptype is affected by 
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inhibition of apoptosis (compare “-“ black and grey bars), although not significantly. Second, 
the different dMyc mutants induce apoptosis, which is not quite obvious and was not 
described before. Third, a big amount of dMyc-induced apoptosis in the eye might take place 
during pupariation, which we never analysed by TUNEL staining. However, due to the 
observed phenotypes the apoptosis must be limited. This experiment demonstrates clearly, the 
strength of dMycΔMB3 in induction of growth, when the “negative” pro-apoptotic effects are 
turned off.  
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Figure 5:  Section electron microscope pictures (SEM) of eyes overexpressing p35 and 
dMyc mutants. Panel F resembles the “GM” phenotype, which we observed 
after strong overexpression of dMyc (Steiger et al., 2008). The phenotype was 
observed for the majority of the flies with the corresponding phenotype. 
 
 
 Label:  Genotype: 
 A y w; GMR-GAL4/+; UAS-p35/pUASTB 
 B  y w; GMR-GAL4/+; UAS-p35/UAS-dMycWT 
C   y w; GMR-GAL4/+; UAS-p35/UAS-dMycΔN 
 D y w; GMR-GAL4/+; UAS-p35/UAS-dMycMB2A 
 E y w; GMR-GAL4/+; UAS-p35/UAS-dMycΔMB2 
F  y w; GMR-GAL4/+; UAS-p35/UAS-dMycΔMB3 
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Figure 6:  Ommatidial size determined from 5 independent eyes per genotype, measured 
after overexpression of dMyc with GMR-GAL4, either alone (grey bar) or in 
combination with p35 (black bar). Co-overexpression of p35 enhances 
ommatidial size. Error bars indicate standard deviation of the means of the 
counted eyes. GMR-GAL4 crossed to control was set to 100% and all other 
ommatidial sizes were calculated to this reference. Stars indicate significant 
difference between the genotypes “GMR-GAL4; UAS-p35/+” vs. “GMR-
GAL4; UAS-p35/UAS-dMyc(mutant)” (p≤0.05).  
 
 
 Label: column: Genotype: 
- grey y w; GMR-GAL4/+; pUASTB/+ 
  black y w; GMR-GAL4/+; UAS-p35/pUASTB 
 WT grey y w; GMR -GAL4/+; UAS-dMycWT/+ 
   black y w; GMR-GAL4/+; UAS-p35/UAS-dMycWT 
ΔN   grey y w; GMR-GAL4/+; UAS-dMycΔN/+ 
   black y w; GMR-GAL4/+; UAS-p35/UAS-dMycΔN 
 MB2A grey y w; GMR-GAL4/+; UAS-dMycMB2A/+ 
  black y w; GMR-GAL4/+; UAS-p35/UAS-dMycMB2A 
 ΔMB2 grey y w; GMR-GAL4/+; UAS-dMycΔMB2/+ 
  black y w; GMR-GAL4/+; UAS-p35/UAS-dMycΔMB2  
ΔMB3  grey  y w; GMR-GAL4/+; UAS-dMycΔMB3/+ 
 black  y w; GMR -GAL4/+; UAS-p35/UAS-dMycΔMB3 
 - WT ΔN MB2A ΔMB2 ΔMB3 
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6. Interaction with dMyc co-factors 
 
In order to determine which factor is responsible for the biological defects we observed in 
vivo with the different dMyc mutants, two known dMyc co-factors, Pontin and GCN5, were 
analysed for their binding ability to the different dMyc mutants. 
6.1  Interaction with Pontin 
 
Pontin, also called Tip49 in humans, is an essential partner for Myc during normal 
development and it plays an important role in the control of Myc-dependent transcription, 
growth and proliferation. Flies carrying the hypomorphic allele dmP0 are normally patterned 
and display only moderate growth defects. Heterozygosity for the dMyc-co-factor Pontin 
showed no effect in a wildtype background, but it dramatically enhanced the defects of 
hypomorphic dmyc mutations. Up to 100% of “dmP0/Y; pontin5.2/+” flies had a strong eye 
defect (Bellosta et al., 2005). Not only the eye is affected by this phenotype but also the 
survival rates are reduced, the duration of development is prolonged and the overall size of 
the animals is decreased, indicating that growth and/or proliferation is generally impaired. 
Pontin is also required on its own for tissue growth in vivo, since homozygous mutant pont-/- 
larvae grow poorly although they hatch normally, as was shown for dmyc-/- mutant larvae. 
Moreover, mitotic clones mutant for either dmyc or pont suffered from cell competition, 
consistent with the idea that dMyc and Pontin control the same processes (Bellosta et al., 
2005). 
The interaction with Tip49 requires Myc Box 2 in c-Myc (Wood et al., 2000), since 
immunoprecipitations from human 293 cells expressing FLAG-c-Myc (mutants) showed that 
a deletion of Myc Box 1 was still able to bind Tip49 to the same extent as full-length c-Myc, 
but a larger deletion of Myc Box 2 was substantially reduced in binding to Tip49. Indeed, 
Bellosta et al., 2005 showed by GST-pull downs that Pont binds physically to dMyc in vitro. 
However, studies to distinguish the direct binding site for Tip49 in Myc are still missing. To 
analyse if Pontin still binds to the mutant dMyc proteins, especially to MB2, we performed 
co-immunoprecipitations of Pont and different dMyc mutants in S2 cells. 
Co-immunoprecipitations were performed upon transfection of UAS-Myc-Pontin together 
with different UAS-HA-dMyc (mutant) plasmids and tub-GAL4. Forty-eight hours after 
transfection, cells were lysed and co-immunoprecipitations were performed as described in 
Materials and Methods. The first Western blot in Figure 7 shows that all tested dMyc mutants 
still physically bind to Pont whereas in control IPs, where dMyc or Pontin were transfected 
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alone, no interaction could be observed (Figure 7, panel A). Supernatants taken before the 
first washing step of the beads (Figure 7, panel B) show that dMyc was present in the control 
IP (when dMyc was transfected alone). Furthermore, all dMyc mutants were equally capable 
of binding to Pont. This indicates that all our dMyc mutants still contain the binding site for 
Pontin. Thus, Pontin is not responsible for the defects we observed and described earlier for 
the different dMyc mutations. 
We were interested, if a dMyc mutation that lacks the ability to bind to Pontin would behave 
similarly as the mutants we already analysed with regard to its biological functions. 
Therefore, we tried to map the correct binding site for Pontin with additional mutations of 
dMyc (see Figure 8) and tested them by co-IP. 
Smaller dMyc mutants, who still contained the N-terminus of dMyc, strongly bound Pontin 
(Δ294C, Δ403C, Δ523C), as demonstrated in Figure 9. Surprisingly, ΔN294, which lacks the 
first 294 amino acids of dMyc, was also still capable of binding to Pontin. However, bigger 
deletions in the N-terminus reduced or completely abolished binding (ΔN403, ΔN523). No 
conclusion can be drawn from ΔN626, since much lower amounts of this protein were 
detected in the transfected S2 cells than of the other dMyc mutants. 
These data suggest that either two binding sites for Pont exist in dMyc, or that there is one 
long interaction site, of which MB2 is an important but not essential part, since 
complementary constructs (Δ294C and ΔN294, that do not overlap each other) showed a 
strong interaction with Pontin. Similarly, Wood et al. 2000 were not able to fully abolish 
binding between their big Myc Box 2 deletions in c-Myc (Δ118-152) and Tip49, which is 
consistent with our data. As a next step, the binding site for Pontin needs to be mapped more 
precisely before any in vivo assays can be done with such a mutation. 
In a second assay we wanted to rescue the eye phenotype of “dmP0/Y; pontin5.2/+” flies by 
overexpression of dMycWT and different dMyc mutants. If one of the mutants would lack the 
binding domain for Pontin in dMyc, it should not rescue the strong eye defect. 
For the rescue experiment, flies carrying the hypomorphic allele dmP0 were provided with a 
ubiquitously expressed dmyc cDNA under the control of the tubulin-promoter. The cDNA 
was flanked by FRT-sites, which will recombine with each other when FLP-recombinase is 
expressed. Since the eyeless promoter was used to express this FLP-recombinase, the dmyc 
cDNA will be eliminated only in the eye and head capsule, thus revealing the hypomorphic 
phenotype in this tissue. The rest of the fly remains unaffected. This line was called ey>dmP0 
for simplification, which stands for the genotype: “w dmP0 tub-FRT-dMyc-FRT-GAL4 ey-
FLP”. 
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As mentioned above, heterozygosity for Pontin in ey>dmP0 flies leads to a strong eye defect. 
By overexpressing dMyc (mutants) in this background, we were able to rescue the eye defects 
(see Figure 10) - not only the reduction in ommatidial number that is very typical for 
“ey>dmP0; pont5.2/+” eyes, but also the roughness of the eye. The roughness that is observed 
after expression of dMycΔMB3 presumably reflects a dMyc overexpression phenotype of the 
strong dMycΔMB3 mutant. A similar roughness is also observed when dMycΔMB3 is 
expressed in a dm+ background (see manuscript, Figure 3). 
Consistent with the interaction studies shown above, also dMycΔN fully rescued the eye 
phenotype, although it was biologically inactive in most of our assays (see manuscript). Thus, 
additional important dMyc co-factors besides Pontin might bind to its N-terminus to control 
Myc`s biological activity. 
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Figure 7:  Binding of Pontin to different dMyc mutants. Shown are S2 cell lysates after 
co-transfection of Pont and dMyc (mutants), immunoprecipitation with 
Protein-G beads and mouse anti-dMyc antibodies. Precipitated proteins were 
resolved by SDS/PAGE and Western blotted for HAdMyc with anti-HA 
antibodies. The text above the picture indicates the expressed proteins. All 
constructs were still able to bind Pont. Panel A: IP, Panel B: supernatants of 
cell lysates after incubation with antibodies and beads. The experiment was 
performed in two independent biological replicates with similar results. 
 
 
 
 
 
 
Figure 8:  Additional dMyc mutant constructs (small dMyc mutations), which were used 
for co-immunoprecipitation assays. All constructs carry an HA-tag at their N-
terminus and were cloned into pUASTB. 
HA-dMyc 
HA-dMyc 
dMyc  WT  –  WT  ΔN  MB2A ΔMB2 
Pont  -  + + + + + 
dMyc  WT  –  WT  ΔN  MB2A ΔMB2 
Pont  -  + + + + + 
MB1  MB2    MB3 b-HLH-LZ 
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Figure 9:  Binding of Pontin to different dMyc mutants. Shown are S2 cell lysates after 
co-transfection of Pont and dMyc (mutants), immunoprecipitation with 
Protein-G beads and mouse anti-HA antibody. Precipitated proteins were 
resolved by SDS/PAGE and Western blotted for dMyc with anti-HA antibody. 
The text above the picture indicates the expressed proteins. All C-terminal 
deletions still allow full binding to Pont. Big N-terminal deletions reduce or 
abolish binding to Pont. Panel A: IP, Panel B: supernatants of cell lysates after 
incubation with antibodies and beads. The experiment was performed in two 
independent biological replicates with similar results. 
 
HAdMyc 
HAdMyc 
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Figure 10:  Scanning electron microscope pictures (SEM) of flies hypomorphic for dmyc, 
heterozygous for pont5.2 and overexpressing different dMyc constructs. The 
strong eye phenotype of control flies (panel A) could be rescued with all 
constructs. The experiment was performed in two independent biological 
replicates. 
 
 
Label:  Genotype: 
A w dmP0 tub>dMyc>GAL4 ey-FLP/Y; pont5.2/pUASTB 
B w dmP0 tub>dMyc>GAL4 ey-FLP/Y; pont5.2/UAS-dMycWT 
C w dmP0 tub>dMyc>GAL4 ey-FLP/Y; pont5.2/UAS-dMycΔN 
D w dmP0 tub>dMyc>GAL4 ey-FLP/Y; pont5.2/UAS-dMycMB2A 
E  w dmP0 tub>dMyc>GAL4 ey-FLP/Y; pont5.2/UAS-dMycΔMB2 
F  w dmP0 tub>dMyc>GAL4 ey-FLP/Y; pont5.2/UAS-dMycΔMB3 
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6.2 Interaction with GCN5 
 
GCN5, a histone acetyltransferase, was found as a component of the SAGA complex, which 
also includes, amongst others, ADA1-3 and TRRAP. The N-terminal domain of c-Myc has 
been reported to interact with GCN5, and deletion of Myc Box 2 causes loss of both 
interaction with TRRAP and GCN5 (McMahon et al., 2000). Recently, it was shown that 
GCN5 is also involved in RNA Pol III-dependent transcriptional activation, since c-Myc 
recruited the co-factors TRRAP and GCN5 to tRNA and 5S RNA genes and stimulated 
acetylation of histone H3 at these loci (Kenneth et al., 2007). 
Therefore, we were interested if a Myc Box 2 deletion abolishes binding to GCN5. Different 
dMyc mutants were expressed in S2 cells to address this question and cell lysates were 
prepared for immunoprecipitation against endogenous GCN5; the associated HAdMyc was 
revealed by Western blotting with an anti-HA antibody. Indeed, dMycWT interacted with 
GCN5 (Figure 11) and a deletion of the N-terminus of dMyc did not abrogate this interaction. 
Furthermore, other tested proteins carrying deletions of Myc Box 2, or of the first 294 amino 
acids of dMyc were still capable of binding to GCN5 (data not shown). Thus, at least part of 
the binding site for GCN5 lies between amino acid 295 and the C-terminus. 
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HAdMyc WT  ΔN179 HAdMyc WT ΔN179 
   
 
Figure 11: Western blot showing physical interaction between HAdMyc and GCN5. S2 
cells were transiently transfected with plasmids coding for the indicated forms 
of HA-tagged dMyc. After 48h, protein complexes were immunoprecipitated 
with an antibody directed against endogenous GCN5. Precipitated proteins 
were resolved by SDS/PAGE and Western blotted for dMyc with anti-HA 
antibody. The text above the picture shows the expressed proteins. dMycWT 
(HAdMycWT) and a deletion of the first 179 amino acids of dMyc 
(HAdMycΔN179) are still able to bind to GCN5. Panel A: IP, Panel B: 
supernatant taken before the first washing step of the beads. HAdMyc alone 
does not bind to protein G beads (data not shown). “IgG” marks the light chain 
of the antibody. 
HAdMyc 
IgG light chain 
HAdMyc 
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7.  Interaction of dMyc mutants with dmax dsRNA 
Expression of dmax dsRNA with the eye-specific GMR-GAL4 driver did not alter ommatidial 
size and overall eye morphology in a wildtype background (Steiger et al., 2008). However, 
when dMyc was strongly overexpressed, dmax dsRNA reduced ommatidial size and strongly 
increased the roughness of the eye. This observation was a first indication that dMyc has 
functions that do not require dMax (Steiger et al., 2008). Specifically, dMyc can induce 
apoptosis in a dMax-independent manner when dMyc is expressed at very high levels, but 
most probably not all dMyc-dependent apoptosis is independent of dMax. In the manuscript 
we showed that dMycΔMB3 is a very potent inducer of apoptosis. Therefore, it appears quite 
possible that this dMycΔMB3-dependent activity is dMax-independent. If this were true, a 
reduction of dMax-levels (by dsRNA) in a dMycΔMB3-overexpression background would 
change the eye phenotype to a lesser extent than when dMax-levels are reduced in the 
presence of overexpressed dMycWT. 
Thus, we crossed flies, which were homozygous for GMR-GAL4 and contained UAS-dMyc 
(mutants) to flies containing 2 different dmax inverted repeats (dmax-IR6-1, dmax-IR5-2). 
Overexpression of either control transgenes (A), dMycWT (B), dMycΔMB2 (C) and of 
dMycΔMB3 (D) in the eye are depicted in Figure 12. Compared to the pictures of the lower 
panel, which included dmax dsRNA, no enhancement of the roughness was observed except 
for panel H, were dMycΔMB3 is expressed. However, dMycΔMB3 also causes a more severe 
eye defect than dMycWT, so it is not so easy to compare modification of the dMycΔMB3- 
and of the dMycWT-phenotype. This observation confirmed that when dMyc is expressed at 
high levels, as it is the case for dMycΔΜΒ3, a reduction of dMax levels enhances the 
roughness of the eye. However, no conclusion can be drawn if the ommatidial size is reduced 
in those eyes (as observed by Steiger et al., 2008), since this has not yet been analysed. It is 
also not clear if the dMycΔMB3-dependent activity is dMax-independent. 
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Figure 12:  Dissection microscope pictures of eyes overexpressing dMyc (mutants) in the 
absence (upper panel) or presence of dmax dsRNA. The ommatidia in panel H 
look rougher than those in panel D, all other eyes seemed unaffected by a loss 
of dmax. The phenotype was observed for the majority of the corresponding 
genotypes (>80%). 
 
 
Label:  Genotype: 
A y w; GMR-GAL4/+; pUASTB/+ 
B y w; GMR-GAL4/+; UAS-dMycWT/+ 
C y w; GMR-GAL4/+; UAS-dMycΔMB2/+ 
D y w; GMR-GAL4/+; UAS-dMycΔMB3/+ 
E y w; GMR-GAL4/+; pUASTB/UAS-dmax-IR(5-2) UAS-dmax-IR(6-1) 
F y w; GMR-GAL4/+; UAS-dMycWT/UAS-dmax-IR(5-2) UAS-dmax-IR(6-1) 
G y w; GMR-GAL4/+; UAS-dMycΔMB2/UAS-dmax-IR(5-2) UAS-dmax-IR(6-1) 
H y w; GMR-GAL4/+; UAS-dMycΔMB3/UAS-dmax-IR(5-2) UAS-dmax-IR(6-1) 
 dmax-dsRNA 
- WT ΔMB2 ΔMB3 
- 
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Discussion of additional experiments 
 
Myc`s role on cis-acting determinants in vivo was investigated in this study. Except for the N-
terminus there are regions in the Myc protein that are fairly conserved from humans to flies 
(MB2, MB3, b-HLH-LZ). The N-terminus of dMyc is required for most dMyc-dependent 
activities, although dMycΔN retains some ability to promote eye development and to rescue a 
lethal dmyc-mutation. In contrast, deletion of the best-conserved motif MB2 had rather mild 
effects and a dMyc mutant derivative lacking this MB2 was even capable of rescuing a dmyc 
null allele to adulthood. Interestingly, a deletion of the acidic MB3 domain not only stabilized 
the protein but also enhanced its ability to induce apoptosis, but not its efficiency to induce 
distinct dMyc target genes (discussed in the manuscript). 
 
MB1 
 
A deletion of the N-terminus of dMyc dramatically reduced all biological functions of dMyc. 
However, dMycΔN could rescue not only ommatidial size of a dMyc null allele (although 
weakly), but it also significantly rescued the reduced ommatidial number in such flies. In the 
additional experiments we could show that such a mutant was moreover capable of binding 
the Myc co-factors Tip49 and GCN5. This interaction might be the reason why dMycΔN 
retains some activity. Together with the previous observations, our results suggest that 
apoptosis and transactivation, as well as the induction of cell growth and proliferation, mostly 
depend on the dMyc N-terminus. This is consistent with the observation for c-Myc S (which 
resembles dMycΔN) in that the human c-Myc S isoform led to viability when expressed in a 
lethal dmyc mutant background. Apoptosis was not induced in those flies (Benassayag et al., 
2005). However, our observations suggest that some co-factors, that might be necessary for 
the induction of cell-autonomous apoptosis or cell growth by Myc, do not bind dMycΔN 
anymore (or have a significantly reduced binding capability), and that dMyc target genes 
involved in those processes are not (or less) activated by dMycΔN. These co-factors need to 
be determined in future experiments. 
 
MB2 
 
The highly conserved MB2 was shown to recruit several co-factors to c-Myc. Among them 
were TRRAP and GCN5, which are involved in the acetylation of histones (McMahon et al., 
1998; McMahon et al., 2000) or Tip48 and Tip49, which function as ATPase/helicases (Wood 
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et al., 2000). MB2 was also shown to be necessary for the induction of apoptosis, 
transformation (Conzen et al., 2000; Oster et al., 2003) and for the blockage of differentiation 
(Freytag et al., 1990). Additionally, the ability to activate and repress target genes was 
dramatically reduced by deletion of MB2 (Cowling and Cole, 2006; Li et al., 1994). However, 
some Myc target genes were still repressed upon deletion of MB2 (Lee et al., 1997; Li et al., 
1994). Myc is also capable of autoregulation by repressing the c-myc locus itself, and this was 
shown to be dependent on MB2 (Oster et al., 2003). 
In contradiction to published observations, a dMycΔMB2 mutant retains substantial activity 
in vivo. Thus, cell growth, cell proliferation and apoptosis were comparable to dMycWT or 
only weakly reduced. The MB2 mutants were even capable to partially rescue a dMyc null 
allele to adulthood (albeit the resulting flies were small). Consistent with this observation, the 
dMyc co-factors Tip49 and GCN5, which were shown to be essential for Myc activity, are 
still capable of binding to dMycΔMB2 (6.1, 6.2). Indeed, Wood et al. 2000 still observed 
residual binding between their big Myc Box 2 deletion (c-MycΔ118-152) and Tip49, which is 
consistent with our data, indicating that a second binding site is partially sufficient for the 
interaction with Pontin. This might also account for the interaction with GCN5 (which is 
recruited to Myc by TRRAP and thus binds the same sites in c-Myc as TRRAP). A deletion in 
N-Myc (Δ110-116=MB2) completely abolished binding to GCN5 (McMahon et al., 2000), 
however, binding of TRRAP to c-Myc required aa 1-110 (N-terminus) and aa 129-145 (MB2) 
(McMahon et al., 1998). Thus, both the N-terminus and MB2 might be important in flies and 
one of those sites is sufficient for binding of GCN5 to dMyc via TRRAP. 
However, this raises the question why dMycΔMB2 had a clearly reduced potential to activate 
target genes compared to dMycWT, since both tested co-factors bind with the same 
efficiency. This might be due to the fact that we have not tested all proteins that have been 
proposed to bind MB2 –like Tip48. On the other hand deletion of MB2 might disrupt the 
binding to a yet unidentified partner for MB2. The MB2 domain might also be required for 
intra-molecular binding, which would normally stabilize the 3D protein structure of Myc.  
A completely different hypothesis is that MB2 might be important for the activation of a 
distinct set of target genes e.g. RNA Pol II & III targets. The c-Myc N-terminus (both aa 1-
110 and aa 106-143) was shown to be necessary for activation of RNA Pol III target genes. 
The mechanism of this interaction is yet unknown but might be dependent on the basal Pol III 
co-factor TFIIIB (Cowling and Cole, 2006). Moreover, we show evidence that transactivation 
by dMycΔMB2 is reduced by using the promoter regions of the RNA Pol II transcribed genes 
CG5033 and nnp1 (see manuscript, results section 2.). If only endogenous dMyc target genes 
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transcribed by RNA Pol II & III are directly affected by a loss of MB2 needs to be 
investigated in future times.  
It was also shown that a deletion in MB2 directly affects transcription, which might explain 
the growth deficits between dMycWT and dMycΔMB2. Myc directly activates CDK7 (the 
kinase subunit of the transcription factor TFIIH), which in turn phosphorylates serine amino 
acids on the C-terminal domain of RNA Polymerase II, necessary for initiation of 
transcription. The MB2 motif was shown to directly interact with CDK7, thus recruiting 
TFIIH to the binding sites of different target genes (Cowling and Cole, 2007). By binding of 
the “Myc-TFIIH”-complex to transcription initiation sites of their target genes, mRNA cap 
methylation is increased and hence translation. Thus, a deletion of MB2 affects transcription 
of target genes and mRNA metabolism. Altogether it is quiet surprising that such a highly 
conserved domain like MB2 is not absolutely essential, but plays only a quantitative role in 
the way that it only reduces/weakens dMyc`s biological functions (e.g. growth, apoptosis, 
transactivation). 
 
MB3 
 
To investigate the role of the less studied but highly conserved MB3 in Myc was one of the 
goals of this study. A PEST domain is located inside this region and such a domain is often 
linked with unstable protein (Rogers et al., 1986). Indeed, compared to dMycWT, 
dMycΔMB3 was more stable in S2 cells. A deletion of MB3 moreover enhanced cell growth 
and apoptosis compared to dMycWT and a dMycΔMB3 mutant could fully rescue a dmyc 
null allele to the same extent as dMycWT. On the other hand dMycΔMB3 had a reduced 
potential to activate transcription in cell culture assays and was impaired to activate RNA 
Polymerase III target genes in vivo. 
Our data provide strong evidence that first, co-expression of p35, a caspase inhibitor, blocked 
dMycΔMB3 induced apoptosis, indicating that this process involves caspases (results section, 
4.). Second, growth could be increased after co-expression of p35 (results section, 5.). Third, 
the expression levels of the pro-apoptotic genes reaper (rpr) and sickle (skl) were not affected 
by overexpression of dMycΔMB3, as assayed by qRT-PCR, suggesting that apoptosis is 
triggered by a different mechanism than by the induction of rpr or skl (results section, 3). 
The fact that dMycΔMB3 is more stable might account for the effects on cell growth and 
proliferation, however it cannot explain the reduced transactivation of target genes by 
dMycΔMB3. 
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We showed that dMycΔMB3 behaves qualitatively differently than dMycWT at the level of 
transcription. This suggests that ubiquitination of dMyc and transcriptional activation of 
distinct target genes is controlled by MB3. It was shown earlier that degradation and 
transcriptional activation are connected and that transcriptional activation domains are often 
linked to ubiquitination sites, so-called degrons (reviewed in Muratani and Tansey, 2003). 
One the one hand, our data are consistent with the possibility that MB3 is the binding site for 
the F-box protein Ago, since a mutation in ago does not further enhance (or reduce) 
ommatidial size after overexpression of dMycΔMB3 compared to dMycWT in the eye, which 
one would expect as reducing the gene dose of ago was demonstrated to enhance dMyc 
stability. The finding that the degron for Ago binding in c-Myc is most similar to dMycMB3 
supports this idea (Moberg et al., 2004). On the other hand, dMycΔMB3 was impaired in the 
activation of tRNALeu and snoRNA U3. Thus, there might be a link between activation of RNA 
Pol III target genes and degradation of dMyc. 
It stands to reason that dMycΔMB3 induced apoptosis is not only a result of increased dMyc 
stability but also of binding to other co-factors or repression/activation of target genes of 
dMyc, involved in the apoptotic pathway. Recently, it was shown that overexpression of 
dMyc or reducing the gene dose of ago leads to apoptosis in “GM” flies (which already 
overexpress three copies of dMyc) (Steiger et al., 2008{Secombe, 2007 #2546). Thus, the 
induced apoptosis observed upon overexpression of dMycΔMB3 might be a direct 
consequence of Myc induced cell autonomous apoptosis and the loss of binding to Ago. 
Which suggests that the apoptosis induced by dMycΔMB3 is based on increased stability of 
the protein. Moreover, the observation that inhibition of apoptosis by p35 increased 
ommatidial size better than dMycWT rather suggests that dMycΔMB3 induced apoptosis is 
increased due to enhanced stability of the protein. However, we cannot rule out that MB3 
suppresses apoptosis by a different mechanism. The qualitative different effects of dMycWT 
and dMycΔMB3 on transcription (see manuscript) further support this idea. However, further 
experiments are necessary to determine the mechanism on how dMycΔMB3 induces 
apoptosis.  
 
 
 95 
 
  
  
  
 Chapter 2  
 
 
 
 
 
 
In vivo mutagenesis screen 
for dMyc co-factors 
 
 
 96 
Summary 
 
Flies carrying the hypomorphic myc allele dmP0 are normally patterned and display only 
moderate growth defects. Experiments with the dMyc-cofactor Pontin/Tip49, an 
ATPase/helicase protein that is also part of the Tip60 complex, have shown that the eye is 
particularly sensitive to a reduction in dMyc activity and that a transcriptional co-factor 
complex containing Pontin is critically required for Myc function in the eye. Encouraged by 
the results with Pontin, we carried out a large-scale loss-of-function mutagenesis screen to 
identify Pontin-like co-factors for Myc. In parallel, the publicly available Exelixis and 
DrosDel collections of large isogenic deletions have been tested for interaction with dMyc. 
The breakpoints of those deletions are molecularly characterized, which facilitated the 
identification of selected genes of interest. In this project we identified two genes that have 
previously been unknown to interact with dMyc: Delta and chinmo.  
Delta (a Notch ligand) interacts genetically with different dmyc mutations, however, other 
components of the Notch signalling pathway did not affect the eye morphology in a dmyc 
mutant background.  
Chinmo was initially found in a screen for factors that specify distinct birth order-dependent 
cell fates in an extended neuronal lineage. Our screen, as well as another screen for factors 
involved in growth control, attributes an additional biological function to Chinmo. We 
provide evidence that Chinmo interacts not only genetically, but also physically with dMyc. 
On the one hand, dMyc is limiting for Chinmo function, since the deleterious defects of 
Chinmo overexpression are reduced by a reduction of dMyc levels; on the other hand, 
Chinmo is necessary for dMyc function in vivo, since homozygous chinmo mutant clones fail 
to overgrow after overexpression of dMyc. A Luciferase assay in S2 cells showed that 
Chinmo can transactivate Myc dependent reporter genes. Moreover, this induction is 
enhanced by the co-overexpression of Myc. Importantly, levels of overexpressed Myc are not 
affected by co-expressed Chinmo in S2 cells suggesting that Chinmo does not enhance dMyc 
stability. Furthermore, co-IP experiments showed a direct interaction between the two 
proteins. Two derivatives of Chinmo have been established that lack either one of the two 
functional domains, an N-terminal BTB/POZ domain or a C-terminal Zn-finger (ZnF) 
domain. Deletion of the BTB domain completely abolished binding to dMyc, whereas a 
deletion of the ZnF did not. Finally, Chinmo activates endogenous dMyc targets involved in 
ribosome biosynthesis. Thus, Chinmo seems to affect the transactivation activity of dMyc. 
The mechanism behind this action and the connection between the functions of dMyc 
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published so far (e.g. in growth control and cell competition) and the role of Chinmo (e.g. in 
neurogenesis) still needs to be investigated. 
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Introduction 
Identification of Chinmo 
 
In order to find new co-factors of dMyc, a loss-of-function screen was performed in our 
laboratory. This screen was based on the hypomorphic allele dmP0 that carries an P-element 
insertion 99 nucleotides upstream of the longest isolated dmyc cDNA (Johnston et al., 1999). 
Homozygous dmP0 females are sterile and males are characterised by a slightly delayed 
development, thin bristles and a weak reduction in body size and viability (reduced to 54%). 
Very rarely, mutant flies exhibit a weak eye defect with small, irregularly shaped, slightly 
rough eyes. Moreover, ommatidial size is significantly reduced (Bellosta et al., 2005). 
Heterozygosity for the dMyc co-factor Pontin shows no phenotypic defects in a wildtype 
background, but it dramatically enhances the defects of the dmP0 mutation. In particular, up to 
100% of males with the genotype “dmP0/Y; pontin+/-“ exhibit an easily discernable eye 
phenotype. Thus, a transcriptional co-factor complex containing Pontin is critically required 
for dMyc function in the eye. 
Stimulated by this result, we initiated an EMS-screen in order to find other postulated co-
factors of the Pontin-containing complex. This screen might also lead to the identification of 
other factors functioning in complexes with similar activities, factors that downregulate the 
abundance of dmyc transcripts or genes that affect dMyc stability. This screen led to the 
identification of a new dMyc interacting gene: chinmo. 
The insect brain 
 
The mushroom bodies (MB) or corpora pedunculata are a pair of structures in the brain of 
insects and other arthropods (Figure A, blue). They are usually described as lobed neuropils 
(dense networks of neurons and glia). They get their name from their roughly hemispherical 
calyx, a protuberance that is joining to the rest of the brain by a central nerve tract or 
peduncle that extend through the midbrain. Mushroom bodies are involved in olfactory 
learning and memory (Zars, 2000). Genes expressed early in their development share 
homology with genes involved in the early development of comparable regions in 
mammalian forebrain (Kurusu et al., 2000). The matrix of the mushroom bodies consists of 
ensembles of intrinsic neurons, which make synapses only within the structure where their 
soma is located, the so-called Kenyon cells. These are derived from globuli cells situated 
above the calyx. Globuli cells are the smallest neurons of the mid-brain. A fruitfly mushroom 
body comprises about 3,000 Kenyon cells. 
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Systematic clonal analysis demonstrates that a single mushroom body neuroblast sequentially 
generates at least 3 types of morphologically distinct neurons. Neurons projecting into the γ 
lobe of the adult MB are born first, prior to the mid-3rd instar larval stage. Neurons 
projecting into the α' and β' lobes are born between the mid-3rd instar larval stage and 
puparium formation. Finally, neurons projecting into the α and β lobes are born after 
puparium formation (Crittenden et al., 1998; Lee et al., 1999). 
The best known input neurons in the Drosophila olfactory system are projection neurons 
(PNs) which connect single glomeruli of the antennal lobe, based upon lineage and birth 
order, to the lateral horn and send side branches into the posterior part of the mushroom 
body, the calyx (Heisenberg, 1998). 
 
Chinmo`s role in the development of the brain 
 
So far, a mechanism identifying temporal identity in the neuroblast lineage was not known. 
In 2006, Zhu et al., published an EMS screen to find genes involved in specification of 
temporal identity in mushroom bodies in mosaic organisms (Zhu et al., 2006). They found 
one mutant in ~3500 screened chromosome arms, which they called chinmo due to the 
observed phenotype (chinmo= chronologically inappropriate morphogenesis). Chinmo 
mosaic flies had fewer γ and α`β` neurons and more late-born pαβ and αβ neurons. The 
affected gene was identified and shown to code for a protein containing a BTB/POZ domain 
and two C2H2 zinc fingers. Chinmo is expressed in early-born γ neurons, to a lower extent in 
the next born α`β` neurons and absent from the latest born pαβ and αβ neurons and 
neuroblasts (Figure B). The group could show that the 5`UTR is essential for establishing a 
temporal gradient of the Chinmo protein. 
In mushroom bodies and projection neurons a loss of chinmo autonomously caused early-
born neurons to adopt the cell fate of late-born neurons. Conversely, overexpression of 
Chinmo in the neuroblast lineage caused late-born neurons to adopt the cell fate of early born 
neurons. Thus, Chinmo specifies at least three different cell fates in the neuroblast lineage 
(high protein= γ neurons, low protein= α`β`neurons, no protein= pαβ neurons). 
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Myc`s role in neurogenesis 
 
Betschinger et al., 2006 demonstrated that dMyc is expressed in larval neuroblasts, but not in 
their differentiating daughter cells. However, in clones mutant for the growth inhibitor brat, 
dMyc was expressed in all cells and the nucleoli were enlarged. Both daughter cells started to 
grow and behaved like neuroblasts leading to brain tumours in those larvae. Thus, Brat 
posttranscriptionally inhibits dMyc in the differentiating daughter cells. Therefore, the effect 
of the brat mutant might be the result of overexpression of dMyc. Orian et al., 2007 could 
show that dMyc and the Notch co-repressor Groucho act together to regulate their common 
target genes vnd and int (downstream targets of EGF signalling) during neuronal 
development in the embryo. Moreover they showed that dMyc promotes neurogenesis in the 
embryonic PNS and the CNS (and possibly the larval PNS). Thus, Myc is expressed in the 
nervous system in flies, where it is required for precursor cell proliferation and possibly cell 
fate determination of neuroblasts. This raises the possibility that dMyc and Chinmo might 
work together to regulate neuronal differentiation. 
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Figure A: Odour information is carried from the third antennal segments and maxillary 
palps (not shown) to the antennal lobes, where receptor fibres are sorted 
according to their chemospecificities in about 40 glomeruli. These represent 
the primary odour qualities, which are reported to two major target areas in 
the brain, the dorsolateral protocerebrum (lateral horn) and the calyx of the 
mushroom body. The inner antennocerebral tract (iACT) connects individual 
glomeruli to both areas. α/α', β/β' and γ mark the three mushroom body 
subsystems (taken from M.Heisenberg, Nature Reviews Neuroscience 4, 266-
275, April 2003). 
 
Figure B: Chinmo mRNA (light-grey) is homogenously expressed during neuroblast 
development. Protein levels (blue) are reduced with further development in 
the neuroblast lineage of the mushroom body in the larval fly brain (upper 
panel). Chinmo specifies temporal identity of neural progeny in a dose-
dependent manner. Five different genotypes are represented. The diagonal 
lines depict the gradient of Chinmo protein expression over time in each 
genotype, with the vertical lines being connected to the corresponding neural 
identities: γ, α′β′, pαβ, and αβ neurons (lower panel) (taken from Chris Q. 
Doe, Cell 127, 2: 254-256). 
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Results 
1. In vivo mutagenesis screen 
 
Males “y w/Y; P{w+}CG31666; P{w+}CG32111” (“OG”) were mutagenised with EMS, a 
chemical agent that induces primarily point mutations randomly in the whole genome. Those 
males were crossed to flies with the genotype “w dmP0 tub-FRT-dMyc-FRT-GAL4 ey-FLP” 
(ey>dmP0, described in Chapter I, results section 6.). F1 flies with the genotype “w dmP0 tub-
FRT-dMyc-FRT-GAL4 ey-FLP/Y; P{w+}CG31666*/+; P{w+}CG32111*/+” were screened 
for eye defects (* =mutagenised). Flies with an obvious eye defect were kept, retested and 
balanced to obtain a stock. In total, 53950 flies were screened and 236 lines were established 
(Scioscia Hsiko Ait, 2004, diploma thesis). Among these lines, 5 complementation groups 
were found, which consisted of only 2 alleles each. This indicates that the screen was not 
saturated. 
In parallel to the EMS-screen, we crossed all available DrosDel and Exelixis deficiencies to 
our tester line (ey>dmP0). DrosDel deficiencies were generated by Ryder et al., 2007 and the 
Exelixis lines by Parks et al., 2004. Those deficiencies consist of large chromosomal deletions 
with characterised breakpoints and have a genetically isogenic background. Together they 
uncover more than 79,5% of the Drosophila genome. Deficiencies on the X-chromosome 
could not be analysed since dmyc is located on this chromosome, and only hemizygous dmP0 
and ey>dmP0 flies show a phenotype. 
A total of 605 deficiency lines were individually crossed to ey>dmP0 virgins and the 
“ey>dmP0/Y” sons heterozygous for the deficiency were screened for eye defects. Table 1 
shows an overview of all tested deficiencies and their genetic interaction. 4,1% of all tested 
deficiencies showed a strong (up to 100% of the male offspring showed a phenotype) or 
medium (more than 1/3rd of the male offspring showed a phenotype) interaction. Deficiencies 
with a weak penetrance (less than 1/3rd of the male offspring showed a phenotype) were not 
further analysed. To reduce the 25 remaining deficiencies to the really interesting ones, 
additional parameters were investigated that are also affected in “dmP0/Y; pontin5.2/+” flies, 
such as the duration of development and adult weight. Based on these additional assays, we 
classified the deficiencies as shown in Table 2. Category 1 contains deficiencies that showed 
at least 2 defects besides the eye defect with ey>dmP0. Category 2 encompasses deficiencies 
that affected one other feature and Category 3 reflects deficiencies that also affected the 
weight of control flies (dmP0rev, a wildtype revertant of the allele dmP0; Montero et al., 2008), 
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albeit more weakly). Deficiencies of Category 1 show the strongest interaction with dmyc and 
therefore we considered them most likely to also functionally interact with dMyc. 
Table 3 shows a summary of candidate genes of the Category 1 deficiencies and an example 
for a Category 3 deficiency. To be able to narrow down the regions of candidate genes inside 
the 25 deficiencies, we tested all overlapping publicly available deficiencies by crossing them 
to the ey>dmP0 flies and scoring eye defects amongst the relevant progeny. Of the 25 
deficiencies 23 were not investigated any further. Of these, 7 deficiencies were not further 
analysed, since additional smaller deficiencies collectively uncovering the same region were 
negative. These deficiencies might contain 2 genes that reveal the interaction with ey>dmP0 
only when simultaneously deleted; alternatively, a background mutation unlinked to the 
deficiency might be responsible for the observed interaction. For 6 deficiencies we were not 
able to narrow down the region of interest to a handable number of genes. For 9 deficiencies  
(highlighted in yellow in Table 2) we were able to narrow down the region of interest to a few 
candidate genes, however, either the publicly available mutations in those genes gave no 
phenotype with ey>dmP0 or no such mutations were available. However, such mutations might 
become available in future times and should then be tested. 
The remaining 2 deficiencies led to the identification of single candidate genes. In a first step, 
we were able to narrow down the region within Df(2L)Exel6005 that interacts with ey>dmP0 
to two genes, chinmo and CG31934, and within Df(3R)ED5249 to 8 genes. Subsequently, we 
tested all available mutations of the candidate genes for interaction with the ey>dmP0 
chromosome. Two genes, chinmo and Delta, showed a phenotype that reflected the phenotype 
observed with the deficiency. Therefore, we focused on those genes for further analysis. 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Interacting deficiencies from the Exelixis and DrosDel collections. In total, 25 
deficiencies were found to show a strong or intermediate interaction with 
ey>dmP0, and further investigated. Df stands for deficiencies. 
 
 
 
 
Interaction strength all Df Exelixis Df DrosDel Df 
  605 476 129 
strong 14 12 2 
medium 11 5 6 
weak 36 27 9 
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Deficiency Weight vVability Development dmP0 ey>dmP0 dmP0rev Category 
Cytological  
location 
Df(2L)ED778 +     + s  1 33E9 34A7 
Df(2R)Exel7123         s   3 49D5 49E6 
Df(2R)Exel6062         s   3 49E6 49F1 
Df(2R)Exel7130 +   + + s + 3 50D4 50E4 
Df(2R)Exel6064         s   3 53C10 53D2 
Df(2R)Exel6067         s   3 55F8 56A1 
Df(2R)Exel6071         s   3 57B3 57B16 
Df(3L)Exel6107 +     + s   1 64E5 64F5 
Df(3L)Exel6111 +       s   2 65E7 65F4 
Df(3L)Exel6123 +   +   s + 3 70D7 70E4 
Df(3L)Exel6135 +   +   s   1 76B11 76C4 
Df(3R)Exel6149     +   s   2 85A2 85A5 
Df(3R)Exel6162         s   3 87A1 87B5 
Df(3R)ED5942 +     + s + 3 91F12 92B3 
Df(2L)Exel6005 +     + m   1 22A3 22B1 
Df(2R)ED1612         m   3 42A14 42E7 
Df(3L)ED4079         m   3 61A5 61B1 
Df(3L)ED4342 pupal lethal m   1 64B1 64B13 
Df(3L)ED4786       + m   2 75F7 76A5 
Df(3R)ED5558       + m   2 86F9 87B10 
Df(3R)Exel6171   +   + m   1 87F14 88A4 
Df(3R)Exel6273         m   3 94B2 94B11 
Df(3R)ED6103 +     + m   1 94D3 94E9 
Df(3R)Exel6192         m   3 94B11 94D3 
Df(3R)Exel6193 +     + m   1 94D3 94E4 
 
Table 2: The 25 strongly or moderately interacting deficiencies were analysed for weight 
reduction, developmental delay, reduced viability and defective eyes upon 
crossing to the dmP0. According to the resulting phenotypes they were then 
subdivided into 3 categories: Category 1 for at least two clear defects, Category 2 
for one clear defect, Category 3 for no defects, or various defects that were also 
seen (more weakly) in control crosses. Dark blue and “s” indicates strong, light 
blue and “m” medium, interactions with ey>dmP0. A “+” stands for a significant 
effect on the analysed aspect. Specifically, a “+” was given when the weight of the 
flies was significantly changed (with p<0.05) as compared to control flies 
(“dmP0rev; Df(x)/+”), when viability was reduced to less than 1/3rd of the expected 
number of flies, when the development was prolonged ≥ 2 days or if the eye 
morphology was affected with dmP0. Deficiencies highlighted in yellow might 
ultimately allow the identification of the responsible “interacting gene”. 
Deficiencies in bold led to the identification of Chinmo and Delta, respectively. A 
“+” in dmP0rev indicates that the Df influenced not only the weight of dmP0 flies but 
also of dmP0rev flies. 
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Table 3:  Genes deleted by the indicated deficiencies are displayed (all Category 1 
deficiencies and one Category 3 deficiency); for simplicity, only named genes 
are listed (i.e. no genes with only “CG” numbers). Highlighted in bold are 
genes of the Tor signalling pathway (Tor, S6k), Dl, chinmo and TFIIEb (RNA 
Polymerase II transcription initiation). Dark blue colour indicates strong, light 
blue medium, interactions with ey>dmP0. “Coord. of 5`3`bp” stands for 
coordinates of 5’/3’ breakpoint and “cyt. loc.” stands for cytological location, 
cat. Stands for category. 
Deficiency selected genes cat. coord. of 5`3` bp cyt. loc. 
Df(2L)ED778 bun, ref2, nub, Pick1, kek1, ACX, Tor 1 12534671 13154415 33E9 34A7 
Df(3L)Exel6107 Ubp64E, Myt1, mad2, Pole2, PGRP-LD, Pmi, Tektin-C, vn, Txl, Cralbp, S6k 1 5712191 5861823 64E5 64F5 
Df(3L)Exel6135 serp, Oat, LCP1, tey, Gß76C, Gyc76C 1 19585782 19709572 76B11 76C4 
Df(3R)ED5942 Dl, Ino80, Dys, Vha13, ort, Nup58, bn1, GluClalpha, bnl 3 15052033 15660826 91F12 92B3 
Df(2L)Exel6005 Eno, RFeSP,cbp, frtz, chinmo, mRpL48 1 1556758 1739118 22A3 22B1 
Df(3L)ED4342 TFIIEß, Hexo1,dyl, Cip4, mRpS6, Syx17, Src64B, Tie 1 4258613 4603313 64B1 64B13 
Df(3R)Exel6171 Mst87F, Nsf2, E5, ems, Art6+9, Ipp, Orc2, rdx 1 9638639 9809255 87F14 88A4 
Df(3R)ED6103 Tango12, klg, Or94a+b, Imd, Gr94a, sav, cenB1A, hh, unk, p53, fzo 1 18714931 19074794 94D3 94E9 
Df(3R)Exel6193 α-Adaptin, Tango 12, cenB1A, klg, Or94a+b, Imd, Gr94a, sav, cenB1A, hh, unk, p53 1 18715437 18991827 94D3 94E4 
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2. Delta 
 
2.1  Introduction to Delta 
 
As will be shown below, the gene within Df(3R)ED5942 that was responsible for the genetic 
interaction with dmyc, could be identified as Delta. 
Delta is a component of the Notch signalling pathway. The ligand Delta (Dl), like the ligand 
Serrate (Ser), binds to the big extracellular domain of the Notch-receptor (Rebay et al., 1991). 
The consequence of this binding is cleavage of the Notch intracellular domain by sequence 
specific proteases including presinilin and nicastrin. The Notch intracellular domain is 
translocated into the nucleus, where it binds to Suppressor of Hairless (Su(H)), together with 
the co-activator Mastermind (Mam). The complex can activate the Notch target genes, such as 
enhancer of split-C, by direct binding of Su(H) to the Su(H) binding sites inside the 
regulatory regions of those genes (Bailey and Posakony, 1995; Lecourtois and Schweisguth, 
1995). In the absence of Delta and Serrate, the Notch receptor remains intact, and the 
repressor Hairless (H), together with the co-repressors Groucho (Gro) and C-terminal binding 
protein (CtBP) binds to Su(H) to repress the activation of Notch target genes (Furriols and 
Bray, 2000; Morel et al., 2001). 
There are several reports that the Notch signalling pathway and Myc cooperate in vertebrates. 
For example, a combination of genetic and molecular data demonstrated that Myc is a direct 
transcriptional target of Notch1, participating as an indispensable downstream effector in 
N1(IC) (intracellular domain of Notch1)-induced tumourigenic action (Klinakis et al., 2006). 
Moreover, Notch signalling not only affects patterning, but also proliferation (Wu et al., 
2007).  
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2.2  Genetic interaction between Delta and dmyc 
 
The gene span of the deficiency in which Delta was found is shown in Figure 1. One other 
line, Df(3R)Exel6184, deleting a small region of 12 genes inside the cytological region that is 
deleted by Df(3R)ED5942, showed no eye phenotype when crossed to ey>dmP0. In contrast, 
two other lines, Df(3R)Dl-M2 and Df(3R)Dl-BX12, showed an easily discernable eye 
phenotype in a dmyc hypomorphic background. Thus, we focused on the region that was 
deleted in all 3 interacting deficiencies which contains only 8 genes. All available mutants 
were ordered and tested for interaction with ey>dmP0. Dl3, which carries a loss-of-function 
mutation in Delta, displayed a strong eye phenotype in a hypomorphic dmyc background 
(Figure 2). The eyes were pear-shaped and rough, resembling the phenotype of “ey>dmP0; Df 
ED5942/+” flies. All other tested mutants did not interact. 
To confirm that dmyc and Dl interact with each other and to rule out that the effect we see is 
due to a background mutation, we ordered different Delta alleles and crossed them to various 
dmyc alleles. Dl3, which is the strongest Dl allele, as well as Df(3R)ED5942 and Df(3R)Dl-
BX12 showed a strong interaction with all the dmyc alleles tested. Those were dmP0, dmP0 
tub>dMyc>GAL4 ey-FLP (P-element insertion in the promoter region), dmPL35 
tub>dMyc>GAL4 ey-FLP (P-element insertion at the end of the 2nd intron), w dm4 
tub>dMyc>GAL4 ey-FLP (null allele) and dm1 (gypsy-element insertion in the 1st intron). 
The different alleles were generated on different genetic backgrounds. The lethal alleles 
dmPL35 and dm4, as well as dmP0, are partially rescued by the tub>dMyc>GAL4 transgene, 
except for the head capsule where the dmyc mutant phenotypes are revealed. In all cases, 
control flies (dmP0rev) were not affected. Dlrev10, an amorphic allele that lacks the promoter 
region, transcription start site and first exon of Delta, only showed an eye defect when 
simultaneously hemizygous for the ey>dmP0 chromosome, but not for any other dmyc allele 
that was tested. Thus, either Dlrev10 is not a null allele or Dl3 is antimorphic (e.g. it might act 
as a dominant-negative allele), since Dl3 showed a stronger genetic interaction with dmyc. 
Dlrev10 only showed an interaction when Ser was additionally mutated. Dl6B, the weakest Dl 
allele, showed no interaction with any dmyc allele (see Table 4). In combination with strong 
overexpression of dMyc (“GM”) a Delta mutation lead to rougher and bigger ommatidia. 
Thus, Delta is the gene, which is responsible for the genetic interaction with dmyc, since other 
Dl alleles gave comparable phenotypes and different alleles of dmyc showed this interaction. 
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Figure 1:  Genes deleted by the deficiency Df(3R)ED5942 (blue arrows). Shown are all 
interacting and non-interacting deficiencies. Interacting deficiencies are 
marked in green, non-interacting deficiencies in red. One deficiency in this 
region, Df(3R)Exel6184, showed no interaction with ey>dmP0, two other 
deficiencies, Df(3R)Dl-BX12 and Df(3R)Dl-M2, showed a positive interaction 
with ey>dmP0 resulting in a rough and dented eye morphology. The region that 
is deleted by all 3 positive interacting deficiencies contains 8 genes, including 
Delta. Numbers indicate molecular coordinates on the 3rd chromosome, right 
arm. 
 
 
 
 
Figure 2: Genetic interaction between Dl and dmyc. Scanning electron microscope 
pictures of eyes that are hypomorphic for dmyc (panel A) or hypomorphic for 
dmyc and heterozygous for Delta (panel B). The rough and pear-shaped eye is 
comparable to the one of “dmP0/Y; pontin5.2/+” flies. Anterior is to the right. 
The depicted phenotype was observed for all flies with the corresponding 
phenotype (n=9). 
 
 
Label:  Genotype: 
A w dmP0 tub>dMyc>GAL4 ey-FLP/Y 
B w dmP0 tub>dMyc>GAL4 ey-FLP/Y; Dl3/+ 
Df(3R)ED5942 
 
Df(3R)Exel6184 
Df(3R)Dl-BX12 
Df(3R)Dl-M2  
Df(3R)ED5942 
molecular 
coordinates 
molecular 
coordinates 
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Table 4:  Different Delta alleles were tested with a series of dmyc alleles for genetic 
interactions revealed by aberrant eye morphologies. Dl3 and Df(3R)Dl-BX12 
are the strongest alleles, which showed an eye defect with all dmyc alleles, 
followed by the deficiency in which Dl was found. Dl6B, a weak Dl allele 
showed no specific eye phenotype in flies that are mutant for dmyc and Dl. 
Green (and “++”) indicates an eye phenotype in at least 80% of the F1, light 
green (and “+”) stands for eye defects in 50-80% of the F1, orange (and “+-“) 
indicates an eye defect in less than 50% of the scored flies, and red means no 
eye phenotype was observed. For each data point at least 16 flies were scored. 
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2.3  Interaction between Notch signalling components and dmyc 
 
The best-described role for Dl is that of a ligand for Notch. This suggests that the Notch 
signalling pathway might interact with dMyc. To investigate if other components of the Notch 
signalling pathway interact with dMyc, various transgenes or mutants for Suppressor of 
Hairless (Su(H)), Hairless (H), Serrate (Ser), Notch (N), Lobe (L), single-minded (sim, a 
Notch signalling target gene) and groucho (gro) were tested for interaction with ey>dmP0 and 
control flies. Whenever an interaction was observed, the corresponding transgene was also 
tested with dmP0 itself. Although Delta and a dominant-negative version of Ser showed a 
genetic interaction with ey>dmP0, all other components of the Notch signalling pathway (or its 
target genes) did not reveal an eye phenotype when hemizygous for the ey>dmP0 chromosome 
(see Table 5). Possibly, those transgenes were expressed too weakly to cause a genetic 
interaction with ey>dmP0.  
From the experiments above we can conclude that Dl and dmyc interact genetically, however 
other Notch signalling components do not seem to play a role for this interaction. As a next 
step, epistasis experiments with dMyc and homozygous mutations for Notch pathway 
components should be done to further investigate how (and if) the two pathways are 
connected. Since we focused on a different candidate dMyc interactor, we did not continue 
our investigations of Dl for the moment. 
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 ey>dmP0/Y ey>dm+/Y dmPO/Y dmPOrev/Y comments 
      
Su(H) - nt nt nt  
Su(H) GOF ++ ++ - -  
H - - nt nt  
H GOF - - nt nt  
L -/+/++ nt -/+/++ -/+/++ 
milder effects with dmP0rev 
than with dmP0 
L GOF ++ ++ - -  
Dl ++ - + -  
Dl GOF nt nt nt nt  
Ser -/+ nt nt nt  
Ser GOF nt nt nt nt  
N - - nt nt  
N GOF + + nt nt  
N LOF + + nt nt  
sim - nt nt nt  
gro - - nt nt  
 
Table 5:  Different components of the Notch signalling pathway were tested for 
interaction with the hypomorphic allele dmP0. Only Dl and a dominant-negative 
allele of Serrate showed an interaction with dmyc and not with control flies. A 
“++” is defined by an eye phenotype in at least 50% of the analysed flies, a “+” 
stands for eye defects in up to 50% of the analysed flies, and a “-“ indicates 
that no eye phenotype was observed in these flies. If more than one sign is 
shown, different transgenes were tested with different outcomes; “nt” indicates 
that this interaction was not tested. GOF stands for UAS-transgenes expressing 
the corresponding cDNA, or a gain-of-function mutant allele in the case of H. 
 
Transgene:  Genotype: 
Su(H) Su(H)1 
Su(H)GOF UAS SU(H)VP16 
 UAS SU(H) 
 UAS SU(H) (III) 
H ey-H15-1 
 sev-H267.1 
H GOF HE31(FRT-82B) 
L L1-5 
L GOF UAS L (III) 
Dl Dl3 
Ser SerlacZ 
 Ser DN1 
N  Nl1N-ts1g2f1 
N GOF UAS ECN (II) 
N LOF UAS-N.dsRNA9G 
 UAS-N.dsRNA14E 
sim sim2 
gro gro1 
 groC105 
 groKG07117 
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3. CG31666/chinmo 
 
3.1  Identification of CG31666/chinmo 
 
3.1.1 Deficiency screen 
 
The Exelixis deficiency Df(2L)Exel6005 resulted in an intermediate eye phenotype in the 
initial screen with ey>dmP0 (see Table 2 and Figure 5, panel A). Further characterisation 
showed that “dmP0/Y; Df(2L)Exel6005/+” flies had a strong eye phenotype and a clear 
reduction in weight, leading us to classify this deficiency as a strong dmyc-interactor 
(Category 1, Table 3). 
Df(2L)Exel6005 is located on the left arm of the 2nd chromosome at cytological location 
22A3-22B1 and deletes 17 genes. Two other deficiencies Df(2L)Exel8004 and 
Df(2L)Exel7007, that overlap Df(2L)Exel6005, did not show a genetic interaction with 
ey>dmP0, but the deficiencies Df(2L)frtz14 and Df(2L)frtz24 positively interacted with 
ey>dmP0 (see Figure 3). Thus, only 2 genes remained as possible new dmyc interacting genes, 
CG31666 and CG31934 (see Figure 3). 
In parallel, all available mutations uncovered by Df(2L)Exel6005 were tested for interaction 
with ey>dmP0. However, all mutations outside of the region of overlap between 
Df(2L)Exel6005, Df(2L)frtz14 and Df(2L)frtz24 showed no interaction with ey>dmP0. No 
alleles were reported for CG31934 and no transgenes were available. Therefore, CG31934 
could not be tested for a genetic interaction with dmyc. Fortunately, it was not necessary 
anymore to analyse CG13943 since we found out that another gene was responsible for the 
interaction with dmyc, CG31666. CG31666 also called Chinmo showed a dominant 
interaction with dmyc. We tested 3 different chinmo alleles (chinmo108, chinmo110, chinmo134; 
a gift from H.Stocker) for interaction with ey>dmP0 flies: flies with the genotype “w dmP0 
tub>dMyc>GAL4 ey-FLP/Y; chinmoX/+” were analysed for irregular ommatidia. All 3 alleles 
resulted in a rough and dented eye comparable to the phenotype that we observed in 
combination with the deficiency (see Figure 4). Thus, the gene that causes the phenotype in 
ey>dmP0; Df(2L)Exel6005 is chinmo. 
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Figure 3:  Gene span of interacting deficiency Df(2L)Exel6005. Shown is the cytological 
band that is deleted and all tested interacting and non-interacting deficiencies. 
Interacting deficiencies are marked in green, non-interacting deficiencies in 
red. Two other deficiencies in this region showed no interaction with ey>dmP0, 
Df(2L)Exel8004 and Df(2L)Exel7007. In contrast, Df(2L)frtz14 and 
Df(2L)frtz24 showed an eye phenotype with ey>dmP0. The region that overlaps 
between the interacting deficiencies and that is not affected by the non-
interacting deficiencies contains only 2 genes, CG31666 (Chinmo) and 
CG31934. The same conventions apply as for Figure 1. 
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Df(2L)Exel8004  Df(2L)Exel7007 
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Figure 4:  Interaction between the 3 chinmo alleles and ey>dmP0 (right column). The eyes 
are clearly distorted for all 3 chinmo alleles. Control ey>dm+ flies (left column) 
are unaffected. The control chromosome is isogenic with the chinmo alleles 
and shows no interaction with ey>dmP0 (top row). The depicted phenotypes 
were observed for a majority of the flies with the corresponding phenotypes 
(n>50%). The experiment was performed in two independent biological 
replicates. Anterior is to the right. 
 
 
Label:  Genotype: 
A y w tub>dMyc>GAL4 ey-FLP/Y; FRT-40/CyO, y+ 
B y w tub>dMyc>GAL4 ey-FLP/Y; FRT-40 chinmo108/CyO, y+ 
C y w tub>dMyc>GAL4 ey-FLP/Y; FRT-40 chinmo110/CyO, y+ 
 D y w tub>dMyc>GAL4 ey-FLP/Y; FRT-40 chinmo134/CyO, y+ 
 E w dmP0 tub>dMyc>GAL4 ey-FLP/Y; FRT-40/CyO, y+ 
 F w dmP0 tub>dMyc>GAL4 ey-FLP/Y; FRT-40 chinmo108/CyO, y+ 
 G w dmP0 tub>dMyc>GAL4 ey-FLP/Y; FRT-40 chinmo110/CyO, y+ 
H  w dmP0 tub>dMyc>GAL4 ey-FLP/Y; FRT-40 chinmo134/CyO, y+ 
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3.1.2. Rescue of the eye phenotype caused by Df(2L)Exel6005 and ey>dmP0 
 
We received 2 UAS-transgenes of Chinmo (kind gift of H.Stocker). These transgenes are 
presumably weak, since they carry only 2 UAS-sites (enhancer sequences that are bound by 
the transcriptional activator GAL4 and thereby mediate transcriptional activation in transgenic 
flies expressing GAL4; the extent of transcriptional activation increases with the number of 
UAS-sites, and typical UAS-transgenes carry at least 5 such sites).  
Even though these transgenes express a protein lacking one amino acid (Ser) as compared to 
the published Drosophila reference proteome, they were able to rescue the phenotype 
displayed by “w dmP0 tub>dMyc>GAL4 ey-FLP/Y; Df(2L)Exel6005/+” flies almost to 
wildtype appearance (see Figure 5). 
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Figure 5:  Rescue of the “ey>dmP0/Y; Df(2L)Exel6005/+” eye phenotype by 
overexpression of a Chinmo transgene. Panels B and C show eyes from flies 
carrying two different Chinmo transgene insertions. The pear-shaped and 
dented eye phenotype is rescued completely in those flies. The depicted 
phenotypes were observed for a majority of the flies with the corresponding 
phenotypes (>80%). The experiment was performed in two independent 
biological replicates. Anterior is to the right.  
 
  
Label:  Genotype: 
A w dmP0 tub>dMyc>GAL4 ey-FLP/Y; Exel6005/+ 
B w dmP0 tub>dMyc>GAL4 ey-FLP/Y; Exel6005/UAS-ChinmoT1.1 
C w dmP0 tub>dMyc>GAL4 ey-FLP/Y; Exel6005/+; UAS-ChinmoT1.2/+ 
 
 
A C B 
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3.1.3 Chinmo gene and protein 
 
Chinmo is a large gene comprising 9 exons and spanning a total length of 45`368 base pairs. 
The ORF starts at the end of the 5th exon and ends at the beginning of the 9th exon and codes 
for a protein of 604 amino acids. There are 3 transcripts (RA, RC, RD) that give rise to the 
same protein, and a fourth transcript (RB), which has a predicted second STOP codon and 
will give rise to a protein of 794 amino acids. This second STOP codon was never confirmed 
by ESTs (Figure 6). 
The Chinmo protein has two recognisable domains, a BTB/POZ (Broad complex, Tramtrack, 
Bric à Brac or poxvirus and zinc finger) domain at the N-terminus and two C2H2 zinc fingers 
at the C-terminus. BTB/POZ domains are found in proteins that are involved in diverse 
biological processes, like DNA damage response or cell cycle progression. BTB/POZ 
domains mediate homo-dimerisation and in some instances hetero-dimerisation and binding 
to DNA (Bardwell, Treisman, 1994).  
Zinc fingers are involved in DNA binding. Classical C2H2-type zinc fingers (Znf) contain a 
short beta hairpin and an alpha helix (beta/beta/alpha structure), where a single zinc atom is 
held in place by Cys2His2 (C2H2) residues in a tetrahedral array. The C2H2 Znf motifs 
recognise DNA sequences by binding to the major groove of DNA via a short alpha-helix in 
the Znf, spanning 3-4 bases of the DNA (Wolfe et al., 2000). C2H2 Znfs can also bind to RNA 
and proteins. 
Interestingly, the zinc-finger transcription factor Miz-1 that mediates repression by Myc also 
contains a BTB/POZ domain and Zn-fingers (Wanzel, 2003). So far, the fly homologue of 
Miz-1 has not been identified - many fly proteins contain BTB/POZ domains and Zn fingers, 
but none of them shows recognisable similarity to Miz-1 outside of these domains. Thus, 
taking into account the genetic interaction with dmyc, Chinmo might be a functional homolog 
of Miz-1 in flies. 
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Figure 6: Schematic diagram of chinmo transcripts. The transcripts RA, RC and RD 
contain the same ORF, coding for a protein of 604 amino acids. Transcript RB 
is derived from an alternative splicing between exons 8 and 9, and contains an 
ORF with a predicted second stop-codon, coding for a protein of 794 amino 
acids length. Both protein isoforms contain a BTB/POZ domain and two C2H2 
zinc fingers (Znf) that are shown in yellow in the RD isoform. Numbers 
indicate nucleotides (nt) and amino acids (aa) (right) and exons (bottom). 
Green shows the open reading frame (ORF) and red the untranslated region 
(UTR). 
 1 2 3 4 5 6 7 8 9 
 RD 
 RA 
 RB 
6032nt, 604aa 
5052nt, 604aa 
 4914nt, 794aa 
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3.1.4. ey-FLP screen (“pinhead” screen) 
 
Interestingly, Chinmo was also found earlier in an ey-FLP-screen for mutations in genes, 
which are involved in growth control (S. Oldham & E. Hafen, pers. communication). This so-
called “pinhead screen” was based on the FLP/FRT-system (Newsome et al., 2000; Xu and 
Rubin, 1993). This system allows the generation of homozygous mutant clones by site-
specific mitotic recombination. By expressing FLP recombinase under the control of eyeless 
regulatory sequences (ey-FLP) the recombination events are restricted to the developing head 
capsule. This promoter provides continuous high levels of FLP activity throughout the 
proliferative phase of eye and head development, resulting in a high frequency of mosaicism. 
Mitotic recombination occurs between two FRT sequences on homologous chromosome 
arms. One chromosome arm carries the FRT insertion as well as the mutation of interest and 
the other chromosome arm carries a w+ marker and a cell lethal mutation (which prevents the 
survival of homozygous cells). The recombination results in 2 different daughter cells: an 
mutant cell bearing two copies of the mutant allele and a wildtype sister cell; the former is 
marked by the absence of the w+, whereas the latter is w+. To induce random mutations, males 
with the genotype “y w ey-FLP/Y; FRT-40/FRT-40” were mutagenised with EMS and 
crossed to females “y w ey-FLP; FRT-40 cl w+/CyO, y+.” The offspring was screened for 
unbalanced flies with mosaic eyes. Flies with a smaller or bigger head were kept and 
established as stocks, complementation groups were established and some of the responsible 
genes causing a small head-phenotype were mapped. 
One complementation group resulting in a small head was shown to affect the 
chinmo/CG31666 gene. Eye section of chinmo alleles performed by A.Sulzer (Sulzer, 2003, 
diploma thesis) showed that the reduction in head size was based on a cell number reduction 
and not caused by a cell size reduction. Further interaction studies with different components 
of the Insulin signalling pathway, which affects growth and proliferation without affecting 
pattern formation, indicated that Chinmo does not function in the Insulin signalling pathway. 
 
3.1.4.1 Characterization of the chinmo alleles 
 
From the ey-FLP-screen, 3 different chinmo alleles were obtained (Figure 7). Allele chinmo110 
carries a C to T transition, which leads to an amino acid exchange from histidine (CAT) to 
tyrosine (TAT). Allele chinmo108 has a deletion of 11 bp in the end of the 7th exon. This 
deletion leads to a frame shift and a premature STOP after 30 aa. Allele chinmo134 is a base 
substitution from cytosine to thymine in the beginning of the 7th exon. This mutation leads to 
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a substitution of a codon for glutamine (CAG) with a STOP codon (TAG). In all three alleles 
the zinc finger domain is either mutated (chinmo110) or completely deleted (chinmo108, 
chinmo134). A. Sulzer showed that chinmo110 was the weakest allele, followed by chinmo108 
and chinmo134 (Sulzer, 2003, diploma thesis). 
To characterise the strength of the different chinmo alleles in a different way we crossed them 
among one another and with the deficiency that deletes chinmo (Df(2L)Exel6005). The lines 
were balanced with a balancer (CyO, GFP), in order to distinguish the mutant from the 
heterozygous flies. Egg-lays were performed on apple agar plates and 100 eggs per cross were 
transferred onto fresh apple agar plates. The offspring was screened for heteroallelic mutant 
animals. All heteroallelic combinations cause embryonic lethality. Therefore, no conclusion 
can be drawn about the allelic strengths, however this experiment confirms that the 
Df(2L)Exel6005 indeed deletes chinmo, since not a single fly carrying both a chinmo allele 
and the deficiency was obtained. 
Amongst other phenotypes, “dmP0/Y; Df(2L)Exel6005/+” flies have a clear reduction in 
weight, compared to control flies. Control flies weigh 0,694g in average, whereas “dmP0/Y; 
Df(2L)Exel6005/+” flies weigh 0.588g in average; for comparison, “dmP0/Y; pontin5.2/+” flies 
weigh 0,598g in average. To determine if the different chinmo alleles also cause a reduction 
in weight, flies carrying the different alleles were crossed to dmP0 or dmP0rev flies and 20 
appropriate sons were analysed for their weight and compared to control flies (“dmP0/Y; 
iso/+”, where “iso” stands for a chromosome that is isogenic with Df(2L)Exel6005). Only 
chinmo108 showed a significant reduction in weight. However, also wildtype flies were 
affected. Thus, the mutations of flies carrying the different chinmo alleles might not be strong 
enough to cause a weight reduction with dmP0. 
Flies carrying the genotype “dmP0/Y; chinmoX/+” were also tested for a developmental delay 
and a reduced viability. None of those flies had a prolonged development and only chinmo110 
showed a slightly reduced viability in a dmP0 background. 
These results show that the different chinmo alleles do not behave like the pontin5.2 allele with 
respect to dMyc dependent processes like growth. Thus, Chinmo might not be involved in 
these processes or the alleles are to weak to cause such an effect. However, they strongly 
affect the proper regulation of eye size and shape when dMyc levels are reduced. 
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Figure 7:  Schematic diagram of the different chinmo alleles. chinmo110 has most 
probably a non-functional Zn-finger due to a C-T transition that changes the 
first conserved histidine to a tyrosine. chinmo108 carries a deletion after the 
BTB/POZ domain, followed by a frame-shift and a premature stop codon,  and 
allele chinmo134 contains a G-T transversion, which leads to a premature 
STOP. The BTB/POZ domain is located at amino acids 32-128 and the two 
zinc finger domains at amino acids 517-540 and 545-568. The numbers to the 
right indicate the amino acid coordinates of the mutant codons. The yellow 
boxes to the right indicate the 2 C2H2 zinc fingers of Chinmo. 
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3.1.4.2 Confirmation of “pinheads” 
 
To validate the small heads that were observed in the ey-FLP-screen, we crossed the different 
chinmo alleles to FRT-40 cl w+. All three crosses produced flies with small heads 
(“pinheads”). The phenotype for chinmo134 was even stronger than the one that was observed 
in the ey-FLP-screen. The pictures to the right clearly show a reduction in ommatidial number 
and a rough eye phenotype for all alleles. The highest fraction of homozygous mutant 
ommatidia was obtained for chinmo110 indicated by very rare w+ ommatidia (see Figure 8). 
This observation confirms the small heads and the relative allelic strengths of the different 
chinmo alleles that were observed in the ey-FLP screen (Sulzer, 2003, diploma thesis). 
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Figure 8: Phenotypes of the Chinmo mosaic eyes. The heads for chinmo108 (panels B) 
and chinmo110 (panels C) are clearly smaller than control heads (panels A). The 
head for chinmo134 (panels D) is clearly distorted. The overall eye size is 
reduced for all alleles and the eyes are rough (right panels). Anterior is to the 
right. Homozygous mutant tissue is represented by w- ommatidia. The depicted 
phenotypes were observed for a majority of the flies with the corresponding 
phenotypes (100% of at least 2 analysed flies per genotype). The experiment 
was performed in two independent biological replicates 
 
 
Label:  Genotype: 
A y w tub>dMyc>GAL4 ey-FLP; FRT-40/FRT-40 cl w+ 
B y w tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo108/FRT-40 cl w+ 
C y w tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo110/FRT-40 cl w+ 
 D y w tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo134/FRT-40 cl w+
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3.1.5. In vivo mutagenesis screen 
 
All lines from the in vivo mutagenesis screen (described earlier) that carried mutations on the 
second chromosome were crossed to the deficiency Df(2L)Exel6005 and tested for non-
complementation in order to find a mutation in chinmo. Forty-four balanced screen lines were 
tested and one line, 380C1 resulted in offspring with a strongly reduced viability; the 
heteroallelic flies mostly died as pupae and only 1/5th of the expected flies eclosed. These 
adults displayed a severe eye phenotype with rough, dented eyes and a reduced number of 
ommatidia and defective wings with blisters. 
To prove that line 380C1 carries a mutation in chinmo, the 3 existing chinmo alleles were 
crossed to line 380C1. Indeed, the offspring that was obtained from the cross with chinmo134 
died as pupae. Some of these pupae were dissected and shown to have split heads, short 
mouthparts and small and rough ommatidia. The crosses with chinmo108 and chinmo110 also 
resulted in pupal lethality, however in these crosses 1/5th of the expected flies reached 
adulthood. Those flies showed clear defects: Their wings were smaller and blistered, the 
thoraxes and the heads split, ommatidia small and rough, and the ocelli, a type of 
photoreceptor organs, were missing (Figure 9). This indicates that the allele 380C1 is indeed a 
new chinmo allele. From now on 380C1 will be referred to as chinmo380C1. However, since 
heteroallelic combinations of the alleles chinmo108, chinmo110 and chinmo134 result in 
embryonic lethality, but heteroallelic combinations with chinmo380C1 reach pupal stage, 
chinmo380C1 most probably is a hypomorphic allele. 
In order to find the mutation in chinmo380C1, we sequenced chinmo`s predicted exons 1, 2, 4, 5 
and 9. So far, we have not found a mutation. Exon 3 and parts of exon 6, 7 and 8 still need to 
be analysed. However, if the mutation affects regulatory regions outside the coding 
sequences, we will not be able to find them by sequencing of the exons. It is also possible 
(although unlikely) that the non-complementation might be a result of a dominant intergenic 
non-complementation, i.e. affect a gene other than chinmo. 
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Figure 9:  Transheteroallelic combinations of the screen line 380C1 with 
Df(2L)Exel6005 and different chinmo alleles resulted in completely distorted 
flies. The heads are split, the eyes are smaller with rough and dented 
ommatidia, the wings carry blisters and are smaller, and the thoraxes are split. 
The strongest phenotype was seen in trans with chinmo134, since all 
chinmo308C1/134 flies die as pupae. Panel D shows a dead pupa. The depicted 
phenotypes were observed for a majority of the flies with the corresponding 
genotypes. The experiment was performed in two independent biological 
replicates. 
 
 
Label: Genotype: 
A y w; chinmo380C1/Df(2L)Exel6005 
B y w; chinmo380C1/FRT-40 chinmo108 
C y w; chinmo380C1/FRT-40 chinmo110 
D y w; chinmo380C1/FRT-40 chinmo134 
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3.1.6 Additional alleles 
 
The Bloomington stock centre provides 2 different chinmo alleles: chinmoM33, an EMS 
induced allele that carries a missense mutation in the BTB/POZ domain, which leads to an 
amino acid alteration from phenylalanine to isoleucine (F88I), and chinmok13009, which carries 
a P-element insertion in the first exon of chinmo. The Szeged Drosophila stock centre 
provides one allele: chinmoSH1971, which carries a P-element insertion in the first exon of 
chinmo. All 3 alleles are recessive lethal. Flies with the genotype “ey>dmP0/Y; chinmoM33/+” 
showed a weak eye phenotype (in 11% of 18 analysed flies) and flies with the genotype 
“ey>dmP0/Y; chinmo k13009/+” showed a strong eye phenotype (in 33% of 10 analysed flies). 
However, chinmoSH1971 did not interact at all with ey>dmP0. 
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3.2  Effects of Chinmo on dMyc-dependent processes in vivo 
 
3.2.1. A reduction in Chinmo levels strongly influences growth in dmyc null flies 
 
Hemizygous dmyc null mutants (dm4) appear to have a normal embryonic development and 
larvae hatch with normal frequencies. However, within 24 hours of hatching, these larvae are 
smaller than wildtype. After moulting into second instar, these larvae stop growing and most 
die soon afterwards (Pierce et al., 2004). 
Flies that are null for dmyc but carry a ubiquitously expressed cDNA that rescues the null 
mutant phenotype in the whole fly (w dm4 tub>dMyc>GAL4 ey-FLP), except in the eye, 
reach adulthood. However, their ommatidial size and number are clearly reduced. We were 
interested if a mutation in chinmo would enhance this phenotype since we could already show 
that chinmo affects eye development in a dmyc hypomorphic background, and a stronger 
dmyc allele might lead to an even more severe eye phenotype. Therefore, we analysed the 
eyes of flies with the genotype “w dm4 tub>dMyc>GAL4 ey-FLP/Y; chinmoX/+” (see Figure 
10). In all 3 cases very few ommatidia, if any, were left. chinmo134 showed the strongest 
effect. Those flies were dissected from their pupal cases, since they are not able to eclose 
anymore. These results confirm a strong genetic interaction between chinmo and dmyc with a 
second, independent dmyc allele. 
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Figure 10:  Interaction between the 3 chinmo alleles and dm4 (right). The eyes are clearly 
distorted for all 3 chinmo alleles. Control flies are unaffected (left columns). 
The control chromosome (top row) is isogenic with the chinmo alleles. 
Anterior is to the right. The depicted phenotypes were observed for a majority 
of the flies with the corresponding phenotypes. The experiment was performed 
in two independent biological replicates at two different temperatures (25°C, 
18°C).  
 
 
Label:  Genotype: 
A y w tub>dMyc>GAL4 ey-FLP; FRT-40/CyO, y+ 
B y w tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo108/CyO, y+ 
C y w tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo110/CyO, y+ 
 D y w tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo134/CyO, y+ 
 I w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40/CyO, y+ 
 J w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo108/CyO, y+ 
 K w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo110/CyO, y+ 
 L w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo134/CyO, y+ 
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3.2.2 Chinmo and dMyc function in partially redundant pathways  
 
To address the epistatic relationship between Chinmo and dMyc, we analysed doubly mutant 
flies. When dMyc levels are reduced (Figure 11E) the overall head size is reduced. When 
dMyc is completely absent (Figure 11I), the head is even smaller. In both cases, the overall 
structure of the head is well formed. Similarly, heads mutant for chinmo are small, but 
normally patterned (Figure 8). However, when Chinmo levels are reduced in a head-specific 
dmyc mutant background, the heads not only get smaller but also completely disrupted and 
they can be hardly recognized as fly heads. In a dmP0 background, chinmo134 showed the 
strongest effects. The doubly mutant flies were not hatching anymore and had to be manually 
dissected from their pupal cases. Alleles chinmo110 and chinmo108 showed comparable effects: 
a reduction in head size and a decreased number of ommatidia. In a dm4 background, no 
Chinmo mutants were able to eclose, and chinmo108 and chinmo134 showed the strongest 
defects, followed by chinmo110. 
These data show that the phenotype caused by the complete absence of dMyc is exacerbated 
by a reduction of Chinmo. Thus, Chinmo retains at least some function in the absence of 
dMyc (as witnessed by the substantial development of “dm4 chinmo+” heads as compared to 
“dm4 chinmo-“ heads). Conversely, assuming that the available chinmo alleles are null alleles, 
dMyc can direct substantial growth and development in the absence of Chinmo (compare 
“dm+ chinmo-“ and “dm4 chinmo-“). Chinmo and dMyc therefore function in (partially) 
redundant pathways whose collective output is needed for head growth and development 
(these pathways are only partially redundant, since both “dm4 chinmo+” and “dm+ chinmo-“ 
heads show clear growth defects). This interpretation may have to be changed if the tested 
chinmo alleles turn out to retain significant activity – in such a case it is possible that dMycs 
role in head development fully depends on Chinmo (but not vice versa). However, these 
results do not role out or confirm the possibility that, in part, dMyc and Chinmo also function 
in the same pathway, as was suggested by our earlier observations of a dominant interaction 
between chinmo and dmyc. 
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Figure 11: Phenotypes of the chinmo mosaic eyes in a dmP0 (E-H) or dm4 background (I-
L). The heads for chinmo108 (panel F), chinmo110 (panel G) and chinmo134 
(panel H) are clearly smaller than control heads (panel E). All heads are clearly 
distorted. The overall eye size is reduced for all alleles (right panels, indicated 
with *). The phenotypes are even more severe in a dm4 mutant background 
(panels I-L). The depicted phenotypes were observed for a majority of the flies 
with the corresponding genotypes (80% of at least 2 analysed flies per 
genotype). Anterior is to the right. The experiment was performed in two 
independent biological replicates. 
 
 
Label:  Genotype: 
E w dmP0 tub>dMyc>GAL4 ey-FLP; FRT-40/FRT-40 cl w+ 
F w dmP0 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo108/FRT-40 cl w+ 
G w dmP0 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo110/FRT-40 cl  w+ 
 H w dmP0 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo134/FRT-40 cl w+ 
I w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40/FRT40 cl w+ 
J w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo108/FRT-40 cl w+ 
K w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo110/FRT-40 cl w+ 
 L w dm4 tub>dMyc>GAL4 ey-FLP; FRT-40 chinmo134/FRT-40 cl w+ 
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3.2.3 Chinmo overexpression transgenes 
 
So far, we only performed experiments in a Chinmo mutant background. We were also 
interested in how overexpression of Chinmo would affect dMyc-dependent processes in vivo. 
For this purpose, we obtained a chinmo cDNA from the Berkeley Drosophila Genome Project 
(BDGP Gold collection clone SD4616). This cDNA clone originates from RNA of 
Drosophila Schneider L2 cells and is cloned in the vector pOT2. We tagged the cDNA with 
an “AU1”-epitope tag and subcloned it first into pBluescript SK+ (Invitrogen) and 
subsequently into pUASTB (see Materials and Methods for detailed description), to produce 
the plasmid pUAS-Chinmo. This plasmid does not contain the 5` and 3`untranslated regions 
of chinmo. 
Transgenic flies for Chinmo were established by using the ΦC31 integrase system. As a 
landing site for pUAS-Chinmo we chose 102D on the 4th chromosome to have the other 
chromosomes free for our investigations (pUAS-ChinmoIV). Later on, pUAS-Chinmo was 
also integrated in the landing site ZH-86Fb by the Hafen laboratory, which kindly provided us 
with 2 different lines. Another UAS-transgene, which we will refer to as UAS-Chinmo3`5`UTR, 
was kindly provided by the group of Tzumin Lee (Zhu et al., 2006). This UAS-Chinmo 
transgene contains the full-length cDNA including the 5’ and 3’ untranslated regions, which 
were shown to be important for proper gene expression (Zhu et al., 2006), but no epitope tag. 
All UAS-transgenes were crossed to flies expressing GAL4 ubiquitously under the control of 
the armadillo or tubulin promoters, or in specific tissues under the control of GMR or 
apterous (eye and dorsal compartment of the wing disc, respectively). However, none of the 
crosses led to adult flies. Most of the flies overexpressing Chinmo died at early pupal stages 
(see Table 6). These results indicate that ectopic expression of Chinmo in at least some 
tissue(s) is not compatible with organismal survival. So far we don’t know, which tissue this 
is. The experiment was performed by crossing flies carrying the transgenes pUAS-ChinmoIV 
and UAS-dMyc to flies carrying the above-mentioned GAL4 drivers. As a control, flies 
carrying a pUAST transgene were used. When dMyc and Chinmo were overexpressed 
together the resulting offspring died earlier than flies overexpressing Chinmo alone. Control 
flies were not affected (data not shown). When the different Chinmo transgenes were crossed 
to flies with the genotype “y w tub>dMyc>GAL4 ey-Flp” the resulting offspring died during 
early pupal stages. For this reason, we were not able to perform the rescue experiment with 
our transgenes, which we had carried out to rescue the eye phenotype of a hypomorphic dMyc 
mutation over the deficiency, which deletes Chinmo with a weak (and wrong) UAS-transgene 
(see 3.1.2. and Figure 5).  
 
 
 132 
Chinmo (III) Chinmo (IV) Chinmo (Zhu et al.) GAL4-driver 
nd late pupal lethal pupal lethal armadillo 
embryonic lethal embryonic lethal embryonic lethal tubulin 
embryonic lethal embryonic lethal embryonic lethal actin5C 
   nd early pupal lethal nd apterous 
early pupal lethal early pupal lethal late pupal lethal GMR 
early pupal lethal early pupal lethal early pupal lethal GM 
 
Table 6:  Overexpression of Chinmo leads to death with different GAL4 drivers. Arm-
GAL4 and tub-GAL4 lead to ubiquitous expression, GMR-GAL4 and “GM” to 
expression in the eye and ap-GAL4 to expression in the dorsal compartment of 
the wing discs. Nd stands for not done. III and IV indicate the chromosomal 
location of the transgene. The different transgenes are similarly expressed. The 
shown phenotypes were observed for a majority of the flies with the 
corresponding genotypes. 
 
 
 
 133 
3.2.4 Overexpression of Chinmo in clones 
 
Overexpression of dMyc in clones in wing imaginal discs strongly enhances growth (Johnston 
et al., 1999). The results of the experiments we have performed up to now demonstrate that 
both, Chinmo and dMyc are necessary to support growth in the eye. This lead to the question, 
whether we can further enhance growth by overexpressing Chinmo and dMyc together in 
clones of wing imaginal discs.  
To address this question, we used a line carrying an act>CD2>GAL4 cassette in combination 
with a UAS-GFP and a hs-FLP transgene. Upon heat-shock, recombination mediated by FLP 
recombinase takes place and leads to random clones within the whole disc, where GFP and 
the transgene of choice are overexpressed. Thus, we were able to directly determine the 
enhancement of clonal growth by dMyc and Chinmo either alone or in combination. After 
setting up the crosses at 25°C, the resulting offspring was heat-shocked at 37°C for 8 minutes 
at 48h or 72h AED. Wing imaginal discs were then isolated 5 days AED and pictures were 
taken on a compound microscope. Finally, the area of each clone was determined. Both 
clones induced at 48h and at 72h lead to the same outcome (Figures 12 and 15). dMyc 
overexpressing clones were at least twice the size of control clones, consistent with published 
observations (Johnston et al., 1999). Interestingly, clones that overexpress Chinmo were 
significantly smaller than control clones. This outcome was unexpected, given Chinmo’s 
positive role in growth control. One possible explanation for this observation is that that 
overexpression of Chinmo induces apoptosis and thus reduces clonal size. This might also 
explain why overexpression of all UAS-Chinmo transgenes leads to lethality. An analogous 
observation was previously made for clones overexpressing dMycΔMB3 (see manuscript, 
Figure 4, 5). Thus, it could be speculated that dMyc induces apoptosis in cooperation with 
Chinmo. 
However, dMyc-overexpression induces the same relative increase in clone size in the 
presence and in the absence of overexpressed Chinmo. Conversely, Chinmo overexpression 
induces the same relative decrease in clone size in the presence and in the absence of 
overexpressed dMyc. Thus, the effects of Chinmo and of dMyc on clone size are largely 
independent. It remains possible, though, that the ability of overexpressed dMyc to trigger 
apoptosis, which becomes apparent only at higher overexpression levels, is partly mediated 
by Chinmo. 
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Figure 12:  Overexpression of Chinmo and/or dMyc in clones in wing imaginal discs. The 
green spots are clones overexpressing GFP in combination with different 
transgenes: - (A), Chinmo (B), dMyc (C) or dMyc and Chinmo (D). The 
clones are 72 hours old. Chinmo clones are smaller than control clones (B vs. 
A), dMyc clones are bigger (C) and clones co-overexpressing dMyc and 
Chinmo reach a clone size between clones overexpressing dMyc and 
overexpressing Chinmo. The experiment was performed in two independent 
biological replicates.  
 
 
Label:  Genotype: 
A y w hs-FLP; act>CD2>GAL4 UAS-GFP/ pUASTB 
B y w hs-FLP; act>CD2>GAL4 UAS-GFP/+; pUAS-ChinmoIV/+ 
 C y w hs-FLP; act>CD2>GAL4 UAS-GFP/UAS-dMyc132 
D y w hs-FLP; act>CD2>GAL4 UAS-GFP/UAS-dMyc132; pUAS-ChinmoIV/+ 
 
 
 
  
 
Figure 13:  Clone size distribution (in pixel). Depicted are the sizes of clones 
overexpressing GFP alone (-), Chinmo (CH), dMyc (dMyc) or dMyc and 
Chinmo (dMycCH).  
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Figure 14:  Size of clones overexpressing Chinmo. dMyc overexpressing clones are twice 
the size of control clones. Asterisks indicate p-values below 0.05 and thus a 
significant change compared to control clones (blue bar). Error bars indicate 
standard deviation of the mean. Measured were clones overexpressing GFP 
alone (-), overexpressing Chinmo (CH), overexpressing dMyc (Myc) or co-
overexpressing dMyc and Chinmo (MycCH); the numbers of measured clones 
are indicated below.  
 
 
 
 
Figure 15:  Overexpression of Chinmo in clones in wing imaginal discs. The green spots 
are clones overexpressing GFP in combination with different transgenes: - (A), 
Chinmo (B), dMyc (C) or dMyc and Chinmo (D). The clones are 48 hours old. 
Chinmo clones are smaller than control clones (B vs. A), dMyc clones are 
bigger (C) and clones co-overexpressing dMyc and Chinmo reach a clone size 
between clones overexpressing dMyc and overexpressing Chinmo. 
 
 
Label:  Genotype: 
A y w hs-FLP; act>CD2>GAL4 UAS-GFP/ pUASTB 
B y w hs-FLP; act>CD2>GAL4 UAS-GFP/+; pUAS-ChinmoIV/+ 
C y w hs-FLP; act>CD2>GAL4 UAS-GFP/UAS-dMyc132 
 D y w hs-FLP; act>CD2>GAL4 UAS-GFP/UAS-dMyc132; pUAS-ChinmoIV/+ 
 
++  +CH   Myc+  MycCH 
26 33  26 24 
- CH     dMyc      dMycCH 
26   33       24           26 
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Figure 16:  Clone area distribution (in pixel). Depicted are clones overexpressing GFP 
alone (-), Chinmo (CH), dMyc (Myc) or dMyc and Chinmo (MycCH). 
 
 
 
 
 
Figure 17:  Size of clones overexpressing Chinmo and/or dMyc. dMyc overexpressing 
clones are twice the size of control clones. Asterisks indicate p-values below 
0.05 and thus a significant change compared to control clones (blue bar). Error 
bars indicate standard deviation. Measured were clones overexpressing GFP 
alone (-), overexpressing Chinmo (CH), overexpressing dMyc (Myc) or co-
overexpressing dMyc and Chinmo (MycCH); the numbers of measured clones 
are indicated below.  
- CH    Myc     MycCH 
50   50      50        50 
 
 
 137 
3.2.5 Overexpression of Chinmo leads to apoptosis 
 
Clonal size upon overexpression of Chinmo is reduced compared to control clones. To 
confirm that this size reduction is due to induction of apoptosis, we overexpressed Chinmo in 
the dorsal compartment of the wing imaginal discs with apterous-GAL4.  
Thus, we analysed wing imaginal discs that either overexpressed dMyc, Chinmo or both 
together. Since we could not dissect any discs after overexpression of Chinmo (they were too 
small or absent), we used the GAL80 temperature-sensitive system to overexpress the 
transgenes during a defined period. GAL80ts binds to and represses GAL4 under permissive 
conditions, and dissociates from GAL4 upon incubation at higher temperature (≥29°C). 
GAL80ts is expressed under control of the α−tub84B promoter and therefore inhibits GAL4 in 
the whole fly. Females with the genotype “w; ap-GAL4/CyO, y+; GAL80ts” were crossed to 
males either carrying a pUAS-Chinmo, a UAS-dMyc transgene, or both together. They were 
kept at 25°C for 4 days and on 29°C for another day. Five days AED, uncrowded wandering 
third instar larvae were dissected for their wing imaginal discs and stained for cleaved 
caspase-3. The pictures below clearly show that overexpression of Chinmo leads to apoptosis 
(Figure 18C). Apoptosis is also observed when dMyc is overexpressed, but to a lesser extent 
(Figure 18B), as described earlier (Montero et al., 2008). Co-overexpression of both Chinmo 
and dMyc leads to a massive induction of cell death (Figure 18D).  
As a control for the GAL80ts system, a parallel cross was set up with the same flies but held at 
29°C for the whole time. Those flies died at pupal stages (as do flies with the genotype “ap-
GAL4; pUAS-Chinmo”). As a second control, the parents of the original cross were 
transferred to fresh tubes after 3 days and their offspring kept at 25°C. The resulting flies with 
the genotype “y w; ap-GAL4/+; UAS-dMyc/GAL80ts; pUAS-ChinmoIV/+” and “ y w; ap-
GAL4/+; GAL80ts/+; pUAS-ChinmoIV/+” had strong wing defects; the wings were smaller, 
bent down, and had blisters. This indicates that the GAL80 system could not repress all GAL4 
activity at 25°C.  
This observation could explain why overexpression of Chinmo transgenes with different 
GAL4 drivers leads to death prior to eclosion of the adult fly. However, they are in apparent 
contradiction with the results of the clonal experiment, where co-expression with dMyc 
increased the size of Chinmo-overexpressing clones; if dMyc and Chinmo co-operate in the 
induction of apoptosis, such clones would have been expected to be smaller than control 
clones or clones expressing either protein alone. It is conceivable, though, that the co-
expression of dMyc has a net positive effect on clonal size (if dMyc-induced additional 
growth is bigger than the dMyc-induced extra apoptosis), or that the different expression 
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strength of the GAL4-drivers in the two experimental systems affects the degree to which 
dMyc induces apoptosis in either situation. 
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Figure 18:  Anti-cleaved caspase 3 stainings of wing imaginal discs after overexpression 
of Chinmo and/or dMyc. Chinmo overexpression resulted in massive apoptosis 
as indicated by the white dots. The white line marks the area where the 
transgenes are expressed by apterous-GAL4. The depicted phenotypes were 
observed in a majority of the corresponding wings (n=10 for A-C, n=5 for D). 
 
 
Label:  Genotype: 
A w; ap-GAL4/+; tub-GAL80ts/pUASTB 
B w; ap-GAL4/+; tub-GAL80ts/UAS-dMyc 
C w; ap-GAL4/+; tub-GAL80ts/+; pUAS-ChinmoIV/+ 
D w; ap-GAL4/+; tub-GAL80ts/UAS-dMyc; pUAS-ChinmoIV/+ 
 
 
 140 
3.2.6 Overexpression of dMyc in a chinmo mutant background 
 
So far, our data provide evidence that chinmo genetically interacts with dmyc to induce 
growth in the eye. Yet, there is no direct evidence for the dependence of dMyc on Chinmo to 
induce growth. To address this possibility, we used the MARCM (Mosaic Analysis with a 
Repressible Cell Marker) system (Lee and Luo, 1999) to overexpress dMyc in wing imaginal 
disc clones homozygous mutant for chinmo. Mosaic analysis using this technique relies on 
generation of homozygous mutant cells from heterozygous precursors via mitotic 
recombination. It combines the GAL80 repressor protein with the GAL4/UAS binary 
expression system and the FLP/FRT-system to genetically label clones. In the MARCM 
system, the activity of GAL4 is repressed by the GAL80 protein, resulting in unmarked cells 
that are heterozygous for both GAL80 and a mutation. After FLP/FRT-dependent site-specific 
mitotic recombination, homozygous mutant daughter cells emerge that lack GAL80 and hence 
possess an active GAL4 that can activate the reporter gene, UAS–GFP, and additional UAS-
transgenes that may be present. Those clones are the only ones to show green fluorescence. 
The other daughter cells have two copies of GAL80, therefore GAL4 remains inactive and as 
a result no UAS-transgenes are expressed.  
We established two different lines, one with the genotype “y w; (FRT-40 chinmoX; UAS-
dMyc)/ (SM5; TM6B,Tb)”, and the other line without the dMyc transgene. ChinmoX stands 
for the 3 different chinmo alleles from the ey-FLP-screen. Those flies were crossed to the 
MARCM line “y w hs-FLP UAS-GFP; (FRT-40 tub-GAL80; tub-GAL4)/(SM5; TM6B,Tb). 
Clones were induced in the offspring 48h AED by a brief heat-shock (20 minutes at 37°C) 
and at 120h AED uncrowded wandering non-Tubby larvae were collected and further 
analysed. The areas of at least 20 clones per genotype were determined. Overexpression of 
dMyc leads to an increase in clone size of 40%. This is not as strong as we observed earlier 
(see manuscript, Figure 5), but still significant, possibly because tub-GAL4 drives lower 
levels of dMyc overexpression than the act-GAL4 driver used in the earlier experiments. 
Clonal size is not reduced in chinmo mutant clones and the same results were obtained with 
different alleles. dMyc did not induce growth anymore in a chinmo mutant background (see 
Figure 20, 21). Thus, dMyc is dependent on Chinmo expression to induce cellular growth. 
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Figure 19:  Illustration of the MARCM system. Panel A shows the mother cells: 5 
different transgenes are located on different chromosome arms, the second 
chromosome carries a mutation in chinmo, distal of the FRT-site and in trans 
to tub-GAL80. After heat-shock, the FLP-recombinase induces mitotic 
recombination between the FRT-sites (yellow) which gives rise to two 
daughter cells, each of which is homozygous for the chromosome arm distal to 
the FRT-site (B,C). The cells in A and B neither express GFP nor any other 
transgene, since GAL80 inhibits the expression of tub-GAL4. The cell in C 
expresses GFP and other UAS-transgenes, and in addition, it is homozygous 
mutant for chinmo. Depending on the line we used, Myc is also expressed in 
those cells. 
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Figure 20:  Clones homozygous mutant for the different Chinmo alleles (B, C, D), and 
overexpressing dMyc (F, G, H). Overexpression of dMyc in clones that are 
homozygous mutant for chinmo does not induce any overgrowth. Clones are 
green since they co-express UAS-GFP. The depicted phenotypes were 
observed in a majority of the corresponding wings (n=20). 
 
 
Label:  Genotype of green fluorescent cells: 
A y w hs-FLP UAS-GFP; FRT-40/FRT-40; tub-GAL4/MKRS 
 
B  y w hs-FLP UAS-GFP; FRT-40 chinmo108/FRT-40 chinmo108; tub-GAL4/+ 
 
C y w hs-FLP UAS-GFP; FRT-40 chinmo110/FRT-40 chinmo110; tub-GAL4/+ 
 
D y w hs-FLP UAS-GFP; FRT-40 chinmo134/FRT-40 chinmo134; tub-GAL4/+ 
 
E y w hs-FLP UAS-GFP; FRT-40/FRT-40; tub-GAL4/UAS-dMyc 
 
F  y w hs-FLP UAS-GFP; FRT-40 chinmo108/FRT-40 chinmo108;  
  tub-GAL4/UAS-dMyc 
 
 G  y w hs-FLP UAS-GFP; FRT-40 chinmo110/FRT-40 chinmo110;  
   tub-GAL4/UAS-dMyc 
 
H  y w hs-FLP UAS-GFP; FRT-40 chinmo134/FRT-40 chinmo134; 
  tub-GAL4/UAS-dMyc 
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Figure 21: Size of clones overexpressing dMyc relative to control clones. Area of control 
clones (+) was set to 100%. Clonal size is increased upon overexpression of 
dMyc (2nd bar), however dMyc cannot induce growth anymore in a Chinmo 
mutant background (dark bars). Error bars indicate standard deviation. More 
than 20 clones per genotype were measured. The numbers under the x-axis 
indicate the chinmo alleles (“+” = wildtype). 
 
 
Label:  Genotype of green fluorescent cells: 
+  y w hs-FLP UAS-GFP; FRT-40/FRT-40; tub-GAL4/MKRS 
 
+  dMyc  y w hs-FLP UAS-GFP; FRT-40/FRT-40; tub-GAL4/UAS-dMyc 
 
 108  y w hs-FLP UAS-GFP; FRT-40 chinmo108/FRT-40 chinmo108; 
  tub-GAL4/+ 
 
108   dMyc y w hs-FLP UAS-GFP; FRT-40 chinmo108/FRT-40 chinmo108; 
  tub-GAL4/UAS-dMyc 
 
110   y w hs-FLP UAS-GFP; FRT-40 chinmo110/FRT-40 chinmo110; 
  tub-GAL4/+ 
 
 110   dMyc  y w hs-FLP UAS-GFP; FRT-40 chinmo110/FRT-40 chinmo110; 
 tub-GAL4/UAS-dMyc 
 
134   y w hs-FLP UAS-GFP; FRT-40 chinmo134/FRT-40 chinmo134; 
  tub-GAL4/+ 
 
 134   dMyc  y w hs-FLP UAS-GFP; FRT-40 chinmo134/FRT-40 chinmo134; 
 tub-GAL4/UAS-dMyc 
 -          dMyc       -          dMyc         -          dMyc         -          dMyc 
+      108         110             134 
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3.2.7 Overexpression of Chinmo in a dmyc mutant background 
 
As shown earlier, a mutation of both dmyc and chinmo in the eye led to the conclusion that 
both proteins cooperate to regulate growth in the eye. The MARCM clones (3.2.6) revealed 
that dMyc is dependent on Chinmo to induce growth in the wing imaginal discs. We were 
therefore interested, if the converse is also true, i.e. if Chinmo also (partially) depends on 
dMyc for the execution of its activities (be it growth or the induction of apoptosis). For this 
purpose, we used the “tub>dMyc>GAL4 ey-FLP” system to overexpress Chinmo only in the 
head, either in a wildtype (dm+), a dmP0, or a dm4 mutant background.  
Flies with the genotype “y w tub>dMyc>GAL4 ey-FLP/Y; pUAS-ChinmoIV/+” normally die 
at early pupal stages or even before. By reducing dMyc levels, not only the rate of 
metamorphosis was accelerated (the pupae were clearly differentiated and most of them died 
at late pupal stages), but also about 1/10th of the expected number of flies eclosed (Figure 22). 
The overall survival was better in the dmP0 background as compared to the dm4 background 
(10% vs. 5%; n ≥ 4). However, in either case the eclosed flies do not look very healthy, since 
they have only few ommatidia, a distorted head structure and dark spots on the eyes that are 
signs of cell death (Figure 22E). Note also that incubation of the flies at 18° instead of 25° did 
not increase the rate of survival, although GAL4 is known to be less active at the lower 
temperature, and hence less Chinmo is expected to be expressed at 18°. 
These results are consistent with our previous observation that overexpression of Chinmo 
leads to apoptosis. In addition, they show that physiological levels of dMyc are required for 
whatever Chinmo does when it is overexpressed, since a reduction of dMyc levels is able to 
reduce Chinmo function. 
 
 
 145 
 
 
 
 
Figure 22: Reduction of dMyc levels allows Chinmo overexpressing flies to survive to 
adulthood. In a wildtype background no Chinmo overexpressing adult flies 
were obtained (top row, white rectangle). The middle column shows eye 
morphology upon overexpression of dMyc. Anterior is to the right. The 
experiment was performed in two independent biological replicates.  
 
 
Label: Genotype: 
A   y w tub>dMyc>GAL4 ey-FLP; pUASTB/+ 
B   y w tub>dMyc>GAL4 ey-FLP; UAS-dMyc/+ 
C   w dmP0 tub>dMyc>GAL4 ey-FLP; pUASTB 
D   w dmP0 tub>dMyc>GAL4 ey-FLP; UAS-dMyc/+ 
E   w dmP0 tub>dMyc>GAL4 ey-FLP; pUAS-ChinmoIV/+ 
F   w dm4 tub>dMyc>GAL4 ey-FLP; pUASTB/+ 
G   w dm4 tub>dMyc>GAL4 ey-FLP; UAS-dMyc/+ 
H   w dm4 tub>dMyc>GAL4 ey-FLP; pUAS-ChinmoIV/+ 
 
 
ey>dm+ 
ey>dmP0 
 
ey>dm4 
 
control  UAS-dMyc pUAS-Chinmo 
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3.3  Molecular mechanism of Chinmo action - effect on dMyc levels 
 
3.3.1 dMyc levels are not elevated upon Chinmo overexpression 
 
In our previous experiments we showed that Chinmo and dMyc interact genetically. How this 
interaction takes place on a molecular basis concerned us in our next enquiries. 
One possibility is that Chinmo overexpression elevates dMyc protein levels (e.g. by 
increasing dMyc stability) and all genetic interactions (act > clones, MARCM clones, 
pinheads) would be consistent with this. To test this possibility, we transfected S2 cells with 
UAS-dMyc alone or together with UAS-Chinmo and investigated if ectopic dMyc levels were 
increased upon co-expression with Chinmo. Cells were harvested after 48h and proteins were 
separated by SDS- PAGE and analysed on a Western blot (Figure 23). dMyc levels seemed to 
be enhanced upon overexpression of Chinmo, however also Tubulin levels (which served as a 
loading control) were elevated. To quantitate the dMyc and Chinmo protein amounts 
contained in the different samples, we repeated the assay but this time with fluorescent 
antibodies and the LI-COR Odyssey system. In contrast to chemiluminescence, fluorescent 
detection is static, since the fluorescence signal intensity is proportional to the amount of 
fluorophor, and this does not change with time (as long as the fluorophor is excited). Thus, 
proteins can be accurately quantified. The two proteins were detected with secondary 
antibodies that were conjugated with two different fluorescent dyes in order to discriminate 
between them (Figures 24 and 25). Two different measurements of the band intensity of two 
independent experiments- one exposed with the Licor system and one exposed with the 
chemiluminescence kit- revealed that dMyc levels in S2 lysates are equal if dMyc is 
overexpressed alone or in combination with Chinmo. Thus, Chinmo overexpression does not 
alter overexpressed dMyc levels in cell culture, suggesting that the genetic interactions 
described above are not due to a stabilisation of dMyc protein by Chinmo. 
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Figure 23:  Western blot of S2 cells after overexpression of dMyc or dMyc and Chinmo 
together. dMyc levels are not elevated upon Chinmo overexpression. Tubulin 
is used as a control for protein levels. HRP-conjugated antibodies were used 
for visualization. Cell lysates were taken 48h after transfection. The 
experiment was performed in two independent biological replicates with the 
same outcome.  
              
 
 
Figure 24:  Western blot of S2 cells after overexpression of dMyc or dMyc and Chinmo 
together and analysis with the Licor Odyssey system. dMyc levels are not 
elevated upon Chinmo overexpression. Tubulin is used as a control for protein 
levels. Fluorescent antibodies were used for visualisation. Cell lysates were 
prepared 48h after transfection. 
 
 
 
Figure 25: Protein levels in cells that overexpress dMyc either alone or in combination 
with Chinmo (CH). dMyc levels are increased upon Chinmo overexpression, 
however Tubulin levels are also increased. Therefore, the increase is not dMyc 
specific. Shown are averages of two independent measurements. Standard 
deviations indicate the error of the mean. 100% corresponds to the intensity 
observed in S2 cells overexpressing dMyc alone. 
Myc 
 
Tubulin 
 
Myc 
 
Tubulin 
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3.3.2 Endogenous dMyc levels are not elevated upon Chinmo overexpression  
 
As a further experiment to address a possible effect of Chinmo on dMyc levels, we 
overexpressed Chinmo in S2 cells. Two parallel samples were treated with dsRNA against 
GFP or against dmyc (see Figure 26). dsRNA treatment against dmyc efficiently reduced 
endogenous dMyc levels as compared to the control sample treated with dsRNA against GFP. 
The blot shows that dMyc levels are unchanged in S2 cells overexpressing Chinmo, 
suggesting that Chinmo also does not affect endogenous dMyc amounts. We realise, however, 
that in such transient transfection experiments Chinmo is expressed only in a fraction of all 
cells (typically 20-50%), and that minor changes in dMyc protein levels that are limited to 
these transfected cells might go unnoticed in this experiment, where lysates of all cells 
(transfected and untransfected) are probed for the amount of dMyc. A definitive answer to the 
question whether Chinmo affects dMyc levels will require the use of cells stably expressing 
Chinmo. Such cells have been generated in the meantime (section 3.4.4), and the 
corresponding experiment will be carried out. 
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Figure 26: Western blot of S2 cell lysates. Endogenous dMyc levels are not increased 
upon overexpression of Chinmo. dMyc levels are greatly reduced after 
incubation with dmyc dsRNA for 48h (panel A). The dmyc dsRNA was 
directed against the 5`UTR of dmyc. The blot was stripped and re-probed with 
antibodies against the AU1-tag of Chinmo (panel B). The same experiment 
was performed twice with the same outcome. 
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3.4  Molecular mechanism of Chinmo action - effect on dMyc targets 
 
3.4.1 Chinmo transactivates dMyc targets  
 
Our previous experiments show that dMyc and Chinmo genetically interact, and they suggest 
that Chinmo does not affect dMyc levels. Nevertheless, Chinmo affects dMyc-dependent 
biological processes. Since these processes are thought to be caused by dMyc`s regulation of 
its target genes, Chinmo might be necessary for full transactivation of dMyc target genes. To 
address this possibility, we investigated the ability of Chinmo to transactivate dMyc 
dependent reporters. In a first experiment we analysed pure overexpression of Chinmo. We 
transfected tubulin-GAL4 and pUAS-Chinmo, either alone or in combination with UAS-
dMyc, together with a dMyc-dependent luciferase reporter pair (see manuscript). Forty-eight 
hours after induction, the cells were lysed and relative reporter expression was analysed in a 
Wallac luminometer. Consistent with previous observations, dMyc overexpression increases 
the relative reporter ratio by about 2 fold as compared to control (UAS-dMyc without tubulin-
GAL4; see Figure 27). Interestingly, Chinmo was able to transactivate the dMyc-dependent 
reporter on its own to the same extent as dMyc. When both transgenes were expressed at the 
same time, relative reporter activity was 45% higher as compared to cells expressing either 
Chinmo or dMyc alone. 
This result raises the possibility that Chinmo acts as a co-activator of dMyc and it argues 
against the hypothesis that Chinmo might be the homologue of Miz-1, a dMyc co-repressor. 
However, Chinmo could still behave like Miz-1 in a different context (e.g. a different type of 
dMyc targets could behave differently than the targets represented by the luciferase reporter 
with respect to Chinmo activity, and furthermore Chinmo might have different properties 
upon high level overexpression than at endogenous levels). 
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Figure 27:  Activity of a CG5033-luciferase reporter upon overexpression of dMyc and/or 
Chinmo (CH). Chinmo is able to activate this dMyc reporter to the same extent 
as dMyc alone. Co-overexpression of dMyc elevates relative Luciferase levels 
even further. Cell lysates were taken 48h after transfection. Relative reporter 
activity after dMyc transfection was set to 100%. Error bars indicate standard 
deviation of two independent experiments. 
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3.4.2 Chinmo depends on dMyc to transactivate dMyc target genes 
 
Chinmo activates a dMyc-dependent luciferase reporter to the same extent as dMyc. When 
dMyc and Chinmo are co-overexpressed, the transactivation potential is even elevated. In the 
following experiment we investigated whether the activation of a dMyc-reporter by Chinmo 
is dependent on the presence of dMyc. Chinmo, dMyc, tub-GAL4 and both reporter 
constructs, Renilla and firefly luciferase, were transfected in S2 cells in the presence or 
absence of dsRNA against dmyc. The dsRNA only degrades endogenous dmyc mRNA since it 
targets the 5`UTR of dmyc. Forty-eight hours after transfection of the S2 cells, Luciferase 
levels were measured in the cell lysates. Again, dMyc and Chinmo were able to transactivate 
the dMyc reporter and co-overexpression of both resulted in an enhanced transactivation 
potential (see Figure 28). Downregulation of endogenous dmyc levels reduced relative 
reporter activity in the sample overexpressing dMyc by 26%. When endogenous dmyc levels 
were downregulated in cells overexpressing Chinmo, the transactivation potential of Chinmo 
was clearly reduced. This was also the case when endogenous dmyc was depleted in cells 
overexpressing dMyc and Chinmo together. However, in both cases overexpressed Chinmo 
elevated relative reporter activity as compared to control samples even upon depletion of 
dmyc (Figure 28, compare sample “dsRNAdmyc” with “CH + dsRNAdmyc”, and “dMycCH” 
with “dMycCH + dsRNAdmyc”). Thus, Chinmo is dependent on endogenous dmyc for 
efficient activation of a dMyc-dependent reporter, but partially activates this reporter even in 
the absence of dmyc. It still needs to be determined, though, whether this hypothetical dMyc-
independent activation of the reporter is mediated by low levels of dMyc that might persist 
upon dsRNA against dmyc.  
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Figure 28: Transactivation of the CG5033-based dMyc-dependent reporter in the presence 
or absence of dmyc dsRNA. Chinmo only weakly transactivates the reporter 
when dMyc levels are reduced. Error bars indicate standard deviation of two 
independent experiments. Reporter activity was set to 100% for the sample 
expressing ectopic dMyc together with dsRNA against endogenous dmyc. Cell 
lysates were taken 48h after transfection. CH stands for pUAS-Chinmo, dMyc 
for UAS-dMycWT. dsRNA targets the 5`UTR of dmyc and only depletes 
endogenous dmyc mRNA, ectopically expressed dMyc is unaffected.  
dsRNAdMyc       -           dsRNAdMyc        -           dsRNAdMyc        -        dsRNAdMyc  
+                          dMyc                                CH                              dMycCH 
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3.4.3 dMyc is not dependent on Chinmo for full transcriptional activation 
 
Chinmo is dependent on the cooperation with dMyc to fully activate dMyc target genes in cell 
culture. We were interested if dMyc requires Chinmo for full transcriptional activation of 
dMyc target genes in S2 cells, as it was the case for induction of cell growth in clones in wing 
imaginal discs (MARCM clones). For this purpose, we synthesised dsRNA against chinmo. 
To test whether the dsRNA is functional, S2 cells were transfected with UAS-Chinmo, tub-
GAL4 and dsRNA against chinmo and analysed at different time points thereafter (see Figure 
29). Ninety-six hours after transfection, Chinmo levels were strongly reduced and 
undetectable on a Western blot, suggesting that all ectopically expressed Chinmo protein has 
decayed by that time. However, it might be argued that this observation could also be 
explained if overexpression of Chinmo causes apoptosis (as suggested by our earlier 
experiments with Chinmo overexpression in the fly) such that all cells expressing Chinmo 
have died by 96 hours after the transfection, and the only cells remaining in those wells are 
those that haven`t taken up any DNA. However, such a scenario is unlikely, since Chinmo 
overexpression can stimulate relative luciferase activity after 48h (when Chinmo protein is 
clearly present, Figure 28) and to comparable levels at 96h after transfection (see below, 
Figure 31, 42), arguing that undiminished quantities of Chinmo protein persist in cell 
populations even after 4 days – and hence that within 96h chinmo dsRNA eliminates all 
ectopically expressed Chinmo (and, by inference, endogenous Chinmo as well). 
Thus, we repeated the Luciferase assays in the presence of chinmo dsRNA and analysed 
luciferase activity at 96h after transfection. In a first experiment we transfected cells with a 
control plasmid, pUASTB, alone or in combination with dsRNA against chinmo or dMyc. 
Figure 30 shows the resulting luciferase ratios. The expression of the reporter was decreased 
by 2.5 fold in the presence of dsRNA against dmyc, but dsRNA against chinmo had no effect. 
In a second experiment, we overexpressed Chinmo and dMyc alone or together, in the 
presence or absence of dsRNA against chinmo. This experiment was performed in order to 
make sure that the knockdown of Chinmo reduces the effects of Chinmo overexpression on 
dMyc target genes. The dsRNA was at least partially functional, since it reduced the reporter 
activity of the samples expressing Chinmo (compare samples “dMycCH” with “dMycCH + 
dsRNAch”, and “CH” with “CH + dsRNAch”), although in both cases some residual Chinmo-
dependent activity remained (compare samples “dMycCH + dsRNAch” with “dMyc”, and 
“dsRNAch” [which has only background reporter activity – see Figure 30] with “CH + 
dsRNAch”). However, no effect of chinmo dsRNA on dMyc transactivation potential could 
be observed (compare samples “dMyc” and “dMyc + dsRNAch”). 
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This suggests that Chinmo is not necessary for dMyc to transactivate its target genes in S2 
cells. It further raises the possibility that Chinmo is not expressed in S2 cells. Indeed, 
according to the FLIGHT database (which contains microarray expression profiles of different 
cell lines) Chinmo was not detected in such experiments in Schneider S2, KC, S2R+ or S2C 
cells.  
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Figure 29:  Reduction of transiently expressed Chinmo with co-transfected dsRNA in S2 
cells. Cell lysates were taken at the indicated timepoints and directly used for 
Western blotting. Chinmo levels are strongly reduced after 96h. To detect 
Chinmo a primary antibody against the AU-tag of UAS-AU-Chinmo was used.  
 
 
 
Figure 30:  Transactivation of a dMyc-dependent reporter in the presence or absence of 
chinmo or dmyc dsRNA. Reduction of Chinmo levels does not reduce 
transcriptional activation of a dMyc-dependent reporter. Error bars indicate 
standard deviation for two independent experiments. Luciferase levels were 
analysed 96h after transfection. Control cells “-“ were set to 100%. dsRNA 
targets the 5`UTR of dmyc and only depletes endogenous dMyc, ectopically 
expressed dMyc is unaffected. 
 
 
 
Figure 31:  Transactivation of dMyc target genes in the presence or absence of chinmo 
dsRNA (dsRNAch) upon overexpression of Chinmo and/or dMyc. Reduction 
of Chinmo levels does not influence transcriptional activation of target genes 
by dMyc. Lysates were taken 96h after transfection. Error bars indicate 
standard deviation from two independent experiments. Relative reporter 
activity was set to 100% for the sample containing overexpressed dMyc. 
Chinmo 
dsRNA chinmo 
        duration/h 
Chinmo 
dsRNAch          -             dsRNAch             -             dsRNAch             -         dsRNAch  
+                          CH                                     dMyc                               dMycCH 
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3.4.4 A cell line that stably expresses Chinmo 
 
Our earlier experiments with transient transfection of Chinmo in S2 cells suffered from the 
drawback that only a limited (and unknown) fraction of all cells expressed the transfected 
Chinmo. To allow inducible expression of Chinmo in all cells of a pool, a chinmo cDNA was 
cloned under the control of a metallothioneine promoter, and transfected together with 
another plasmid containing a blasticidin resistance gene (pCoBlast) in S2 cells, that were then 
grown in selection medium containing blasticidin and thus, only cells that had taken up the 
plasmid survived.  
After establishment of the cell line, the cells were tested with different copper sulphate 
concentrations and at different time points for induction of Chinmo expression. As depicted in 
Figure 32, the highest expression of Chinmo was obtained at 24 hours after the addition of 
CuSO4 to 1 mM. For all further experiments these conditions were used. 
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Figure 32:  Western blot of S2-MT-Chinmo cell lysates after induction with copper 
sulphate. Highest induction was obtained at 24 hours with a concentration of 
1mM CuSO4 per ml medium. The “-“ sample corresponds to non-transfected 
cells that were collected at time 0. Each lane corresponds to half a well of a six 
well plate (2.5 Mio. cells). To detect AU1-Chinmo rabbit anti-AU1 antibodies 
were used. 
Chinmo 
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3.4.5. Chinmo can activate endogenous dMyc targets  
 
Luciferase assays demonstrated that Chinmo can transactivate a dMyc-dependent reporter 
upon overexpression in S2 cells. Thus, we were interested if Chinmo is able to activate 
selected endogenous targets of dMyc upon overexpression. Five million S2 or S2-MT-
Chinmo cells were treated with 1 mM CuSO4 or remained untreated. Twenty-four hours after 
induction cells were lysed in TRIZOL and total RNA was extracted. After verification of the 
quality of the RNA on a bioanalyzer, cDNA was generated and the expression of selected 
genes was analysed by qRT-PCR. 
A set of direct dMyc target genes had been identified earlier by microarray analysis in our lab 
(Hulf et al., 2005). A specific subset of those genes contained a dMyc binding site, the so-
called E-box, downstream of their transcription start sites. Three of these genes CG5033, 
nnp1, and fibrillarin (all three transcribed by RNA polymerase II) were included in our 
selection. Another RNA Pol II-transcribed gene, CG12295, containing an upstream E-box, 
was also tested. CG12295 is involved in synaptic vesicle fusion to presynaptic membranes 
and in cation transport (Ly and Verstreken, 2006). Also tested was snoRNA46, a small RNA-
coding gene situated within an intron of a Pol II-transcribed protein-coding gene. Small 
nucleolar RNAs (snoRNAs) are a class of small RNA molecules that guide chemical 
modifications (methylation or pseudouridylation) of ribosomal RNAs (rRNAs) and other 
RNA genes (tRNAs and other small nuclear RNAs (snRNAs)).  
In addition, snoRNA U3 and tRNALeu, genes transcribed by RNA Polymerase III, were 
included in our investigations, since it had been shown, that dMyc also controls the 
transcription of RNA Polymerase III dependent small RNA genes (Gomez-Roman et al., 
2003; Steiger et al., 2008). Two biologically independent replicates were analysed per cell 
type and induction. Their levels were normalized to the reference genes actin5C, Rab6 and 
Sec24 and plotted against those from uninduced S2 cells (Figure 33). 
The induction of Chinmo was quite efficient, since mRNA levels were 17-fold higher in 
induced than in uninduced S2-MT-Chinmo cells (blue bar, second row), whereas the baseline 
levels are equally low in uninduced S2 and S2-MT-Chinmo cells.  
However, dmyc expression was not increased upon Chinmo overexpression, which is 
consistent with our previous observation that Chinmo overexpression does not affect dMyc 
protein levels (3.3.1). In contrast, 3 out of 4 E-box containing genes were strongly 
upregulated upon overexpression of Chinmo, namely nnp1 (1.5 fold), CG12295 (>2fold) and 
fibrillarin (2 fold).  
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The small RNA gene snoRNA46 was not significantly affected by overexpression of Chinmo 
(p>0.05). Thus, Chinmo is indeed able to positively regulate endogenous dMyc target genes. 
Four out of 5 genes, which were upregulated upon Chinmo overexpression, are involved in 
the processing of rRNA. Whether this activation requires dMyc remains to be tested. 
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Figure 33: mRNA levels upon induction of chinmo relative to uninduced S2 cells. 
Transcript levels of different dMyc target genes as determined by qRT-PCR 
(normalised to the reference genes actin5C, Sec24 and Rab6) are shown for 
S2-MT-Chinmo cells with Chinmo induction (S2-MT-CH+), without induction 
(S2-MT-CH), and S2 cells with (S2+) or without induction (S2). Transcript 
levels in uninduced S2 cells were set to 100%. Elevated Chinmo levels do not 
influence dmyc RNA levels, but affect 3 E-box containing target genes of 
dMyc, nnp1, CG12295 and fibrillarin. CG5033, another E-box containing 
gene, the small RNA gene snoRNA46, and two other RNA genes, tRNALeu and 
snoRNA U3 are not affected. Error bars indicate standard deviation from two 
independent biological replicates. 
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3.5. Molecular mechanism of Chinmo action - interaction of dMyc & Chinmo 
 
3.5.1 Chinmo and dMyc interact physically 
 
The data presented so far argue for a possible role for Chinmo as a co-activator of dMyc. 
These findings prompted us to explore if dMyc and Chinmo interact physically. A physical 
interaction with dMyc has for example been shown before for Pontin, the dMyc co-factor that 
prompted us to set up the screen in which Chinmo was found (Bellosta et al., 2005). 
To assay a direct interaction, S2 cells were transfected with HA-dMyc alone or in 
combination with AU1-Chinmo. Forty-eight hours after transfection, cell lysates were 
prepared for co-immunoprecipitation. The resulting IP in the upper panel of Figure 34 shows 
that Chinmo interacts physically with dMyc. dMyc is only immunoprecipitated when Chinmo 
was present in the sample. The lysates in the lower panel show that dMyc was expressed in 
both samples. This observation presents evidence that Chinmo can form a complex with 
dMyc and is consistent with the notion that Chinmo functions as co-activator of dMyc. 
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Figure 34: Western blot of co-immunoprecipitated cell lysates. dMyc was transfected into 
S2 cells alone or in combination with Chinmo, 48h after transfection the 
Chinmo-associated proteins were isolated by anti-AU1 IP and analysed by 
Western blot with anti-HA antibodies. The upper panel shows the IP, the lower 
panel the “supernatant” of cell lysates after incubation with antibodies and 
beads. Similar results were obtained in different independent experiments. 
IP 
supernatant 
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3.5.2 Mapping of the binding site for Chinmo in dMyc 
 
Co-immunoprecipitations between Chinmo and dMyc showed that both proteins interact 
physically. To locate the precise binding site for Chinmo in the dMyc protein, we performed 
co-IP experiments between Chinmo and different dMyc mutants (details on the different 
constructs are described in the manuscript in Materials & Methods). In a first round we tested 
interactions between Chinmo and the dMyc mutants consisting of the N-terminus or 
containing deletions of the N-terminus, Myc Box 2, Myc Box 1+2 (ΔN-terminus) or of the N- 
and C-termini. The upper panel in Figure 35 depicts the resulting co-immunoprecipitations. 
That indeed all dMyc mutants are expressed is shown in the lower panel of Figure 35, where 
the supernatants of the co-IPs were loaded. All mutants were still able to bind Chinmo. For 
the N-terminus alone no conclusion can be drawn since it migrates at the same position as the 
light chain of the IgGs. 
Since all of the mutants still bound Chinmo, we repeated the co-IP with additional dMyc 
mutants (see Materials + Methods for details), who contain bigger deletions, in order to 
narrow down the region for the binding site. The results of the co-IPs between Chinmo and 
the tested dMyc mutants are graphically illustrated in Figure 36. Interaction with Chinmo was 
reduced when the first 403 aa of the dMyc protein were missing and completely abolished 
with dMyc fragments lacking the first 523 aa or 626 aa. These observations indicate that the 
binding site for Chinmo in dMyc lies between amino acid 1-403. 
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Figure 35:  Western blot of anti-HA co-immunoprecipitates. Chinmo was transfected into 
S2 cells in combination with the indicated dMyc mutants, 48h after 
transfection the Chinmo-associated proteins were isolated by anti-AU1 IP and 
analysed by Western blot with anti-HA antibodies. The upper panel shows the 
IP, the lower panel the supernatant (after binding of the lysates to antibodies 
and beads). All tested dMyc mutants still bind Chinmo. 
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Figure 36:  Schematic diagram of small dMyc mutants tested in co-immunoprecipitations 
for interaction with Chinmo. The binding site for Chinmo was located to aa 1-
403 of the dMyc protein. The green lines indicate dMyc mutants that interacted 
with Chinmo, red lines stand for dMyc mutations that did not interact with 
Chinmo. Dashed lines indicated a weak interaction between Chinmo and the 
respective dMyc mutant. Numbers correspond to the first (Nxxx) or last 
(xxxC) amino acid present in the indicated mutant. The black line reflects the 
putative binding site for Chinmo in dMyc. The blue box reflects the N-terminal 
HA epitope tag. 
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3.5.3 Chinmo mutants  
 
Chinmo binds to a centrally located region of the dMyc protein. Our next goal was to 
determine the interaction site for dMyc in Chinmo. There are two recognizable domains 
within the Chinmo protein: A BTB/POZ domain in the N-terminal part and 2 C2H2 zinc 
fingers located at the very C-terminus (for a precise description of the domains see 3.1.3). The 
BTB/POZ domain is located at aa 32-128 (according to Prosite), other predictions prospect aa 
22-128 (Pfam), the two zinc fingers are located at aa 517-540 and 545-573. We established 2 
different Chinmo mutants by deletion mutagenesis. ChinmoΔBTB lacks amino acids 32-128 
and carries an amino acid substitution of two amino acids (Thr32 + Arg33) instead, and 
ChinmoΔZnf lacks amino acid 517-604 (shown in Figure 37). Both constructs were cloned 
into pUASTB, as was the wildtype Chinmo plasmid.  
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Figure 37: Schematic diagram of the established Chinmo mutants. ChinmoΔBTB lacks 
the BTB/POZ domain and ChinmoΔZnf lacks the complete C-terminus 
including the two C2H2 zinc fingers. Numbers indicate coordinates of the 
corresponding deletions. Coordinates indicate the first and last deleted amino 
acid.  
ChinmoΔBTB 
ChinmoΔZnf 
Chinmo 
32 128 
517 604 
 
BTB/POZ Zn  Zn 
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3.5.4 A ChinmoΔBTB mutant is not able to transactivate dMyc target genes 
 
Overexpression of Chinmo transactivates target genes to the same extent as dMyc and this 
effect can be further increased when dMyc is co-overexpressed. However, Chinmo`s ability to 
transactivate dMyc target genes is largely dependent on dmyc. For this reason and because of 
the finding that Chinmo interacts physically with dMyc, we propose that Chinmo acts a dMyc 
co-activator. To investigate if the two Chinmo mutants described above were still able to 
transactivate dMyc target genes, we performed a Luciferase assay. S2 cells were transfected 
with two luciferase reporter constructs and plasmids coding for wildtype or mutant Chinmo, 
alone or in combination with dMyc. Cell lysates were prepared 48h after transfection and 
relative Luciferase levels were measured.  
As described before, Chinmo was able to transactivate dMyc target genes and this activation 
was enhanced by the presence of dMyc (see Figure 38, first 4 bars). A deletion of the 
BTB/POZ domain completely abolished Chinmo`s transactivation ability, suggesting that this 
domain is necessary for transcriptional activation by Chinmo. In contrast, a deletion of the 
zinc fingers even enhanced Chinmo`s transactivation ability, however co-overexpression with 
dMyc did not enhance this activation further.  
To investigate if the transactivation potential of ChinmoΔZnf is dependent on dMyc, we 
repeated the Luciferase assay, but this time used dsRNA against endogenous dmyc to deplete 
dmyc. The second experiment confirmed the results of the first experiment that the deletion of 
the BTB domain abolishes and the deletion of the Zn fingers enhances Chinmo`s 
transactivation potential (see Figure 39). Not surprisingly, a reduction of endogenous dmyc 
levels strongly reduced this activity. Thus, also the massive boost caused by overexpression 
of a ChinmoΔZnf mutant is largely dependent on dMyc. 
Altogether these data demonstrate that the BTB/POZ domain is necessary for Chinmo to 
transactivate dMyc target genes. Moreover, these data show that a deletion of the zinc fingers 
in Chinmo enhances Chinmo`s transactivation potential. 
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Figure 38:  Relative Luciferase levels after overexpression of Chinmo (wildtype or 
mutants), either alone or together with dMyc. A deletion of the BTB/POZ 
domain completely abolished transactivation, whereas a deletion of the zinc 
fingers increases the signal even more. Lysates were taken 48h after 
transfection. Error bars indicate standard deviation from two independent 
experiments. Relative reporter level of the sample containing overexpressed 
dMyc was set to 100%. 
 
 
 
Figure 39:  Relative Luciferase levels after overexpression of Chinmo variants or 
overexpression of Chinmo variants upon downregulation of dmyc. The ability 
of Chinmo variants to transactivate dMyc target genes is largely dependent on 
the presence of dMyc, since reduction of endogenous dmyc levels strongly 
reduces Chinmo`s transactivation ability. Lysates were taken 48h after 
transfection. Error bars indicate standard deviation from two independent 
experiments. Relative reporter activity for the sample overexpressing dMyc 
was set to 100%. 
         +             dMyc            -               dMyc              -             dMyc             -           dMyc  
                                               CH                            ΔBTB                            ΔZnf 
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3.5.5. dMyc binds Chinmo most probably via the BTB/POZ domain 
 
Encouraged by the previous results, we performed co-immunoprecipitations in order to test if 
binding to dMyc is affected in the Chinmo mutants. S2 cells were transfected with wildtype 
Chinmo or Chinmo mutants. Eight-eight hours after transfection cell lysates were prepared, 
immunoprecipitated and Western blotted (Figure 40). As shown earlier, wildtype Chinmo and 
dMyc physically interact with each other. Moreover, a deletion of the zinc fingers did not 
affect this binding (Figure 40A). However, no conclusion can be drawn yet for the interaction 
between dMyc and ChinmoΔBTB, since ChinmoΔBTB was only weakly expressed. dMyc 
was expressed in all samples, as shown in the central panel where the supernatants were 
analysed. Additionally, we investigated the expression levels of Chinmo (Figure 40B, where 
the blot was stripped and re-probed with anti-AU1 antibodies). This blot also suggests that a 
deletion in the BTB/POZ domain decreases Chinmo stability.  
This experiment raises the possibility that binding to dMyc is required for transactivation by 
Chinmo, and that a deletion of the BTB domain might abolish both. However, it is equally 
possible that the lower abundance of ChinmoΔBTB accounts for its reduced transactivation 
potential, and that binding to dMyc is not required for this transactivation. To distinguish 
between these possibilities, conditions need to be found under which comparable levels of 
wildtype Chinmo, ChinmoΔBTB and ChinmoΔZnf can be expressed in S2 cells and assayed 
for their interaction with dMyc and their effect on a dMyc-dependent reporter. 
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Figure 40:  Western blot of co-IPs between dMyc and Chinmo variants. A deletion of the 
BTB/POZ domain abolishes co-IP with dMyc whereas a deletion of the zinc 
fingers has no effect on the interaction between Chinmo and dMyc. Moreover, 
Chinmo stability seems to be affected by these mutations. S2 cells were 
transfected with UAS-Myc in combination with a control plasmid (pUASTB), 
pUAS-Chinmo, pUAS-ChinmoΔBTB or pUAS-ChinmoΔZnf. Cell lysates 
were prepared 48h after transfection; Chinmo-complexes were 
immunoprecipitated with anti-AU1 antibodies and Western blotted with anti-
HA antibodies (A). After exposition the blot was stripped and re-probed with 
anti-AU1 antibodies to detect Chinmo (B). The lower band in panel B shows 
the IgG light chain. ΔBTB indicates pUAS-ChinmoΔBTB and ΔZ indicates 
pUAS-ChinmoΔZnf. 
 
α-AU1 IP 
Chinmo 
IgG light chain 
α-HA 
IP 
supernatant 
 
 
 173 
3.6 Mechanism: The next layer 
 
3.6.1 Interaction with guftagu 
 
Most cellular processes require a tightly controlled coordination between synthesis and 
degradation of proteins. Ubiquitin ligases (E3) are multiprotein complexes that specifically 
recognize their substrates and mediate their ubiquitin-dependent degradation. Two classes of 
E3 ligases have been characterized: HECT-type and RING-H2-type E3s (reviewed in 
Glickman and Ciechanover, 2002). There are two major types of RING-H2 E3 ligases: the 
APC/C (anaphase-promoting complex/cyclosome) and the SCF complex (Skp1, Cullin, F-
box) (reviewed in Deshaies, 1999). Recent work has revealed that the SCF complex is the 
prototype of an emerging family of Cullin-based ligases including the well-defined ECS 
complex (ElonginC–Cul2–SOCS) and the Cul3-based ligases (Geyer et al., 2003; Xu et al., 
2003). 
Cullin-based E3 ligases target substrates for ubiquitin-dependent degradation by the 26S 
proteasome. The structural homology between BTB proteins and Skp1 or ElonginC led to the 
hypothesis that BTB proteins might also directly interact with Cullins (Schulman et al., 2000). 
The functional relevance of a Cul3–BTB protein complex was demonstrated in C. elegans. In 
this system, a complex containing CUL-3 and the BTB protein MEL-26 is required for the 
ubiquitin-dependent degradation of the microtubule-severing protein MEI-1 in early embryos. 
Degradation of MEI-1 by the CUL-3/MEL-26 complex after meiosis is essential for the 
assembly of the mitotic spindle (Kurz et al., 2002; Pintard et al., 2003). There are two regions 
in MEL-26 required for interaction with CUL-3 ([M243, I245, D247]; [D281, Y283, L285]). 
Direct alignment with Chinmo did not show any homologies to this region, however, when 
the ortholog of MEL-26 was used (CG12537/Rdx/CG9924, according to Wormbase) 3 
conserved regions were found, all located in between the BTB/POZ domain of Chinmo. 
Moreover, the transcription factor PLZF (promyelocytic leukaemia zinc-finger protein) 
interacts with CUL-3 in a two-hybrid assay, suggesting that a CUL3-based complex may 
indeed regulate transcription by controlling the stability of PLZF (Furukawa et al., 2003). 
Because of these precedents, we were interested to determine if Chinmo might act as a 
component of a CUL3 complex to influence transcriptional regulation by dMyc.  
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In Drosophila, there is only one homolog of CUL3, called Guftagu. The guftagu (gft) gene 
consists of 5984 base pairs and codes for a protein of 773 amino acids. There are 3 different 
transcripts which all give rise to the same protein. Guftagu not only affects ubiquitin-
dependent protein catabolic processes but also the induction of apoptosis and the regulation of 
cell cycle. For our experiments, different gft mutants and a gft RNAi line were tested for 
interaction with dMyc, in order to investigate if dmyc interacts in a similar way with gft/Cul3 
as observed for Chinmo. We tested interaction of the hypomorphic allele ey>dmP0 and of 
“GM” (y w; GMR-GAL4 UAS-dMyc132/+; UAS-dMyc13 UAS-dMyc42/+) (both of which 
show an eye-specific phenotype) with different gft mutants. As controls, we crossed ey>dm+ 
and GMR-GAL4 to the gft mutants. The gft mutants were the following: gft06430 (a P-element 
insertion in the first intron of gft, 228 bp from exon 2), gft2 (a 5bp deletion, resulting in a 
frame shift at amino acid 747 and a premature stop codon at amino acid 748), gftEY11031 (a P-
element insertion outside the coding region in the C-terminus), and a UAS-gft-dsRNA 
transgene. 
gft2 and gft06430 showed no effect in any of the crosses. However, gftEY11031 and the RNAi line 
affected “GM” eyes (see Figure 41D, H). Overexpression of gft RNAi in the eye by GMR-
GAL4 did not change eye morphology (data not shown). The RNAi line additionally affected 
the eye phenotype of ey>dmP0 flies, but control flies were also affected (Figure 41A, B). Thus, 
reduction of Gft levels does not behave in the same way as a reduction in Chinmo levels, 
since chinmo alleles showed a clear defect with ey>dmP0 and not in control flies, moreover 
they did not affect “GM”. 
In a second assay, overexpression of Gft/CUL3 was tested with different ubiquitously 
expressed GAL4 drivers. Overexpression with the strong drivers act5C- and tub-GAL4 lead 
to lethality early in development (during embryogenesis); overexpression with arm-GAL4 
allowed flies to complete development, but 50% of the female offspring had strong wing 
defects with blisters and disrupted wings. These phenotypes are comparable to the Chinmo 
overexpression phenotypes: blisters and disrupted wings were also observed upon 
overexpression of Chinmo with ap-GAL4 (GAL80ts system; 3.2.5). 
Taken together, no strong conclusions can be drawn from these experiments. As Gft is the 
only CUL3 in Drosophila, it would be expected to complex with several BTB/POZ proteins 
in addition to Chinmo, and hence the downregulation of gft should lead to broader defects 
than the loss of chinmo. On the other hand, the relative abundance (as well as the strength of 
the different mutant alleles) might be different for Gft and Chinmo, and therefore the mutant 
phenotypes could very well differ in different experimental situations. Finally, the 
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overexpression of either Gft or Chinmo lead to quite “non-specific” defects that were difficult 
to attribute to specific defects. Thus, our observations do not rule out or in the involvement of 
Gft in dMyc-dependent biological processes in vivo.  
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Figure 41:  Reduction of gft levels in the eye does not affect ey>dmP0 eyes. However, 
strong overexpression of dMyc in a gft mutant background leads to a clear eye 
defect with big and rough ommatidia. Anterior is to the right. 
 
 
Label:  Genotype: 
 A y w tub>dMyc>GAL4 ey-FLP/Y; gftRNAi/+ 
B w dmP0 tub>dMyc>GAL4 ey-FLP/Y; gftRNAi/+ 
C y w/Y; (GMR-GAL4 UAS-dMyc132; UAS-dMyc13 UAS-dMyc42)/(SM5^TM6B) 
D y w/Y; GMR-GAL4 UAS-dMyc132/ gftRNAi; UAS-dMyc13 UAS-dMyc42/+ 
E y w tub>dMyc>GAL4 ey-FLP/Y; gftEY11031/+ 
F w dmP0 tub>dMyc>GAL4 ey-FLP/Y; gftEY11031/+ 
H y w/Y; GMR-GAL4 UAS-dMyc132/gftEY11031; UAS-dMyc13 UAS-dMyc42/+ 
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3.6.2 A dMyc dependent luciferase is not affected by gft RNAi  
 
An RNAi screen to find new dMyc co-factors was previously performed in our lab. A 
selection of about 800 transcription-associated genes was analysed in this screen, including 
guftagu (M.Furrer, pers. communication). However, gft RNAi did not affect a dMyc-
dependent reporter. If Chinmo and Gft work in the same complex, RNAi against guftagu 
might negatively affect the ability of overexpressed Chinmo to transactivate dMyc target 
genes. To address this possibility, S2 cells were transfected with UAS-dMyc or UAS-Chinmo 
in the presence or absence of gft RNAi. Cells were incubated for 96h, to give gft maximal 
time to decay; however, at present we have not confirmed that this RNAi against gft is 
effective and that the protein has been eliminated under these conditions. Ninety-six hours 
after transfection cell lysates were taken and analysed for their relative Luciferase levels 
(Figure 42). Gft dsRNA did not meaningfully reduce relative Luciferase levels in the absence 
of co-expressed proteins, (compare “–“ to gft RNAi). Relative Luciferase levels upon 
overexpression of dMyc were not affected by a reduction of Gft levels, however gft RNAi 
reduced relative Luciferase levels after overexpression of Chinmo by 24%. This is 
comparable to the effect of chinmo dsRNA on relative Luciferase levels after overexpression 
of Chinmo. Thus, gft RNAi reduces Chinmo’s ability to transcriptionally activate the reporter 
construct, but no effect was observed for overexpression of dMyc. Thus, Chinmo and Guftagu 
might act in the same complex to transactivate dMyc target genes. 
However, we have recently obtained a UAS-CUL3 construct and thus we will be able to test 
the efficiency of gft RNAi. Moreover, we need to detect the ectopically expressed Gft by 
antibodies against Drosophila Gft. Furthermore, we can test the effect of overexpression of 
Gft/CUL3 in a Luciferase assay in the presence or absence of dmyc mRNA.  
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Figure 42:  Relative Luciferase levels after overexpression of dMyc and Chinmo in the 
presence or absence of gftRNAi. Reduction of Gft levels does not affect 
transactivation by dMyc but slightly reduces transactivation by Chinmo. 
Lysates were taken 96h after transfection. Error bars indicate standard 
deviation from two independent experiments. The relative reporter activity in 
the sample overexpressing dMyc was set to 100%. 
          -                  gftRNAi                    -                 gftRNAi                -                  gftRNAi              
              +                                               CH                                           dMyc 
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Discussion 
  
In the first part of our investigations we examined the role of the different conserved domains 
of dMyc in vivo and could show that there is a strong requirement for all biological activities 
for the dMyc N-terminus, whereas the evolutionarily conserved MB2 domain is not 
absolutely essential in vivo. However, not only the cis-acting determinants of dMyc that we 
have described in the first chapter were of interest to this study. Also the trans-acting 
determinants influencing dMyc`s action were investigated to get a better understanding of 
Myc`s oncogenic properties. Thus, our further investigations were directed towards the 
proteins (protein complexes) that control dMyc`s biological activities. A screen to find new 
dMyc co-factors was performed and lead to the identification of chinmo and Delta, two novel 
genes that interacted genetically with dmyc and that were further investigated. In the first part 
of the discussion the genetic interaction between Delta and dmyc will be discussed. In the 
second part we present evidence that dMyc is dependent on Chinmo to fulfil at least some 
functions in vivo and that dMyc is an important partner of Chinmo. Genetic interaction studies 
followed by molecular analysis suggest a role for Chinmo as a direct dMyc co-activator. 
 
Identification and characterization of Delta 
 
Delta was found in the deficiency screen as a gene deleted among others in Df(3R)ED5942, a 
deficiency that showed a strong interaction with ey>dmP0. In addition, this deficiency led to a 
weight reduction in a dmP0 background. The region of interest was narrowed down to 8 genes 
and one of them was Delta (Dl). A mutation in Delta led to comparable phenotypes as the 
Df(3R)ED5942, indicating that Dl was the gene responsible for the phenotype seen in 
“ey>dmP0/Y; Df(3R)ED5942/+” animals. We show clear evidence that several dmyc mutants 
are affected by a reduction of Dl levels. Delta is a ligand of the Notch receptor. The Notch 
signalling pathway is mainly involved in cell-cell communications that control multiple cell 
differentiation processes during embryonic and larval life. 
We set out to study the interaction between other components of the Notch signalling 
pathway and Myc to get a better understanding of the interaction between Delta and dMyc, 
but none of the tested factors affected dMyc function (Su(H), H, N, sim, gro, L). These results 
suggest either that Delta is the most limiting factor for the genetic interaction with dmyc, and 
that more severe mutant situations need to be tested for the other Notch-pathway components 
in order to reveal their interaction with dmyc, or that Dl functions outside of the Notch-
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pathway; however, so far such functions have not been described. That Delta is involved in 
the regulation of growth and proliferation independently of Notch is supported by the findings 
that flies heterozygous for Delta and Minutes are very sick, whereas flies heterozygous for 
Notch and Minutes are not affected (A.C.Nagel, pers. communication). 
Recent publications demonstrated that there is a connection between human c-Myc and 
Notch1. It was shown that Notch1 regulates similar biological processes as c-Myc, for 
example angiogenesis, and both of them are disregulated in cancers (reviewed in Bolos et al., 
2007; Zhao et al., 2003). Moreover, c-myc was identified as a direct transcriptional target 
gene of the Notch1 pathway in T cell acute lymphoblastic leukaemia (T-ALL) (Sharma et al., 
2007). Inhibition of Notch1 resulted in cell cycle arrest and apoptosis and decreased c-myc 
levels. Studies in human T-ALL cell lines also demonstrated that a direct Notch1-mediated 
activation of c-myc is required to maintain leukemic growth (Weng et al., 2006). However, 
the molecular mechanism behind this action still needs to be investigated.  
Given this connection in vertebrates, we can speculate that Notch might also control the 
expression of dmyc in flies.  Alternatively, dMyc might act upstream of the Notch signalling 
pathway by affecting Delta, thus activating Notch signalling. Third, both dMyc and Dl might 
act in parallel and redundant pathways to activate Notch, thus affecting eye growth, or they 
might converge on some target genes. 
Based on the vertebrate data, the most appealing hypothesis is the first that suggests that 
Notch signalling controls dMyc activity. Thus, Notch might control dmyc mRNA levels (e.g. 
by controlling the transcription of the dmyc gene) or dMyc protein levels (e.g. by controlling 
dMyc protein stability). To address if Notch affects dmyc mRNA levels, RNA in situ 
hybridisations (or qRT-PCRs) in a Notch mutant background could be performed. 
Hence, further investigations are necessary to determine the interaction between Delta 
(Notch) and dMyc. To understand this interaction might be a small step to get a better 
understanding of normal development or the molecular basis of tumours like acute 
lymphoblastic leukaemia or breast cancer (Efstratiadis et al., 2007).  
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Genetic identification and characterization of Chinmo 
 
Genetic and molecular interaction between chinmo and dmyc 
 
Chinmo, a BTB/POZ domain protein was found in four different genetic loss of function 
screens (for details on the screen see the results section). 
Most of the genetic studies between Chinmo and dMyc were based on the three alleles we 
obtained from the ey-FLP (“pinhead”) screen that was performed in the laboratory of 
E.Hafen. In a hypomorphic dmyc background heterozygosity for those chinmo alleles resulted 
in rough and dented eye phenotypes, which clearly indicates that dMyc and Chinmo interact 
genetically. 
Our data also show that the overall eye size is further diminished when dMyc levels are 
reduced in heads that are predominantly homozygous mutant for chinmo (“pinheads”).  
Conversely, the chinmo mutants reduced the size of dmyc null mutant eyes leading to strongly 
distorted heads and the flies were not able to hatch anymore. This suggests that dMyc and 
Chinmo work in two parallel pathways to control growth and proliferation. Hence, Chinmo 
and dMyc control cell proliferation and cell growth independently. However, we cannot 
exclude that the two proteins function together to control some downstream effects in addition 
to the “Chinmo” and “Myc” pathway. 
Eye size is determined by the combination of ommatidial number and ommatidial size. The 
chinmo alleles caused a small head due to a reduction in ommatidial number and did not 
affect rhabdomere size (Sulzer, 2003, diploma thesis). Therefore, two mechanisms of Chinmo 
action were considered. Chinmo could act as an inhibitor of apoptosis, thus leading to a cell 
number reduction in a chinmo mutant background. The second hypothesis suggests that 
Chinmo might promote cell cycle progression, allowing the cells to reach normal size, with a 
reduced cell number.  
Our observations seem to argue against the hypothesis that Chinmo inhibits apoptosis. First, 
overexpression of Chinmo in the dorsal compartment of the wing disc induced apoptosis, and 
cell death was even more enhanced by co-overexpression of dMyc. If Chinmo inhibited 
apoptosis, we would not expect any apoptotic cells after overexpression of Chinmo. Second, 
overexpression of Chinmo, using different Chinmo transgenes with ubiquitously expressed 
GAL4-drivers, killed the flies mostly early in development. This death might also be linked to 
apoptosis, but we cannot rule out that those animals die for some other reason. Finally, 
overexpression of Chinmo kills wildtype flies (expressing endogenous dmyc) whereas the 
same Chinmo overexpression in a dmyc-mutant background allows some flies to survive. The 
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surviving flies had distinct black spots of apoptotic cells, which are indicative of cell death. 
Taken together, these observations show that elevated Chinmo levels lead to cell death. While 
it is possible that a reduction in Chinmo levels (as obtained in chinmo mutant tissues) has the 
same effect, and that chinmo mutant tissues contain fewer cells as a consequence of increased 
apoptosis, we favour the alternative explanation, that such chinmo mutant tissues suffer from 
impaired cell proliferation. Thus, Chinmo might promote cell cycle progression together with 
dMyc and induce apoptosis independently of dMyc. This combination was also seen by some 
positive regulators of proliferation, which do promote S-phase entry but also induce apoptosis 
when overexpressed (e.g. dMyc, E2F) (Asano et al., 1996).  
One could think of different possibilities how Chinmo behaves when overexpressed. First, 
overexpression of Chinmo might enhance its normal function (e.g. regulation of growth, 
control of asymmetric cell division). Second, Chinmo might have a dominant-negative effect. 
Third, Chinmo overexpression might lead to neomorph effects, thus overexpression of 
Chinmo might overcome its normal function leading to a completely novel function (like 
apoptosis), e.g. if the additional amount of Chinmo protein might reach places where it is 
normally not found. The second hypothesis does most probably not apply since there is no 
dominant-negative effect of Chinmo overexpression, as it does not interfere with endogenous 
Chinmo (by comparison of chinmo mutant heads and heads that overexpress Chinmo). The 
first hypothesis might apply partially since overexpression of Chinmo does not seem to 
enhance eye size (by comparison of the very few animals that survived upon overexpression 
of Chinmo in a dmyc mutant background compared to dmyc mutant flies alone) or clonal size 
(since clonal size is reduced when Chinmo is overexpressed). In contrast, overexpression of 
Chinmo transactivates dMyc target genes to the same extent as dMyc alone and even 
enhances transactivation when co-overexpressed with dMyc. Moreover, Chinmo activates 
endogenous target genes involved in ribosomal biogenesis. Indeed, 3 out of 4 genes involved 
in ribosomal biogenesis were upregulated upon Chinmo overexpression indicating that 
Chinmo overexpression might enhance ribosomal biosynthesis and thus cell growth. 
However, the most likely hypothesis is the third one, since overexpression of Chinmo leads to 
organismal death. Interestingly, the defects of Chinmo overexpression are partially 
suppressed in a dmyc mutant background, which suggests that dMyc is limiting for Chinmo 
function. A reduction in dMyc levels might attenuate the strong effects caused by 
overexpression of Chinmo since some flies who normally die during early pupal stages 
reached adulthood when dMyc levels were reduced. In summary, Chinmo overexpression 
does not enhance its normal biological functions but its molecular functions and Chinmo 
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adopts novel functions when overexpressed, leading to neomorph phenotypes. This 
hypothesis does not allow us to draw any conclusion about Chinmo`s normal biological 
activities, however our data would present some ideas on the novel molecular activities that 
Chinmo adopts when overexpressed, namely the induction of apoptosis. 
As mentioned above, overexpression of Chinmo activated transcription of dMyc target genes 
and a dMyc-dependent reporter, and the latter effect requires endogenous dmyc mRNA. On 
the other hand, depletion of chinmo in S2 cells had no effect on transactivation by dMyc. 
Further investigations suggested that Chinmo is not expressed in S2 cells. Hence, dMyc is not 
dependent on Chinmo to transactivate its target genes in S2 cells, although Chinmo might be 
required in other tissues, and ectopically expressed Chinmo might help to transactivate dMyc 
target genes also in S2 cells. Whether the activation of endogenous target genes by dMyc also 
requires Chinmo was not analysed but will be done in the future. This will be investigated in a 
tissue, where both Chinmo and dMyc are expressed. Since we have not succeeded to visualize 
Chinmo expression in the fly and thus we don`t know where Chinmo is active, we will take 
eye imaginal discs for that purpose. This tissue is appropriate for our experiments because we 
could show that Chinmo and dMyc are required for growth and development in the eye and 
their genetic interaction further suggests that the putative “Chinmo-dMyc” complex is active 
there. Thus, cDNAs derived from chinmo mutant heads with or without overexpression of 
dMyc will be analysed by qRT-PCR to have a look if dMyc is still able to activate certain 
target genes (e.g. genes involved in ribosomal biogenesis that were shown to be activated by 
Chinmo) in the absence of chinmo. One could imagine that Chinmo might be required only 
for certain target genes of dMyc (or in distinct tissues), but overexpression of Chinmo might 
nevertheless have a positive effect also on other targets. However, so far there is no evidence 
that overexpression of Chinmo stimulates growth since clones overexpressing Chinmo were 
not bigger than control clones.  
Since Chinmo activates the transcription of dMyc target genes, we wanted to know by which 
molecular mechanism this occurs. One possibility was that Chinmo stabilizes dMyc and thus 
increases dMyc protein levels, however this was not the case. Our data support a different 
model of interaction- that Chinmo interacts physically with dMyc. To determine the binding 
site of Chinmo in dMyc, co-IP experiments with different dMyc mutants were carried out, 
which together indicate that the binding site lies in the central region of dMyc. The binding 
site for dMyc in Chinmo is most probably the BTB/POZ domain since a deletion of this 
region abolished dMyc binding, but ChinmoΔBTB was also weakly expressed. However, the 
 
 
 184 
observation that BTB/POZ domains function as protein-protein binding domains supports our 
observations (Perez-Torrado et al., 2006).  
There are two possibilities, how BTB-proteins might function: as transcription factors or as 
E3-ligases. One could think that a BTB-transcription factor recruits an E3-ligase to DNA thus 
influencing the transcription of target genes. BTB/POZ domains were for example shown to 
play a role in ubiquitin-dependent degradation by binding to Cullin-based E3 ligases (CUL-3) 
(Schulman et al., 2000). Therefore we were interested to find out if Chinmo mediates E3 
ligase dependent ubiquitination and thus destabilizes and degrades proteins like histones or 
RNA Pol II in a complex with dMyc or dMyc itself. The only CUL-3 homologue known in 
Drosophila is guftagu and this gene was therefore tested for genetic interaction with dmyc. 
Different Gft mutants and a gft RNAi line did not show a significant effect on eye 
morphology in a dmyc mutant background or upon overexpression of dMyc. Moreover, 
depletion of gft did not affect the activation of a dMyc-dependent reporter by dMyc but it 
reduced the activation of Chinmo comparable to dsRNA against Chinmo. This would suggest, 
that Chinmo and Gft might act in the same complex to transactivate dMyc target genes. 
However, we need to demonstrate first if the RNAi against gft was indeed functional by 
detecting Gft levels before and after reduction by RNAi on a Western blot. Whether 
overexpression of CUL-3 affects transactivation of dMyc target genes will be investigated in 
future experiments.  
The observation that a deletion of the BTB/POZ domain inhibited transactivation suggests 
that the BTB/POZ domain is necessary for transactivation of dMyc targets. We could also 
show that the enhanced activation of transcription by ChinmoΔZnf is fully dependent on the 
presence of dMyc because depletion of dmyc abolished this activation. The zinc finger might 
be necessary to induce growth and proliferation since all ey-FLP-screen alleles lack this 
domain or have a mutation in it, and these alleles impair the ability of overexpressed Myc to 
induce growth and proliferation.  A model for the interaction between Chinmo and dMyc is 
depicted in Figure I. 
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The role of Chinmo and dMyc in neuronal development 
 
In the LOF screen, from which Chinmo received its name, Chinmo was found to control 
temporal identity in neuronal progenitors (Zhu et al., 2006). It was shown that overexpression 
of Chinmo throughout the neuroblast lineage of the mushroom body in the Drosophila brain 
transformed late born neurons into early born neurons. This raised the question, whether 
dMyc plays a specific role in neuronal development and if this role is dependent on Chinmo. 
Drosophila neuroblasts divide into a bigger apical daughter cell that retains neuroblast 
characteristics and a smaller basal ganglion mother cell (GMC) that divides once more into 
neurons and glial cells. In 2006, dMyc was demonstrated to influence this neuronal 
development. It was shown that dMyc is expressed in larval neuroblasts but not in the 
differentiating daughter cell. The growth inhibitor Brat posttranscriptionally inhibits dMyc in 
this cell. However, in clones mutant for brat dMyc is overexpressed in all cells, thus both 
daughter cells start to grow and behave like neuroblasts, which leads to neuronal proliferation 
and the formation of larval brain tumours (Betschinger et al., 2006). Moreover, dMyc was 
shown to promote neurogenesis in the embryonic PNS and the CNS (and possibly the larval 
PNS) (Orian et al., 2007). Thus, Myc is expressed in the nervous system in flies, where it is 
required for precursor cell proliferation and possibly cell fate determination of neuroblasts. 
This raises the possibility that dMyc and Chinmo might work together to regulate neuronal 
differentiation e.g. by defining specific neuron types. It will be interesting to determine 
whether this is the case. Corresponding experiments will be carried out, e.g. we will test dmyc 
mutants in the same set-up that was used for the characterization of Chinmo, to see whether 
dMyc is required in the same process as Chinmo. Moreover, we will investigate if 
overexpression of dMyc can transform late born neurons into early born neurons as it was 
shown for Chinmo overexpression.  
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Figure I:  Model of the interaction between Chinmo and dMyc. Chinmo and dMyc act 
both in separate pathways to specify either a temporal gradient in the 
mushroom body neuroblast lineage (Chinmo) or to control biological activities 
like proliferation or apoptosis (dMyc). However, both Chinmo and dMyc also 
act together e.g. in the regulation of cell growth most probably by activation of 
certain target genes. The observation that both proteins interact physically 
supports this model. 
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Conclusion 
 
Our data reveal two novel dMyc interacting genes: Delta, which is involved in the Notch 
signalling pathway and chinmo.  
It is necessary to understand how these trans-acting determinants influence Myc function to 
get a better understanding of Myc`s oncogenic properties. 
We present evidence that dMyc depends on Chinmo to accurately fulfil its biological 
activities in wing imaginal discs. Interestingly, dMyc is limiting for Chinmo since the 
deleterious effects of Chinmo overexpression are suppressed by reduction of dMyc levels. 
Additionally, our data suggest that Chinmo binds dMyc physically via its BTB/POZ domain. 
Moreover, Chinmo activates not only endogenous target genes of dMyc associated with 
ribosomal biosynthesis and it activated the transcription but also a dMyc dependent luciferase 
reporter, and the latter effect requires endogenous dmyc. Thus, Chinmo might be a co-
activator of dMyc, necessary for its biological functions in vivo. 
Chinmo might also be expressed in humans and human c-Myc might interact with this human 
homologue of Chinmo. Therefore, this interaction might be relevant for cancer in some 
tissues.  
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Materials and Methods 
1. Cloning and expression of dMyc proteins 
 
A cDNA for wildtype dMyc with a triple HA-epitope at its N-terminus was subcloned into 
pBluescript SK+ (as an Asp718/EcoRI fragment) and later cloned into a pBS-vector (as an 
Asp718/XbaI fragment) carrying a single ΦC31 attB site, 5 UAS repeats, a hsp70 basal 
promoter, the SV40 polyA signal, a mini-white gene as a marker and an ampicillin resistance 
protein for selection (Bischof et al., 2007). By site-directed mutagenesis the following mutant 
derivatives were created (numbering relative to untagged dMyc): dMycΔN: lacking amino 
acids 1–65 (cloned as Asp718/ApaI/ApaI/XbaI fragment); dMycMB2A: containing “AAAA” 
instead of “DCMW” (cloned as Asp718/SpeI/SpeI/XbaI fragment); dMycΔMB2: “GP” 
substituted for residues 68-84 (cloned as Asp718/ApaI/ApaI/XbaI fragment); dMycΔMB3: 
“F” substituted for residues 405-422 (cloned as Asp718/EcoRI/EcoRI/XbaI fragment). In 
addition, the same cDNAs were cloned under the control of the β-tubulin promoter (see 
Bellosta et al., 2005) into an analogous pBS-vector lacking UAS and hsp70 sequences.  
 
To determine the precise binding site of different proteins, which were shown to interact with 
dMyc, like Pont (Bellosta et al., 2005), Chinmo (D. Schwinkendorf, unpublished), dHCF (M. 
Balbi, personal communication), dLeo1 (M.Furrer, personal communication), different 
smaller dMyc mutations were generated. All mutations contain an N-terminal HA-tag in order 
to allow their visualization on an SDS-PAGE. All C-terminal deletions (N-terminus, Δ294C, 
Δ403C, Δ523C, ΔC) carry an MluI site, followed by a STOP codon and an XbaI site at their 
C-terminus, all N-terminal deletions (Δ626N, Δ523N, Δ403N, Δ294N, ΔNΔC) carry an MluI 
site at their N-terminus. For further Myc mutations of the central part of the protein, the 
different Myc fragments can therefore be combined. As a template for PCR reactions 
pUAST-HA-dMyc was used. C-terminal deletions were subcloned into the same vector after 
elimination of dMyc by Asp718/XbaI. N-terminal deletions were subcloned as MluI/XbaI 
fragment into pUAST-HA (A.Egli, unpublished). For internal deletions the MluI/XbaI 
fragment of any N-terminal deletion can be cloned into any C-terminal deletion construct via 
the same restriction sites. 
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The created constructs were (numbering relative to untagged dMyc):  
N-terminus: lacking amino acids 179-719 
Δ294C: lacking amio acids 294-719 
Δ403C: lacking amino acids 403-719  
Δ523C: lacking amino acids 523-719  
ΔC-terminus: lacking amino acids 626-719 
ΔN626: lacking amino acids 1-626  
ΔN523: lacking amino acids 1-523 
ΔN403: lacking amino acids 1-403 
ΔN294: lacking amino acids 1-294 
ΔN-terminus: lacking amino acids 1-179 
ΔNΔC-terminus: lacking amino acids 1-179 and 626-719 
 
Primer sequences for dMyc mutants/ fragments   
 
construct   primer name     primer sequence (5‘3‘) 
dMycWT    5UPn                  GGGCGAATTGGGTACCCGCGAAATTGCTCG 
  3LPn  GTGGCGCGACGCTTAGTGGGCGAGCTC 
dMycΔN  MBIUPn  GCGGTAAAGGGCCCTTCTAGCGTAATCTGGAACGTC 
  MBILP  GATGGGCCCCCAGAGATCCGCAACATCGAC 
dMycMB2A  MB2UP  CCGTCGACTAGTATGTCCAGCTGTTTGACCAGC 
  MB2LP     CCGTCGACTAGTTGCTGCTGCTGCGATGTTGCGGATCTCTGG 
dMycΔMB2   MBIIdelUP  CACAGGGCCCCTCTGGCTTCATATCCTCCTC 
  MBIIdelLP  CACAGGGCCCGGTAACGGTAATGGAATAGAG 
dMycΔMB3  acidicUP3  GGGGAATTCCAAATTGGGACCATCGTCCAC 
  acidicLP3  GACGAATTCCTACCCACAAATCCCTCGTGC 
 
Primer pairs 
dMycΔN: 5UPn + MBIUPn; MBILP + 3LPn 
dMycMB2A: 5UPn + MB2LP; MB2UP + 3LPn 
dMycΔMB2: 5UPn + MBIIdelLP; MBIIdelUP + 3LPn 
dMycΔMB3: 5UPn + acidicUP3; acidicLP3 + 3LPn 
 
 
construct   primer name     primer sequence (5‘3‘) 
dMyc294C  dMyc_d294C     TTACTCTAGATTAACGCGTCGAATTGGAATGCTGGT 
   TGAGCACATCG  
dMyc403C   dMyc_d403C  GTACTCTAGATTAACGCGTCAAATTGGGACCATCGT 
    CCACCATATCG  
dMyc523C   dMyc_d523C  GTACTCTAGATTAACGCGTCGAACTGGAGGTGGTGA 
    AGCTTGACTGC 
dMycN294   dMyc_dN294  ATTCACGCGTACACGGGTGGCCAACAGCAGTTG 
dMycN403   dMyc_dN403  ATTCACGCGTACGAGACCCCCTCAGATTCCGATG 
dMycN523   dMyc_dN523  AAGCACGCGTACAACAAGGGACGCAAACGATCCAG 
dMycN626   dMyc_dN626  CCACCACGCGTACAAGCGCAATCAGCACAATGA 
Myc fragments hsp70(+60)f  CGCAGCTGAACAAGCTAAACAATC 
Myc fragments SV40polyArev1  GTCACACCACAGAAGTAAGG 
 
Primer pairs 
all C-terminal fragments: primer as described above + hsp70(+60)f 
all N-terminal fragments: primer as described above + SV40PolyArev1 
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2. Cloning and expression of Chinmo proteins 
  
A cDNA (Gold SD 04616) with a single AU1-epitope was subcloned into pBluescript SK+ 
(Stratagene) and finally into a pBS-vector carrying a single ΦC31 attB site, 5 UAS repeats, a 
hsp70 basal promoter, the SV40 polyA signal, a mini-white gene as a marker and an 
ampicillin resistance protein for selection (Bischof et al., 2007). 
By site-directed mutagenesis the following mutant derivatives were created (numbering 
relative to untagged Chinmo): ChinmoΔBTB: “TR” substituted for amino acids 32-128; 
ChinmoΔZnf: lacking amino acids 517-604. 
Establishment of S2-MT-Chinmo: To have an inducible system to express Chinmo in all cells 
of a S2 cell population, chinmo was cloned into a metallothioneine vector (pMTV5His). 
Drosophila S2 cells were plated out to 1 million cells in 1,6ml full media in a six-well-plate 
for 1h. Cells were transfected with 0,4µg (0,2µg/ 0,1µg) pMT-Chinmo DNA plasmid and 
20ng (10ng/ 5ng) Blasticidin resistance plasmid (pCoBlast) and 10µl Cellfectin (Invitrogen) 
in serum-free medium. 15-16h after transfection full media was given for 48h before addition 
of 25µg Blasticidin. Cells were kept in selection medium for 10 days; afterwards, surviving 
cells were plated out in fresh medium containing Blasticidin.  
 
Primer sequences for Chinmo and Chinmo mutants 
 
construct  primer name   primer sequence (5‘3‘) 
Chinmo  CG31666UP  GGGCGAATTGGGTACCCAAAATGGACACCTACCGCT 
     ACATCATGGATCCGCAGCAGC 
Chinmo  CG31666LP  GGTGGCGGCCGCTCTAGATTACTATGGTGAATGATTGCTGGC 
ChinmoΔBTB  cBTBf1  GTGGTACCCAAAATGGACAC 
  cBTBr1  GTTCTAGACTATTAACGCGTCAGTAGATCCGATTTGAACAGA 
  cBTBf2  CAACGCGTCAACAACACATGGGCGACCT 
  cBTBr2  CCTTCACAAAGATCCTCTAGA 
ChinmoΔZnf  cZNr1  CGTCTAGACTATTACTTCTTACCGTCGGCCGTG 
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3. Tissue culture: transfections and biochemistry 
 
3.1 Common to all experiments 
 
Drosophila S2 cells were cultured at 24°C in 1x Schneider‘s Drosophila medium 
(Gibco/BRL), supplemented with 10% fetal bovine serum, 1% Penicillin/Strepavidin. To 
assess dMyc stability, 5x106 cells were seeded per well of a 6-well culture plate and 
transfected in 1ml of serum-free medium containing 10µl Cellfectin (Invitrogen) and 10µg 
plasmid DNA. 
 
3.2 Cycloheximide and steady state protein levels in S2 cells 
 
5µg tub-GAL4 and 5µg UAS-plasmids were used for transfection; 15-16h later, complete 
medium was added for 48h, before cycloheximide (Sigma, ready made) was added to 100 
µg/ml. Cells were harvested at the indicated time points and washed with 1xPBS, lysed in 
Laemmli sample buffer and analysed by SDS-PAGE and immunoblotting.  
Steady-state protein levels were determined analogously, without cycloheximide treatment. 
Primary antibody for Western blotting in both experiments was mouse anti-HA epitope 
(BAbCO) and mouse anti-α-Tubulin (Sigma), as secondary antibodies goat-anti-mouse-HRP 
(Jackson Immuno Research) was used. 
To quantify the intensity of the individual bands Image J software was used. Each band was 
quantified by a rectangle, the background was substracted and the value for time point zero 
was set to 100%. The half-time was quantified with following formula: LN(2)/(LN(100/X)*t; 
whereas X is the percentage of band intensity and t the individual time of cycloheximide 
incubation.  
 
3.3 Co-immunoprecipitation 
 
For co-immunoprecipitation, S2 cells (co-transfected as described above [GCN5, TraI] or 
with 4µg tub-GAL4, 3µg UAS-plasmid, 3µg UAS-plasmid of interest [Pont, Chinmo]) were 
lysed in lysis buffer (250mM NaCl, 50mM Tris [pH 8], 5mM EDTA, 0.5% NP-40) 
containing protease inhibitors (Complete Protease Inhibitor Cocktail, Roche). After 
incubation on ice for 1h, lysates were precleared with protein G-sepharose beads (Amersham 
Pharmacia), followed by incubation with primary antibodies for 3h at 4° C.  
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After another incubation for 1h with protein G-sepharose beads, beads were washed 3 x for 5‘ 
with lysis buffer, SDS sample buffer was added and the samples analysed by SDS-PAGE and 
immunoblotting. Primary antibodies used for co-immunoprecipitation were: mouse anti-c-
Myc epitope (9E10; Developmental Studies Hybridoma Bank), rabbit anti-dGCN5 (kindly 
provided by J. Workman), rabbit anti-AU1 (Alexis Biochemicals); for Western blotting: 
mouse anti-HA epitope (BAbCO), rabbit anti-HA epitope (Dunn Labortechnik GmbH). 
Secondary antibodies were HRP-coupled anti-rabbit or anti-mouse (GE Healthcare, Jackson 
Immuno Research) and for detection the enhanced chemiluminescence kit (Amersham) was 
used. 
 
3.4 Luciferase reporter experiments 
 
Reporter assays were carried out as previously described (Hulf et al., 2005). Briefly, 1.3x106 
cells/well of a 24-well cell culture plate were transfected with 0.65ml serum-free medium 
containing 4.2µl Cellfectin (Invitrogen) and 2.6µg reporter plasmid DNA (consisting of a 1:1 
mix of “CG5033wt-Renilla luciferase” and “CG5033ΔEbox-firefly luciferase” reporters) as well 
as 2.6µg UAS-plasmids (consisting of a 1:1 mix of tub-GAL4 and UAS-plasmids of interest). 
RNAi experiments included an amount of 0.08µg per dsRNA. After 15-16h, 0.65ml complete 
media was added; 24h later, cells were washed in 1xPBS, lysed in 1x Passive Lysis Buffer 
(Dual-Luciferase kit, Promega), and relative reporter expression determined on a Wallac 
luminometer. 
 
Primer sequences for dsRNA 
 
construct  primer name  primer sequence (5‘3‘) 
dsRNAdmyc 5’UTRfwd CAGAGAATCGCTTTGTGGATTG 
 5’UTRrev GCTGAACATAGTTTCCG 
dsRNAchinmo  CG31666RNAif  CGCTAATACGACTCACTATAGGGAGACGGATCTACTGGC 
     CGATGTC 
  CG31666RNAir  CGCTAATACGACTCACTATAGGGAGACAAGATGCCAGTG 
 GATCCGC 
gftRNAi MF_EG_rev CGTAATACGACTCACTATAGGGAGATGGCGCCCCTAGATG 
 MF_EG_fw5 CGTAATACGACTCACTATAGGGAGATAGGTCTAGCCCCGC 
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4. Drosophila lines 
 
Transgenic flies were established by integrating the different attB plasmids into the attP 
landing site ZH-86Fb (Bischof et al., 2007; http://www.frontiers-in-genetics.org/), and 
confirmed by PCR.  
 
PCR conditions 
Volume (total): 25µl. Primer pairs (10µM): 1µl each of iPCRSV40F1 or ZHattP14R 
respectively; genomic DNA: 0.2µg; Taq Polymerase buffer: 2.5µl; dNTP‘s: 0.5µl; Taq 
Polymerase: 0.2µl. Cycling parameters: 5 min 94° C, 35 x [30s 94° C, 30s 62°C, 1min 72° C], 
5min 72°C, HOLD 4°C.  
 
Primer sequences 
construct   primer name     primer sequence (5‘3‘) 
insertion  iPCRSV40F1  CTTGTTTATTGCAGCTTATAATGG 
insertion ZHattP14R TGGTGCTAGAAACACCTTTCGAGCCG 
 
 
4.1 Source of additional flies  
 
GAL4 drivers, gft mutants (Drosophila stock centre at Bloomington) 
BL12175: cn1 P(PZ)gft06430/CyO; ry506 
BL23866: gft2 P(neoFRT)40A/CyO 
BL20656: y1 w67c23; P(EPgy2)gftEY11031 
act-FRT-CD2-FRT-GAL4 (Neufeld et al., 1998) 
GMR-FRT-w+-FRT-GAL4 (Brogiolo et al., 2001) 
tub-FRT-dMyc-FRT-GAL4 (De La Cova et al., 2004) 
ago1 & ago3 (Moberg et al., 2001) 
dmP0 (Johnston et al., 1999) 
dm2 (Maines et al., 2004) 
dm4 (Pierce et al., 2004) 
dmnt1 dm4 (Pierce et al., 2008) 
dmPL35 & dmPG45 (Benassayag et al., 2005) 
UAS-Chinmo on III, chinmo alleles FRT-40 108, 110, 134 (kindly provided by H. Stocker) 
UAS Chinmo FL (Zhu et al., 2006) 
RNAi line gft (Barry Dickson, Vienna, Austria) 
hs-FLP UAS GFP; tub-GAL80 FRT-40; tub-GAL4 (kindly provided by J. E. Treisman). 
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5. Analysis of adult flies 
 
Flies were kept on standard Drosophila medium and testcrosses performed in a climate-
controlled chamber at 25°. 
Scanning electron microscope pictures were taken with a JEOL JSM-6360 LV microscope 
and a magnification of 180x. Flies were frozen at –20°C for at least one day, slowly defrosted 
at 0°C and directly used for electron microscopy. For determination of ommatidial size, the 
area of 20 centrally located ommatidia was determined from 5 fly eyes of the same genotype 
using Adobe Photoshop. The same photomicrographs were also used to determine the total 
number of ommatidia per eye. Obvious fusions of two ommatidia were counted as two 
individual ommatidia.  
To determine adult weights, 1-2 day old adult flies were frozen at –20°C for at least one day, 
defrosted at room temperature and weighed on a Mettler Toledo MX5 microbalance. 
 
6. Immunocytochemistry 
 
6.1 TUNEL staining 
 
For TUNEL staining of wing imaginal discs, wandering third instar larvae were fixed in 4% 
paraformaldehyde for 20’, washed with 1x PBT (0.13M NaCL, 7mM Na2HP04, 3mM 
NaH2P04, 0.1% Tween-20) for 20’, post-fixed in ethanol/PBS (2:1) for 5’ at –20°C, washed 
with 3 changes of 0.1% Tween-20/PBS over 15’, pre-treated with 10mM sodium citrate (pH 
6) for 30’ at 70°C, equilibrated in Equilibration Buffer (ApopTag Red In Situ Apoptosis 
Detection Kit, Chemicon) for 10’, then incubated with TdT enzyme (Chemicon kit) for 1h at 
37°C, Stop/Wash Solution (Chemicon kit) for 10’, Rhodamine-coupled anti-DIG antibodies 
(Chemicon kit) for 30’, and 3 changes of 0.1% Tween-20/PBS (containing 0.5µg/ml Hoechst 
33342 for the first step).  
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6.2 Anti-cleaved caspase 3 staining 
 
For anti-cleaved caspase 3 stainings, wing imaginal discs of wandering third instar larvae 
were fixed in 4% paraformaldehyde/PBS for 20’ at room temperature and washed 3 times 
with 1x PBX (0.13M NaCl, 7mM Na2HP04, 3mM NaH2P04, 0.1% Triton-X100) for 20’. 
Rabbit anti-cleaved caspase 3 (Cell Signalling Technology) was added at 1:300 over night at 
4°C. Samples were washed with PBX, incubated with Texas Red-coupled anti-rabbit 
antibodies (Jackson Immuno Research Lab) and 0.5µg/ml Hoechst 33342 for 2 hours at room 
temperature, and washed again 3 times for 20’ with PBX. 
 
6.3 Overexpressing clones 
 
For clonal area measurements, larvae carrying the act-FRT-CD2-FRT-GAL4 construct, UAS-
GFP and the appropriate UAS-dMyc transgene, were heat-shocked for 10’ at 37°C in a water 
bath, dissected 48h or 72h later, fixed in 4% paraformaldehyde for 20’, and washed with 3 
changes of PBT (containing 0.5µg/ml Hoechst 33342 for the first step) over 60’.  
Wing discs were dissected and mounted in Vectashield Mounting Medium (Vectashield), and 
analysed on a Leica DMRA compound microscope at a 10x ocular magnification. Clonal area 
was determined from at least 40 clones per construct for 48h clones and at least 20 clones for 
72h clones using Adobe Photoshop. 
 
6.4 MARCM clones 
 
Uncrowded wandering L3 larvae either mutant for chinmo, or overexpressing dMyc, or 
mutant for chinmo and overexpressing dMyc or wildtype were dissected for wing imaginal 
discs 120 hours after egg deposition. Heat-shocks were given at 37°C for 20’ after 48h to 
obtain 72h clones. Wing discs were fixed in 4% paraformaldehyde for 20’ and washed with 3 
changes of PBT (containing 0.5µg/ml Hoechst 33342 for the first step) over 60’. Wing discs 
were dissected and mounted in Vectashield Mounting Medium (Vectashield), and analysed on 
a Leica DMRA compound microscope at a 10x ocular magnification. Clonal area was 
determined from at least 20 clones per construct for 48h clones and at least 20 clones for 72h 
clones using Adobe Photoshop. 
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6.5 Steady state protein levels in vivo 
 
Steady state protein levels in vivo were determined from flies expressing HAdMyc transgenes 
under the control of a tubulin promoter (details described above). Uncrowded wandering 
larvae or adult males were directly mashed in Laemmli sample buffer or lysed in lysis buffer 
(250mM NaCl, 50mM Tris [pH 8], 5mM EDTA, 0,5% NP-40) containing protease inhibitors 
(Complete Protease Inhibitor Cocktail, Roche) for 1h. Laemmli sample buffer was added to 
lysates (1:1). Both extracts were loaded on a SDS-PAGE following immunoblotting. Primary 
antibody for Western blotting was rabbit anti-HA (1:1000; Dunn Labortechnik), secondary 
antibody was HRP-conjugated donkey anti-rabbit (1:3000; GE Healthcare). 
 
6.6 QRT-PCR 
 
6.6.1 qRT-PCR dMyc mutants 
 
Male larvae with the genotype “w dm4 tub-FRT-dMyc-FRT-GAL4 hs-FLP; UAS-dMyc”, 
grown under uncrowded conditions, were heat-shocked at wandering stage for 2h at 37°C in a 
water bath, collected 8h later into liquid nitrogen, and stored at -80°. To extract RNA, 10 
whole larvae were homogenized in 1ml TRIZOL (Invitrogen) with a Polytron tissue 
homogenizer, following the manufacturers instructions. Upon precipitation, RNA was 
redissolved in 20µl RNAse-free water and analysed for its integrity on a Bioanalyzer 
(Agilent). Genomic DNA was eliminated using the Turbo DNAse free kit (Ambion) and 
cDNAs were synthesized from 1µg of template RNA using the Omniscript kit (Qiagen). 
Parallel control reactions containing only RNA provided templates for “-RT” samples. 
Quantitative real-time PCR (qRT-PCR) reactions were performed in triplicates on an 
ABI7900 Real Time PCR Instrument (Applied Biosystems), using the SYBR Green PCR 
Master Mix (Applied Biosystems). Data were analysed with SDS 2.0 software (Applied 
Biosystems) and Microsoft Excel, using the ΔΔCt method and the average of the expression 
levels of actin5C, Rab6 and Sec24 as internal reference for each biological sample.  
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Primer sequences 
gene   primer name   primer sequence (5‘3‘) 
Rab6 Rab6forw   TGCACGTGGCCAAGTCCTA 
  Rab6rev   CAGCGAACGCGACTGCTA 
Sec24    Sec24forw   CCACTCCCCTGCCATCCT 
 Sec24rev   ACCCCAAACCCAGCAACA  
CG5033 CG5033F1  TAACCGCTCGGCTTTAATTCA 
 CG5033R1 CCCTTGCTCTTGGAGAATGG  
dmyc(exon2)  qRTPCR2_ex2_dMycf CCCGGCGGAAGTTTGC 
 qRTPCR2_ex2_dMycr CCCGATTTGCGGATAATGTC 
dmyc(exon3) qRTPCR2_ex3_dMycf ACACGCGCTGCAACGAT 
 qRTPCR2_ex3_dMycr GTGGCACGAGGGATTTGTG 
GAL4 GAL4forw   TTGAAATCGCGTCGAAGGA 
 GAL4rev   CTCCAATGGCTAATATGCAGTTAAAA 
CG18610 CG18610forw   TCGTCTGCGACCTGTCCTTT 
 CG18610rev   ACCCAAAACCGATGGAGATTC 
HA-tag HAforw   GATAAACCCGATCAGCAAAAATG 
 HArev   GCCCGCATAGTCAGGAACA 
 
The remaining primers and the PCR conditions have been described (Steiger et al., 2008). 
 
 
6.6.2 qRT-PCR for Chinmo 
 
Drosophila S2 cells or S2 cells which stably express Chinmo after addition of copper sulphate 
(pMT Chinmo) were plated out to a concentration of 5x106 cells per well of a 6-well culture 
plate. Copper sulphate was added to a concentration of 1000 µM for 24h, control cell lines 
were untreated. Cells were harvested and lysed in 1ml TRIZOL (Invitrogen). Total RNA, 
cDNA and qRT-PCR were performed as described above. Data were analysed with SDS 2.0 
software (Applied Biosystems) and Microsoft Excel, using the ΔΔCt method and the average 
of the expression levels of actin5C, Rab6 and Sec24 as internal reference for each biological 
sample. 
 
PCR conditions 
Volume (total): 10µl. Primer pairs (10µM): 0.3µl; cDNA: 0.4µl; 2x SYBR GREEN: 5µl. 
Cycling parameters: 2 min 50° C, 10 min 95° C, 40 x [15 s 95° C, 1 min 60° C]. Dissociation 
curve measurements were included in the PCR run to document the specificity of the 
amplification reaction, and the “-RT” samples demonstrated the absence of contaminating 
genomic DNA. 
 
Primer sequences 
gene   primer name   primer sequence (5‘3‘) 
chinmo CHqRTfwd   GGCCGCGTCGATTGC 
 ChqRTrev   TCATCTTGGTGGCGTTCCAT 
fibrillarin fib_Right   ATGCGGTACTTGTGTGGATG 
 fib_Left   ACGACAGTCTCGCATGTGTC 
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7. Additional Primers 
 
Primer sequences and conditions for analysis of integration site/ sequencing 
 
use construct   primer name         primer sequence (5‘3‘) 
sequencing chinmo  rm3              GGCTGCAAATGCGGCGGC 
sequencing chinmo  rm4              CCATGCACTCCGAACGCGC 
sequencing chinmo  rm5              CCTGAGAGCTAAGGACACCG 
sequencing chinmo  rm6              GCATGCACTTCTCCAGTGCC 
 
analysis dMycMB2A  MIIanalMUT           CCCGCTGGACATACTAGTTGCTGCTGCTGC 
analysis dMycΔN  MIIanalWT              CAGCTGGACATCGCCGGCCACATGCAGTC 
analysis dMycΔMB3  ACanalUP              GGACGATGGTCCCAATTTGG 
analysis dMycWT  BASanalUP              GCCATGGATCGTAATTGGCAGC 
     PBSBLP              GGTTCCTTCACAAAGATCC 
     ACanalLP              GTTCTGATACGGTGTGCTCG 
analysis dMycΔMB2 MB2delanal              TCTATTCCATTACCGTTACCG 
 
 
PCR conditions  
Volume (total): 20µl. Primer pairs (10µM): 1µl each; genomic DNA: 0.4µl; Taq Polymerase 
buffer: 2µl; dNTPs: 1µl; Taq Polymerase: 0.2µl. Cycling parameters: 5 min 95°C, 35 x [30 s 
92° C, 30 s 58°C, 30 s 72° C], 10 min 72°C, HOLD 4°C. 
 
 
 
Primer for analysis of 380C1/BL7492 exons 
 
construct   primer name     primer sequence (5‘3‘) 
genomicDNA  Chex1f  CCACTGCACGCTTGTTCG 
  Chex1r  CACTTCATCCGCTGCAGTT 
  Chex2f  TCTGGGCACAAATGAAATGA 
  Chex2r  TGACAAGTTGTGAATTTTTCATAAAT 
  Chex3f  CCTTGAATACACTGAATACGCG 
  Chex3r  ATGGAAAATTTCAAGTAAAAACACAAC 
  Chex4f  AATCTTATGAATGTTCTCCTTTGCTT 
  Chex4r  AGGGAGCTGCAGTGTTGG 
  Chex5f  GAAAGCAAAACTAATCGCTCAA 
  Chex5r  GAAAATGAAAGGAAGCGAGTC 
  Chex6-9f  TAATATTCATATTCTAACGCATGTGAC 
  Chex6-9r  TGCCATCTTGAGTGTTTTACGT 
  Chex6-9b  GAGCAATAGGATGAGG 
  Chex9f  AGTCATGAACGCCAACAAGG 
  Chex9r  AGAGCCGAAAAAAGGAATTTTG 
  Chex9b  GCCTGAGCACCCTAGC 
 
PCR conditions 
Volume (total): 20µl. Primer pairs (10µM): 1.5µl each; template DNA: 1µg; Buffer HF (GC): 
2µl; DMSO: 0.6µl; MgCl2: 0.5µl; dNTPs: 0.5µl; Phusion Polymerase: 0.2µl. Cycling 
parameters: 5 min 95° C, 35 x [30s 94° C, 30s 62°C, 30s 72° C], 10 min 72°C, HOLD 4°C. 
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